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1 Summary 1 
1 Summary 
Metachromatic leukodystrophy (MLD) is a monogenic, autosomally recessively inherit-
ed lysosomal storage disease. Certain mutations of the arylsulfatase A (ASA) gene 
cause misfolding or absence of ASA. Physiologically ASA is responsible for the lyso-
somal degradation of 3-O-sulfogalactosylceramide (sulfatide), a main lipid component 
of myelin. Lack of ASA activity results in accumulation of sulfatide and consequently 
in demyelination processes, causing severe central nervous system pathology leading to 
premature death.  
Two therapeutic approaches for MLD were pursued in this thesis: enzyme replacement 
therapy (ERT) and chaperone therapy. For ERT recombinantly produced enzyme is in-
jected intravenously. However, the blood brain barrier (BBB) prevents efficient 
transport into the brain, the main target of the disease. Therefore options to increase 
brain delivery were investigated. To this end ASA was bound to four different nanopar-
ticle preparations that have been described to increase brain delivery of therapeutics. 
Inclusion during polymerization was unfeasible due to loss of ASA activity. Adsorption 
of ASA to the nanoparticle surface was efficient, however rapid and complete desorp-
tion was observed in presence of serum in vitro. In contrast, stable binding by direct 
crosslinking or high-affinity methods significantly reduced desorption in presence of 
serum. Two nanoparticle systems were thereon investigated with respect to their poten-
tial to increase brain delivery of ASA in vivo. However, contrary to the working hy-
pothesis, brain delivery was not enhanced upon binding to nanoparticles in comparison 
to free ASA, although the overall biodistribution of ASA was altered. This was ex-
plained by rapid uptake via mannose 6-phosphate (M6P) receptor endocytosis. To re-
duce uptake by peripheral cells, a M6P binding domain was coupled to nanoparticles in 
order to physically shield ASA’s M6P residues that are recognized by M6P receptors on 
these cells. Indeed, in first in vitro experiments, shielding of ASA resulted in a reduc-
tion of uptake by M6P receptor expressing cells. In vivo, this effect would be expected 
to lead to prolonged blood circulation times and an increase in brain delivery. 
Chaperone therapy aims at restoring activity of misfolded enzyme molecules by stabi-
lizing correct folding intermediates. Typically, pharmacological chaperones are small-
molecule enzyme inhibitors and ideally cross the BBB. By means of high throughput 
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screenings one ASA inhibitor was identified and subsequently characterized biochemi-
cally. This compound is to be further tested with respect to its use as a pharmacological 
chaperone. 
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2 Introduction 
2.1 Lysosomes 
To understand lysosomal storage diseases and corresponding therapeutic approaches, it 
is necessary to consider physiological functioning of lysosomes. Lysosomes are cellular 
organelles and consist of a limiting, external membrane harboring hydrolytic enzymes. 
Depending on the cell type, one cell can contain up to 100 lysosomes. The lysosomal 
lumen is acidic (pH 4.6 - 5.0) due to continuous active import of protons by adenosine 
triphosphate (ATP) dependent membrane proton pumps of the V-type (Ohkuma et al. 
1982). The primary function of lysosomes is the degradation of macromolecules to 
components of low molecular weight. These are then transported to the cytosol and used 
for the de novo synthesis of cellular macromolecules. For these degradation processes, 
the lysosome contains approximately 40 different hydrolases - proteases, glycosidases, 
lipases, nucleases, phosphatases and sulfatases (Luzio et al. 2007), which share a com-
mon pH optimum at lysosomal pH (Coffey and Duve 1968). This ensures that in case of 
lysosomal rupture, the hydrolases do not destroy cellular components, thereby granting 
survival of the cell. On the luminal membrane of lysosomes, glycosylated membrane 
proteins form a glycocalyx preventing uncontrolled membrane-protein and -lipid diges-
tion by lysosomal enzymes (Kundra and Kornfeld 1999).  
Extracellular macromolecules are transported to the lysosome via endocytosis or phago-
cytosis. During this process the lipid bilayer of the cell membrane invaginates and ulti-
mately leads to the formation of an endosome. Intracellular macromolecules such as 
damaged cell organelles or dysfunctional proteins can be engulfed by a lipid bilayer, 
forming autophagosomes. Both autophagosomes and endosomes ultimately transport 
their cargo to lysosomes to allow for their degradation. The precise molecular mecha-
nism of this transport has not yet been fully elucidated. Four theories are discussed:  
(1) Endosomes mature into lysosomes by acidification of their lumen; (2) Vesicles 
transport the cargo from endosomes to lysosomes; (3) Endosomes repeatedly fuse with 
and detach from lysosomes transiently (‘kiss and run’); (4) Endosomes and lysosomes 
fuse resulting in a hybrid cellular compartment. Increasing evidence favors the latter 
two theories (Luzio et al. 2007).  
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The synthesis and transport of lysosomal hydrolases involve the endoplasmic reticulum, 
the Golgi apparatus including the trans-Golgi network, and endosomes (Figure 2.1). 
Soluble lysosomal enzymes are translated at the rough endoplasmic reticulum and are 
translocated into their lumen by recognition of a 20-25 amino acids long signal se-
quence at their N-terminus. During this process the signal sequence is removed by sig-
nal peptidases. At certain asparagine residues (amino acid recognition sequence: Asn-
X-Ser/Thr) oligosaccharides are added (N-glycosylation). After vesicular transport to 
the Golgi apparatus, N-glycans of soluble lysosomal enzymes are specifically modified: 
First, N-acetylglucosaminyl-1-phosphotransferase (EC 2.7.8.17, short GlcNac-
phosphotransferase) adds N-acetylglucosamine-1-phosphate to terminal mannose resi-
dues of N-glycans. Then N-acetylglucosamin-1-phosphodiester-α-N-acetylglucosamini-
dase (‘uncovering enzyme’, EC 3.1.4.45) removes the N-acetylglucosaminyl residues, 
thereby uncovering mannose 6-phosphate (M6P) residues (Braulke and Bonifacino 
2009; Coutinho et al. 2012a). 
2 Introduction 5 
Figure 2.1: Sorting of lysosomal enzymes.  
After their synthesis at the endoplasmic reticulum and attachment of N-glycans, lysosomal en-
zymes are transported to the Golgi apparatus. There, phosphate residues are attached to man-
noses of the N-glycans by combined actions of GlcNac-phosphotransferase and the ‘uncovering 
enzyme’ yielding M6P residues. Upon their recognition by the mannose 6-phosphate receptors 
(MPRs) in the trans-Golgi network, lysosomal enzymes are transported to late endosomes by 
vesicular transport. After dissociation from the MPRs due to the acidic pH of late endosomes, 
their cargo is transported to the lysosome. The MPRs recycle back to the Golgi apparatus to be 
available for further rounds of transport. A fraction of both the MPRs and lysosomal enzymes is 
also transported to the cell membrane (adapted from Coutinho et al. 2012). 
 
These M6P residues are recognized by mannose 6-phosphate receptors (MPRs), present 
in the trans-Golgi network. Two MPRs are known today – the MPR46, also known as 
cation-dependent and the MPR300, also known as cation-independent M6P-receptor 
(Ghosh et al. 2003). After binding of their ligands, adaptor protein 1 (AP1) binds to the 
cytosolic domains of the MPRs and clathrin-coated pits form, leading to budding off of 
vesicles containing the MPRs and their cargo. However, 5-20% of the lysosomal pro-
teins escape transport to the lysosome and are secreted. The vesicles fuse with early 
endosomes. In the process of maturation of early to late endosomes the pH drops to 5.5. 
This leads to dissociation of the MPRs from the M6P containing hydrolases, which are 
subsequently transported to the lysosome. After release of their cargo in late endo-
somes, the MPRs are transported back to the trans-Golgi network, becoming available 
Cell
membrane
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for further rounds of transport (Braulke and Bonifacino 2009). Both MPRs are also 
found on the cell surface, but only the MPR300 has been shown to be involved in the 
internalization process of M6P containing ligands (Nadimpalli and Amancha 2010). 
Secreted lysosomal hydrolases can thus be recognized by MPRs on the cell surfaces of 
the same or neighboring cells. Consequently these lysosomal enzymes are endocytosed 
and transported into the lysosome. The phenomenon that cells deficient for a lysosomal 
enzyme can take up functional enzyme secreted by another cell has first been observed 
by Fratantoni et al. (1968) and is the basis for most therapies of lysosomal storage dis-
orders (‘cross correction’). 
Besides the most common MPR-mediated transport route described here, sortilin and 
lysosomal integral membrane protein 2 (LIMP-2) have also been shown to contribute to 
lysosomal transport of some newly synthesized lysosomal proteins (e.g. β-
glucocerebrosidase) (Reczek et al. 2007; Coutinho et al. 2012b).  
2.2 Lysosomal storage diseases 
Approximately 50 lysosomal storage disorders (LSDs) have been identified. Tradition-
ally, LSDs are subcategorized according to the storage material found in the lysosomes, 
causing the disease. In mucopolysaccharidoses and sphingolipidoses, glycosaminogly-
cans and sphingolipids accumulate, respectively (Futerman and van Meer 2004; Heese 
2008). However, several defects exist in which more than one macromolecule accumu-
lates showing the limitations of this classification. 
The reason for this intralysosomal accumulation is usually lack of activity or absence of 
one or more lysosomal enzymes. An overview of typical LSDs, the affected enzymes 
and the accumulating storage material is given in table 2.1. For instance, in Gaucher 
disease, a sphingolipidosis, lack of glucosylceramide-β-glucosidase results in accumula-
tion of glucosylceramide, especially in macrophages. Consequently, patients suffering 
from Gaucher disease, type I, show hepatosplenomegaly, but also anemia, thrombocy-
topenia and bone damage. Some LSDs cannot only be caused by lack of activity of a 
lysosomal hydrolase, but also by dysfunction of activator proteins, such as saposins. 
One example is saposin C, serving activation of glucosylceramide-β-glucosidase. 
Saposin C deficiency also leads to (juvenile) Gaucher disease (Kolter and Sandhoff 
2006). 
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Table 2.1: Example lysosomal storage disorders – corresponding defective proteins and 
accumulating storage materials (adapted from Ballabio and Gieselmann 2009). 
 
Most LSDs are monogenic and autosomally recessively inherited diseases. The reason 
for absence or lack of hydrolase activity is usually a genetic defect leading to complete 
loss of expression or expression of truncated or defective lysosomal enzymes. Frequent-
ly, point mutations merely cause a reduction, not a depletion of activity. A clear correla-
tion between genotype and the age of onset of the disease is not coercible – the same 
mutation may lead to different severities of the disease from one patient to another as 
external genetic or environmental factors have a major impact on disease manifestation 
(Futerman and van Meer 2004; Aerts et al. 2005). 
The combined incidence of all LSDs is 1:8,000 life births (Schultz et al. 2011), the most 
common LSD, Gaucher disease, type I, has an incidence of 1:50,000-200,000 life births 
(Kolter and Sandhoff 2006). The symptoms vary from LSD to LSD, primarily depend-
ing on the function and occurrence of the accumulating macromolecule in vivo 
(Futerman and van Meer 2004). Only few LSDs primarily affect peripheral organs and 
not, or to a significantly lesser extent, the brain (e.g. Fabry disease: -galactosidase A 
deficiency). About 70% of all LSDs result in accumulation of storage material in the 
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brain, in many cases leading to central nervous system (CNS) pathology (Begley et al. 
2008). 
2.3 Therapeutic approaches for lysosomal storage disorders  
Five major strategies are currently pursued by researchers and physicians for treatment 
of LSDs: cell-, gene-, substrate reduction-, chaperone- and enzyme replacement thera-
py. None of these strategies is effective for all LSDs – the strategy rather needs to be 
adjusted to each LSD and its specific symptoms. The underlying principles of the men-
tioned treatment options will be explained here.  
One example of a cell based therapeutic approach is hematopoietic stem cell therapy 
(HSCT), which has been in use for 30 years. Hematopoietic stem cells of a healthy do-
nor are engrafted in the bone marrow of LSD patients. These cells and their progeny 
produce and secrete active enzyme, whose lack causes the LSD in the patient. The en-
zyme is then taken up by MPR300-dependent endocytosis allowing for metabolic cross 
correction. HSCT is most efficient when performed before the age of two years. Clinical 
benefits are evident for treated mucopolysaccharidosis, type I, (Hurler’s disease) pa-
tients with substantial reduction of glycosaminoglycan storage and amelioration of the 
pathology (Beck 2010; Noh and Lee 2014). Theoretically, LSDs with CNS pathology 
can also be treated, as a subset of the transplanted cells may infiltrate the CNS 
(Brazelton et al. 2000; Asheuer et al. 2004). However, clinical trials using HSCT for 
several other LSDs, such as mucolipidosis type II (I-cell disease), mucopolysaccha-
ridoses types II (Hunter syndrome) and III (Sanfilippo syndrome), showed limited to no 
effect in terms of neuropathology (Lund et al. 2014; Noh and Lee 2014). 
Gene therapy aims at transducing patient-own cells by the use of e.g. lentiviral vectors. 
After transduction, cells express normal or supranormal levels of functional target lyso-
somal enzyme. Due to cross correction, neighboring cells can also take up the functional 
enzyme. Viral vectors are either directly injected into tissues, transducing the cells in 
the periphery of the injection site, or cells, e.g. hematopoietic stem cells, are isolated 
from patients, transduced and then re-implanted (‘ex vivo gene therapy’). Although pre-
clinical experiments in mouse models were promising, clinical trials using gene therapy 
were therapeutically inefficient for Gaucher (type I), mucopolysaccharidosis (type II) 
and Batten diseases (Byrne et al. 2012). One example of a more successful phase I clin-
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ical trial of ex vivo gene therapy for metachromatic leukodystrophy will be discussed in 
chapter 2.6.  
Substrate reduction therapy (SRT) is a relatively newly evolving therapeutic option. In 
contrast to all other approaches aiming at reducing storage material by increasing its 
degradation, the aim of SRT is to decrease the de novo synthesis of the accumulating 
component. To that end, small compounds are used to inhibit target enzymes responsi-
ble for synthesis of the accumulating storage material. In 1998, first trials were per-
formed using N-butyl-deoxynojirimycin (Miglustat) for SRT of Gaucher disease. 
Miglustat is an imino sugar, functioning as a reversible inhibitor of glucosylceramide 
synthase, thereby reducing production of the storage material of Gaucher disease, glu-
cosylceramide. Today, Miglustat is not only clinically approved for treatment of Gau-
cher, type I disease, but also for Niemann Pick, type C in the European Union (Venier 
and Igdoura 2012). 
A similar approach is chaperone therapy, also employing small compounds as inhibi-
tors. The molecular targets are misfolded lysosomal enzymes, responsible for failure in 
degradation of storage material. In the endoplasmic reticulum, these inhibitors bind re-
versibly to the active site of the enzyme. By acting as a chaperone, a portion of the en-
zymes is correctly-folded and escapes the endoplasmic-reticulum-associated protein 
degradation pathway (ERAD), physiologically responsible for degradation of misfolded 
proteins. Ideally, once reaching the lysosome, the inhibitor dissociates from the enzyme 
in a pH-dependent manner, releasing at least partially active enzyme. Consequently 
storage material is degraded, preventing progression of the disease. The compound 1-
deoxygalactonojirimycin (DGJ) is a competitive inhibitor of -galactosidase A and has 
now reached phase III clinical trials for chaperone therapy of Fabry disease (Suzuki, 
2013). Further compounds have been identified and used in preclinical and clinical trials 
for chaperone therapies of GM1- and GM2-gangliosidosis and Gaucher disease (Maegawa 
et al. 2007; Bendikov-Bar et al. 2013; Suzuki 2013). Both substrate reduction and chap-
erone therapy use small molecules for treatment. These are likely to traverse the blood 
brain barrier (BBB) and can frequently even be administered per os.  
Enzyme replacement therapy (ERT) is the most widely used approach for LSDs. Re-
combinantly produced, purified enzyme is usually administered intravenously. After its 
distribution by the blood circuit, cells throughout the body are able to take up recombi-
nant enzyme primarily via MPR-mediated endocytosis and subsequent transport to the 
10  2 Introduction 
lysosome. One exception is the enzyme β-glucocerebrosidase that is also the first en-
zyme that has been successfully used for ERT of Gaucher disease, type I. First clinical 
trials were performed in the 1980’s by Brady et al. using β-glucocerebrosidase of hu-
man placental origin. As mentioned before, mainly macrophages are affected in Gau-
cher disease. It has been shown that ERT is more efficient when the N-linked oligosac-
charides of β-glucocerebrosidase are enzymatically modified to display mannose resi-
dues, which are recognized by mannose receptors (MR) present on macrophages. Later, 
recombinantly produced enzyme, subsequently enzymatically modified, was shown to 
be equally efficient for ERT of Gaucher disease (Desnick and Schuchman 2012). Until 
today, the United States Food and Drug Administration (FDA) and the European Medi-
cines Agency (EMA) have authorized drugs for ERT of five other LSDs (Fabry and 
Pompe diseases, as well as mucopolysaccharidoses, types I, II, VI) (Boudes 2013). 
However, success of ERT is limited to LSDs with pathology of peripheral tissues and 
organs. Typically, LSDs with CNS pathology cannot be treated with traditional ERT as 
the BBB prohibits transport of intravenously injected enzymes into the brain (Aerts et 
al. 2005).  
2.4 Metachromatic Leukodystrophy 
Metachromatic leukodystrophy (MLD) is a LSD with an incidence of approximately 
1:100,000 life births (Gieselmann and Krägeloh-Mann 2010). The disease is character-
ized by severe CNS pathology. Historically, three forms of the disease are roughly dis-
tinguished by their age of onset. Late infantile MLD is the most severe form and starts 
at age 1-2, the juvenile form at 4-12 years. The adult form of the disease is character-
ized by a relatively late age of onset starting at 16 years of age or beyond. In very mild 
forms of the disease, patients may reach 60 years of age until the first symptoms occur. 
The course of all three forms of the disease is fatal. Patients with infantile MLD usually 
have the shortest life span (few years), whereas on average patients with the adult form 
of MLD pass away within 15 years after diagnosis. Although the first symptoms vary 
depending on the type of the disease, the end stage symptoms are similar for all forms: 
ataxia, blind- and deafness, dementia, muscular dystrophy, spastical paralysis and tetra-
plegia (Kolodny 1989). The course of the disease of a juvenile patient is depicted in 
Figure 2.2, A.  
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Figure 2.2: Metachromatic leukodystrophy (MLD). 
A)  Clinical course in a patient with juvenile MLD. As CNS pathology increases over time, 
patients develop ataxia, blindness, deafness, dementia, muscular dystrophy, spastical paral-
ysis and tetraplegia and ultimately die prematurely (modified after Kolodny 1989). 
B)  Alcian blue stainings in brains of 19 months old MLD mice (ASA-/-) in comparison to 
wildtype (ASA+/+) mice. Alcian blue stains sulfatide storage material, accumulating primari-
ly in the brain of ASA deficient mice, which is also observed in MLD patients (adapted 
from Wittke et al. 2004). 
C)  Demyelination in the brain of an animal model of MLD. Electron micrographs of the corpus 
callosum of mice heterozygous for ASA (no phenotype) and ASA deficient mice, addition-
ally carrying a transgene for overexpression of cerebroside-sulfotransferase (CST), respon-
sible for sulfatide production, in myelin producing cells. In contrast to ASA+/- mice, CST-
tg/ASA-/- mice show reduction of thicknesses of myelin sheaths indicative of demyelination. 
Scale bar represents 1 µm (modified after Ramakrishnan et al. 2007). 
 
The cause of the symptoms of MLD is the accumulation of 3-O-sulfogalactosyl-
cerebroside, or short sulfatide, and lysosulfatide (Blomqvist et al. 2011) (Figure 2.2, B). 
Sulfatide is one of the main lipid components of myelin (4-6%) (Eckhardt 2008). Mye-
lin is produced by oligodendrocytes in the CNS and by Schwann cells in the peripheral 
nervous system (PNS). Presence of myelin and so called myelin sheaths enable saltatory 
conduction of action potentials in neuronal axons and are indispensable for the signal 
transduction in the nervous system. Accumulation of sulfatide in oligodendrocytes and 
Schwann cells leads to demyelination in the CNS (Figure 2.2, C) and PNS and is re-
sponsible for the CNS symptoms of the disease. The molecular link between accumula-
tion of sulfatide and demyelination is still poorly understood. Besides in myelin-
producing cells, sulfatide storage also occurs in neurons, astroglia and macrophages 
(Eckhardt 2008). In a mouse model where sulfatide specifically accumulates in neurons, 
lethal seizures were observed after acoustical stimulation, indicating that sulfatide ac-
cumulation in neurons may contribute to the pathogenesis of MLD (Gieselmann and 
Krägeloh-Mann 2010; van Zyl et al. 2010).  
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Under physiological conditions, sulfatide is degraded by the lysosomal enzyme aryl-
sulfatase A (ASA). In case of MLD, ASA is deficient or inactive. Consequently sul-
fatide cannot be degraded, leading to its accumulation. Sulfatide hydrolysis further de-
pends on presence of the activator protein saposin B, extracting sulfatide from mem-
branes, rendering it accessible for ASA. Rare cases of activator-deficient MLD due to 
saposin B deficiency have been reported (Kuchar et al. 2009; Gieselmann and 
Krägeloh-Mann 2010). 
Like most LSDs, MLD is monogenic and autosomally recessively inherited. In contrast 
to other LSDs, the genotype roughly correlates with the severity of the disease. As a 
rule of thumb: the higher the residual ASA activity, the milder the progression of the 
disease. Many mutations of the ASA gene causing amino acid substitutions of the ASA 
polypeptide, for example G86D, Y201C and D255H, have been identified to lead to 
ASA instability in the endoplasmic reticulum, resulting in its degradation (Hermann et 
al. 2000; Poeppel et al. 2005). Patients homozygous for these mutations or mutations 
causing production of truncated, inactive ASA (‘null allele’) are commonly affected by 
the most severe (late infantile) form of MLD due to early accumulation of sulfatide. 
Homozygosity for mutations that lead to partially active ASA that passes the ERAD 
quality control system and reaches the lysosome, may cause juvenile MLD, depending 
on the residual ASA activity levels. Other juvenile MLD patients may be heterozygous 
for one ‘null allele’ and one, which results in a low level of active ASA or a defect of 
oligomerization in the lysosome (Gieselmann and Krägeloh-Mann 2010). A frequent 
mutation (P426L) is known to lead to failure in octamerization accompanied with accel-
erated degradation by cathepsin L in comparison to wildtype ASA. Patients homozy-
gous for these mutations have the least severe, adult form of MLD (von Bülow et al. 
2002). Humans with more than 10% of the physiological ASA-activity levels show no 
signs of the disease (Gieselmann et al. 1989; Gieselmann et al. 1991). 
2.5 Arylsulfatase A 
ASA, or cerebroside sulfatase (EC 3.1.6.8), consists of 507 amino acids including the 
endoplasmic reticulum-signal peptide (18 amino acids). In order to be able to bind and 
cleave off the sulfate of sulfatide, the cystein residue at position 69 needs to be oxidized 
to form formylglycine (3-oxoalanin). This modification is performed in the endoplasmic 
reticulum by action of the formylglycine-generating enzyme (FGE), otherwise known as 
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sulfatase-modifying factor 1 (SUMF1). If FGE is not functional, ASA and other sulfa-
tases lack activity, leading to so called multiple sulfatase deficiency, a LSD with symp-
tomatic features of MLD and mucoploysaccharidosis types II-IV and VI (Dierks et al. 
2009). 
ASA has three N-glycosylation sites (N158, N184, N350), all of them carry oligosac-
charides of the high mannose type. Statistically each molecule of ASA contains 3.4 ± 
0.08 phosphates. As no phosphorylation sites are known for the ASA polypeptide, these 
phosphates are attributed to M6P-residues (Schröder et al. 2010). Interestingly, only two 
(N158 and N350) of the three N-glycosylation sites are phosphorylated (Sommerlade et 
al. 1994). Therefore one of these sites carries two M6P residues. As described in chapter 
2.1, these M6P residues are necessary for recognition by the MPRs for directional 
transport to the lysosomes. 
ASA forms oligomers in a pH-dependent manner. At the neutral pH of the endoplasmic 
reticulum and Golgi, ASA dimerizes. Under acidic conditions in lysosomes, four ASA-
dimers are reported to form octamers. Clustering of eight molecules of ASA leads to 
shielding off of cathepsin L-binding sites, preventing rapid degradation by this lysoso-
mal papain-like protease (von Bülow et al. 2002). 
2.6 Therapeutic Approaches for Metachromatic 
Leukodystrophy 
For MLD, a LSD with severe CNS pathology, no curative therapy has been approved 
for clinical use. However, much data has been generated in preclinical and clinical stud-
ies for MLD treatment in the last decades. Cell-, gene- and enzyme replacement thera-
pies have been evaluated for MLD, but not substrate reduction or chaperone therapies. 
Traditional HSCT with healthy donor hematopoietic stem cells showed varying success 
in treatment of MLD. After treatment, a patient with juvenile MLD showed decelerated 
disease progression in comparison to an untreated sibling (Krägeloh-Mann et al. 2013). 
In four patients with adult MLD, HSCT even halted disease progression (Solders et al. 
2014). However, for late infantile MLD, HSCT only delayed neurological deterioration 
and death without providing curative treatment (Batzios and Zafeiriou 2011). 
A similar approach employing patients own hematopoietic stem cells was recently 
shown to lead to more success for patients with late infantile MLD. Hematopoietic stem 
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cells were harvested and transduced with a lentiviral vector encoding for functional 
ASA (ex vivo gene therapy). After infusion into the patient, these cells and their proge-
ny produced high amounts of ASA, leading to supranormal levels of ASA in the cere-
brospinal fluid. In contrast to untreated siblings of same genotype, the treated children 
showed no deterioration of their mental and physical condition (Biffi et al. 2013). 
The cell based therapies described here have three profound drawbacks: (1) Patients 
need to be treated before onset of the symptoms. As there is no screening of newborns 
for MLD, this treatment is only feasible for a minority of patients with known familial 
MLD occurrence. (2) Harvesting and infusion of hematopoietic stem cells is complicat-
ed, invasive and may have life-threatening consequences (e.g. graft-versus-host-
disease). (3) Lentiviral random integration into the genome, as performed by Biffi et al. 
2013, imposes the risk of tumor formation, in this case leukemia. 
In contrast, ERT is better controllable. In most cases of LSDs inactive enzymes are pro-
duced, therefore usually no immunogenic effects are observed when recombinantly pro-
duced enzyme is injected. Instead, the major obstacle for ERT is the BBB, prohibiting 
efficient brain delivery of systemically administered ASA. 
In mouse models of MLD, only high dose treatment carried out over a period of several 
weeks led to minor uptake of recombinant, human ASA by the brain (Matzner et al. 
2005; Matzner et al. 2009b). Consequently sulfatide storage was decreased as was visu-
alized by Alcian blue staining and measured quantitatively by lipid analyses. Treated 
mice performed significantly better in behavioral tests (e.g. rotarod performance). Based 
on these positive results, two clinical ERT studies have been conducted with late infan-
tile MLD patients, but only the results of one study have been reported so far. Although 
a reduction of sulfatide levels in the cerebrospinal fluid was observed in the reported 
study, treatment with up to 2.5 mg of ASA per kg body weight did not result in im-
provements of motor or cognitive function. Instead, 64% of treated patients showed 
adverse events (í Dali and Lund 2009). The results of the second study with higher dos-
es administered in shorter intervals (weekly instead of biweekly) will show whether 
high dose treatment benefits late infantile MLD patients. Importantly, this treatment 
may never become available for all patients, as it is very cost intensive. To reduce costs 
and adverse effects attributed to the high doses, ways to increase therapeutic efficiency 
of ASA need to be found by increasing transport across or by circumvention of the 
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BBB, as this barrier prevents uptake of intravenously injected ASA by the brain, the 
main target in MLD. 
To transport ASA into the brain, Stroobants et al. 2011 implanted so called ‘osmotic 
miniature pumps’, continuously supplying recombinant ASA into the right lateral ven-
tricle of ASA-/- mice over a period of four weeks. ASA was unevenly distributed 
throughout the brain as ASA activity and consequently reduction of sulfatide levels 
were only found in the forebrain and brain stem. Nevertheless, treated mice performed 
better in behavioral tests in comparison to their mock-treated littermates. Currently, a 
clinical trial (NCT01510028) with intrathecal injections of ASA is performed, but no 
results have been reported yet. Although neurosurgeons perform similar operations rou-
tinely, the risks accompanied with introduction of a needle into the ventricle or spinal 
cord of patients remain high. Moreover, not all areas of the brain can be reached by 
these methods.  
Recently, fusion proteins consisting of ASA and BBB-penetrating peptides have been 
generated (Böckenhoff et al. 2014). Of the five intravenously injected fusion proteins, 
only one, consisting of ASA and the Low-Density Lipoprotein (LDL) receptor binding 
domain of apolipoprotein E (apoE), was shown to lead to significantly elevated ASA 
levels in the brains of treated ASA-/- mice in comparison to controls treated with un-
modified ASA. Nevertheless, the effect size was relatively low; a 1.7-fold increase in 
brain levels and a 1.6-fold increase in therapeutic efficacy were reported. 
Although these two studies show promising results, further efforts have to be made in 
order to increase brain delivery of ASA without putting the patients at a risk beyond the 
pale. To that end strategies to overcome the BBB need to be pursued.  
2.7 The blood brain barrier 
The BBB serves to protect the brain from potentially harmful endogenous and exoge-
nous molecules of the blood, thereby sustaining the brain’s homeostasis. It is highly 
evolutionary conserved among vertebrates proving the importance of its function. The 
BBB primarily consists of endothelial cells lining the blood vessels in the brain, which 
are tightly connected to each other by means of so-called tight junctions. Pericytes and 
perivascular astrocyte endfeet further contribute to the BBB, forming a ‘second line of 
defence’ by building up a metabolic barrier (Abbott et al. 2006; Abbott et al. 2010). 
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In general, only small (< 500 Da), lipophilic substances as well as gases (CO2, O2) and 
water pass this barrier without restriction (Figure 2.3, a, b). Most other substances es-
sential to the brain, are shuttled across the BBB either via specific transporters (e.g. glu-
cose and amino acids, Figure 2.3, a) or actively by receptor mediated transcytosis (e.g. 
insulin, transferrin and apolipoproteins, Figure 2.3, d). Positively charged proteins (e.g. 
cationized albumins) are also able to cross the barrier by adsorptive transcytosis after 
ionic interaction with negatively charged cell surface binding sites (Figure 2.3, e) 
(Abbott et al. 2010). 
ATP binding cassette transporters, such as p-glycoprotein are expressed at the luminal 
membrane of brain capillary endothelial cells and further contribute to the efficiency of 
the BBB by actively returning (possibly) neurotoxic substances to the blood (Löscher 
and Potschka 2005). 
 
Figure 2.3: The blood brain barrier (BBB) - structure and endogenous transport mecha-
nisms. 
The BBB primarily consists of endothelial cells connected to each other by tight junctions. 
Some small water-soluble and lipophilic substances are able to traverse the BBB passively (a, 
b). Nutrients like glucose, amino acids, but also nucleosides are transported through the endo-
thelial cells via transport proteins (c). Larger molecules like proteins are recognized by recep-
tors on the endothelial cell surface and are actively transported via receptor mediated transcyto-
sis (d). The same process, without involvement of receptors, is reported to occur after unspecif-
ic, charge dependent adsorption of plasma proteins to the endothelial cell surface (e) (adapted 
from Abbott et al. 2006). 
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2.8 Transport of drugs across the blood brain barrier 
There are numerous diseases with CNS pathology necessitating transport of drugs 
across the BBB. One may distinguish between three basic approaches: (1) circumven-
tion of the BBB by direct infusion into the brain/cerebrospinal fluid, (2) systemic ad-
ministration of drugs in combination with a transient disruption of the BBB (induced by 
e.g. ultrasound or vasoactive compounds) and (3) systemic administration of drugs that 
are modified with, or attached to a brain targeting moiety, exploiting endogenous trans-
porting routes across the BBB (Chen and Liu 2012). The first two options are highly 
invasive, consequently imposing serious risks for treated patients and are disregarded 
here. Instead two strategies of the third option will be introduced in more detail. 
2.8.1 Polymeric nanoparticle mediated brain delivery of therapeutics 
Nanoparticles are spherical objects with a diameter of 1-1000 nm. Although nanoparti-
cles have been described as early as 1955, it was not until 1995 that the potential of pol-
ymeric nanoparticles to cross the BBB had been discovered and exploited for drug de-
livery (Kreuter et al. 1995). From thereon different kinds of materials and surface modi-
fications of nanoparticles have been identified to increase brain delivery of therapeutics 
in numerous studies. 
Several desirable criteria for brain delivery of nanoparticles have been ordained (Olivier 
2005). First of all, nanoparticles should be biodegradable and non-toxic. Polymeric na-
noparticles consisting of poly(butyl cyanoacrylate) (PBCA), poly(lactic acid) (PLA) or 
poly(lactic-co-glycolic acid) (PLGA) core materials are biodegradable and have been 
successfully used to this end. PLA and PLGA have been approved by the FDA for clin-
ical use (Duncanson et al. 2007). Furthermore polymers of natural origin, e.g. chitosan 
and human serum albumin (HSA) fulfill these criteria (Kumari et al. 2010).  
Another criterion for in vivo studies is the stability of the nanoparticles in the blood and 
their clearance. It is known that uncoated nanoparticles are rapidly cleared from the 
blood stream by monocytes and macrophages of the mononuclear phagocyte system 
(MPS) after their opsonization (Owens and Peppas 2006). These cells are primarily 
found in the lymph nodes, spleen, liver and lung. The surface properties of nanoparti-
cles play a pivotal role in recognition by the MPS and consequently their overall biodis-
tribution. Surface charged nanoparticles have been reported to be more prone to uptake 
by the MPS than non-charged or weakly negatively charged nanoparticles in vitro 
18  2 Introduction 
(Roser et al. 1998; Zahr et al. 2006). Further reduction of MPS recognition was first 
achieved by masking the nanoparticle’s surface with polyethylene-glycol (PEG) and 
then with surfactants. These so called ‘stealth nanoparticles’, were reported to have 
longer blood circulation times and reduced tissue accumulation at the sites of the MPS. 
These effects have been explained by sterical hindrance, thereby decreasing adsorption 
of opsonic proteins (Andrieux and Couvreur 2009).  
Besides preventing rapid clearance by the MPS, surfactant coating has been shown to 
increase targeting to specific organs, especially the brain in experiments using an anal-
gesic peptide, dalargin, which is physiologically unable to pass the BBB. After dalargin-
loaded PBCA-nanoparticles were surfactant coated with polysorbates, dalargin delivery 
to the brain was suggested by measuring increased pain tolerance (Kreuter et al. 1997). 
It was thereon hypothesized that surfactant coating leads to recruitment of apolipopro-
teins, which indeed was confirmed in vitro (Petri et al. 2007). These nanoparticle-bound 
apolipoproteins are likely recognized by Low Density Lipoprotein (LDL)- or Scaven-
ger-Receptors present on the endothelial cells of the BBB, leading to receptor-mediated 
transcytosis (Figure 2.4 A). This theory is supported by the observation that in compari-
son to wildtype mice, apolipoprotein E (apoE) knockout mice are less pain resistant 
after intravenous injections of above mentioned dalargin nanoparticle formulation 
(Kreuter 2001). Independent in vivo studies using the same nanoparticle system (Figure 
2.4, B) or albumin nanoparticles, surface decorated with covalently bound apoE con-
firmed this hypothesis (Michaelis et al. 2006; Zensi et al. 2009; Koffie et al. 2011). 
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Figure 2.4: Proposed transport mechanism of surfactant coated, polymeric nanoparticles 
across the BBB and proof for apolipoprotein E involvement. 
A)  Surfactant coating of (drug loaded) nanoparticles is thought to lead to recruitment of 
apolipoproteins of the blood, enabling their LDL-/Scavenger-Receptor mediated transcyto-
sis at the endothelial cells of the BBB.  
B)  Hoechst staining in brains of apolipoprotein deficient mice (APOE-/-) mice that received 
intravenous injections of Hoechst-loaded PBCA-nanoparticles without and after preincuba-
tion with apoE (‘Hoechst NP + apoE’). Hoechst stains DNA. This confirms that brain deliv-
ery of nanoparticles depends on the presence of apolipoproteins (Koffie et al. 2011). 
 
A wide range of therapeutics has been bound to nanoparticles for brain delivery 
(Wohlfart et al. 2011). These include analgesic drugs as described above (e.g. dalargin 
and loperamide), anticancer drugs like doxorubicin, methothrexate and campthotecin, 
but also peptide hormones (vasoactive intestinal peptide) and growth factors (nerve 
growth factor, NGF). This shows that not only small molecules, but also proteins can be 
transported into the brain employing nanoparticles. 
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2.8.2 Elongation of the blood circulation times to increase brain delivery 
of therapeutics 
In 2008, Grubb et al. showed increased brain delivery of β-glucuronidase, the lysosomal 
enzyme deficient in mucopolysaccharidosis VII (Sly syndrome), by increasing its blood 
circulation time (Grubb et al. 2008). This was achieved by chemical modification of 
M6P-residues of β-glucuronidase, thereby abolishing recognition by MPRs of peripher-
al cells. This procedure resulted in an increase of its plasma half life time from 11.7 
minutes to 18 hours. Notably, uptake by the brain increased 5.7-fold in comparison to 
mice treated with non-modified enzyme. The authors offer three possible explanations 
for enhanced brain delivery of modified enzyme: (1) Brain endothelial cellular uptake 
of modified enzyme by fluid phase pinocytosis. Although the rate of this unspecific 
uptake is slow in comparison to receptor mediated endocytosis, it may be favored by the 
relatively high concentrations and long circulation times of the modified enzyme. (2) 
Modified, but not unmodified enzyme may be taken up by a novel receptor at the BBB. 
(3) Delivery into the brain via the ‘extracellular route’, which has been previously pro-
posed for delivery of small amounts of albumin, erythropoietin and antibodies (Banks 
2004). 
These findings were confirmed for another lysosomal enzyme, sulfamidase, the enzyme 
deficient in mucopolysaccharidosis IIIA (Rozaklis et al. 2011). Chemical modification 
also led to an increase in plasma half life time and consequently to increased brain de-
livery in comparison to unmodified enzyme. Surprisingly and in contrast to the findings 
of Grubb et al. (2008), no reduction in substrate accumulation in brain cells of treated 
mucopolysaccharidosis IIA mice was observed after weekly treatment over four weeks 
with modified enzyme. This observation may be explained by a failure of modified en-
zyme uptake by brain cells, as MPR-mediated endocytosis is not possible and needs to 
take place by unspecific pinocytosis. Indeed, the authors did not find sulfamidase stain-
ing in neuronal and glial cells, but only in endothelial cells, the meninges and the cho-
roid plexus.  
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2.9 Aim of this study 
The aim of this thesis is to develop new therapeutic options for metachromatic leu-
kodystrophy.  
To use nanoparticles for ERT of ASA, five different strategies to combine ASA and 
nanoparticles are pursued. More precisely, incorporation, adsorption, covalent attach-
ment and two high-affinity binding methods of ASA to nanoparticles are investigated 
with respect to their efficiency of binding, their stability in serum and their potential to 
increase brain delivery in vivo. In the course of these experiments, four different core 
materials are used: PBCA, PLA, PLGA and HSA. One of the high-affinity methods 
involves the use of a MPR300 receptor fragment, which is covalently bound to nanopar-
ticles to then bind ASA with high affinity. This receptor fragment, consisting of the 
domain 9 of the MPR300, is expressed, purified and characterized with respect to its 
potential to bind ASA and to decrease MPR-dependent uptake by peripheral cells in 
vitro. 
In the second part of this thesis, the goal is to find ASA inhibitors for future use as 
pharmacological chaperones for misfolded ASA (chaperone therapy) and/or for estab-
lishment of a cell culture model of MLD. To that end, a suitable ASA activity assay is 
established in order to perform high-throughput screenings. Potential inhibitors are 
characterized concerning their inhibitory potential (IC50), their type of inhibition, their 
specificity towards ASA and their stability over time.  
 
22  3 Materials 
3 Materials 
3.1 Chemicals 
All chemicals were of analytical grade and purchased from Sigma Aldrich, Invitrogen, 
Roth-Chemicals, Merck, Pierce / Thermo-Scientific. Metamizole, primaquine and sul-
fathiourea were a gift by the working group of Prof. Müller, Pharmazentrum, University 
of Bonn.  
Chemical Manufacturer Location Catalogue num-
ber 
‘Compound A’: 1-{[6-(1,5-
dimethyl-1H-pyrazol-4-yl)-3-
methyl-1-propyl-1H-
pyrazolo[3,4-b]pyridin-4-
yl]carbonyl}-4-[(1-ethyl-1H-
pyrazol-4-
yl)methyl]piperazine 
Ambinter Orléans, France Amb10591193 
2-iminothiolane Thermo Scientific Waltham, MA, 
USA 
26101 
4-nitrocatechol sulfate Sigma Aldrich Schnelldorf, 
Germany 
N7251 
Cystamine HCl Sigma Aldrich Schnelldorf, 
Germany 
30050-25G-F 
EDC Pierce / Thermo 
Scientific 
Rockford, IL, 
USA 
22980 
Maleimide activated neu-
travidin 
Pierce / Thermo 
Scientific 
Rockford, IL, 
USA 
31007 
Maleimide-PEG2-Biotin Thermo Scientific Waltham, MA, 
USA 
21902 
Malhex-NH-PEG-O-C3H6-
CONHS, 5000 Da 
RAPP Polymere Tübingen, Ger-
many 
135000-65-35 
NHS-PEG12-maleimide Thermo Scientific Waltham, MA, 
USA 
22112 
Poloxamer 188 (Pluronic-F 
68) 
Sigma Aldrich Schnelldorf, 
Germany 
P5556 
Polysorbate 80 (Tween 80) Sigma Aldrich Schnelldorf, 
Germany 
P1754 
Streptavidin agarose, high 
capacity 
Thermo Scientific Waltham, MA, 
USA 
20357 
TCEP Roth Chemicals Karlsruhe, Ger-
many 
HN95.1 
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Compounds identified by  
Virtual Screening 
Enamine Monmouth 
Junction, 
NJ, USA 
Z1109095852 
Enamine EN300-65803 
Enamine EN300-30445 
Enamine Z808676678 
Sigma Aldrich Schnelldorf, 
Germany 
03844749 
Sigma Aldrich 01725406 
Sigma Aldrich 03130439 
Sigma Aldrich 04831674 
3.2 Enzymes 
Enzyme Name / batch Manufacturer Location 
Arylsulfatase A li310 Zymenex Hillerod, Denmark 
Arylsulfatase B Naglazyme® BioMarin London, UK 
DNA restriction enzymes PfoI, Eco 47III, 
PasI, XbaI, PstI, 
SacI, SacII 
Thermo Scientific Waltham, MA, USA 
Endoglycosidase EndoHf New Englad Biolabs Ipswich, MA, USA 
3.3 Nanoparticle preparations 
Polymer Batch # Stabilizer Mean diameter [nm] zeta-potential 
HSA (n/a) n/a 195.1 -42.4 
PBCA 160511 Dextran70000 186.1 -8.0 
PLA 559 HSA 182.0 n/a 
992 HSA 142.7 -28.5 
1027 HSA delipid. 309.2 -23.0 
1166 HSA delipid. 174.0 -22.4 
1226 HSA 115.5 -19.6 
PLGA 555 HSA 219.0 n/a 
1235 PVA 200.0 n/a 
1236 HSA delipid. n/a n/a 
1290 PVA 299.9 -3.2 
1309 PVA 137.0 -8.3 
1310 PVA 75.0 -6.1 
1311 HSA delipid. 191.0 -19.5 
1312 HSA delipid. 178.0 -27.0 
1380 HSA delipid. 357.2 12.6 
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1437 PVA 148.4 -10.4 
1452 PVA 196.3 -15.1 
1507 PVA 173.4 -19.7 
1561 HSA 100.7 -34.0 
LGFG200 n/a 227.4 n/a 
Amine mod. PLGA LGFG200N n/a 227.4 n/a 
 
Human serum albumin (HSA) and poly(n-butyl-cyanoacrylate) (PBCA) nanoparticles 
were kindly provided by the working group of Prof. Dr. J. Kreuter, Institute for Phar-
maceutical Technology, University of Frankfurt a.M., Germany. Poly(lactic acid) and 
poly(lactic-co-glycolic acid) nanoparticles (PLA and PLGA, respectively) were provid-
ed by Dr. S. Gelperina, Nanosystems Ltd., Moscow, Russia. Amine modified PLGA 
(LGFG200N) and another unmodified PLGA nanoparticle batch (LGFG200) were pur-
chased from Phosphorex Inc., Hopkinton, MA, USA.  
3.4 Cells 
Cell line / strain Species Origin 
Embryonic fibroblasts  Mus musculus Own preparation from C57BL/6 mice 
XL-1 blue Escherichia coli Bullock, 1987 
X-33 Pichia pastoris Invitrogen 
3.5 Mice 
In in vivo studies murine ASA deficient (ASA-/-) mice were used. This mouse model of 
MLD has been first described by Hess et al. 1996. 
3.6 Primers 
Oligonucleotides were synthesized by MWG Biotech, Ebersberg, Germany. 
Primer Sequence Size [bp] 
A AAGCTGCAGTTGTCAGAGTGGAAGGGGAC 29 
B TTCTAGAGGGCAGGCATACTGCGTTC 26 
C  GACTGGTTCCAATTGACAAGC 21 
D  GCAAATGGCATTCTGACATCC 21 
E AGCCCCTGGGCCTCCAGGACACCATCG 27 
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F TTCTAGAGGGCAGGCATACTGCGTTC 26 
G AAGCTGCAGTTGTCAGAGTGGAAGGGGAC 29 
H GTGCCGCGGTCACAGTAGAAGAAGATGGCTGTGGAC-
CGCTGATAAACCTTATGGCAAGTGTCCCCCCCCGTGAACTG-
CATTTTTAAC 
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3.7 Instruments 
Instrument Model Manufacturer 
Analytical balance CP124S-0CE Sartorius 
Autoclave Varioklav® EC  Thermo 
Balance PC 4400 Mettler 
Cell culture microscope Axio Vert.A1 Zeiss 
Centrifuges 5418 Eppendorf 
 
5810R Eppendorf 
 
X-15R Beckman Coulter 
 
Function Line Labofuge 400e Heraeus / Thermo 
Cryopreservation system MVE TEC 3000 CHART 
Disperser Ultra-Turrax T25  IKA 
Documentation system for 
agarose gels 
BioDoc Analyze Biometra 
Documentation system for 
Western blots 
Fusion Solo Vilber Lourmat 
Electrophoresis equipment for 
agarose gels 
PerfectBlue gel system Peqlab 
Electrophoresis equipment for 
SDS-PAGE 
Mini-PROTEAN® Tetra Cell  Bio-Rad 
Electroporation device GENE PULSER® II  Bio-Rad 
Electrotransfer system PerfectBlue Semi-Dry Electro 
Blotter 
Peqlab 
Flat bed scanner V700 Photo Epson 
Heat plate Hot Plate 062 Labotect 
Heating block TH 26 HLC 
Incubator  3121 Heraeus / Thermo 
Incubator for eukaryotic cells 
 
Forma Scientific 
Laminar flow cabinet LaminAir® HB 2448 Heraeus / Thermo 
Magnetic stirrer ARE Heating Magnetic stirrer VELP – Scientifica 
Mass spectrometer HCT Ultra – PTM discovery 
system 
Bruker Daltonics 
Micropipettes Research series Eppendorf 
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Microplate reader GENios Tecan 
Microplate washer Hydro Flex Tecan 
Multi-channel micropipette Transferpette S-12 Brand 
Peristaltic pump Peristaltic Pump P-1 Pharmacia Fine Chemicals 
pH electrode pH Electrode BlueLine 18 pH Schott 
pH meter pH-Meter 761 calimatic Knick 
Photometer DU 640 Beckman 
Power Supply PowerPac 300 Bio-Rad 
Shaking device for cultivation 
of bacteria 
Controlled Environment In-
cubator Shaker  
New Brunswick Scientific  
Spectrophotometer NanoDrop 2000 Thermo 
Thermal cycler T3 Thermalcycler Biometra 
Thermal shaker ThermoMixer comfort Eppendorf 
Ultrasonic bath 1210 Branson 
Ultrasonic disperser UP 50 H Hielscher 
Vacuum pump n/a HLC 
Vortex mixer VORTEX Genius 3 IKA 
Water bath  1083 GFL 
Water purification system NANOpure Barstead 
3.8 Software 
GraphPad Prism 6; by GraphPad Software, USA 
ImageJ 1.38x; by Wayne Rasband, National Institute of Health, USA 
3.9 Ready to use reaction kits 
Kit Manufacturer Catalogue number 
PureLink® Gel Extraction Kit Invitrogen K2100-12 
PureLink® HiPure Plasmid Midiprep Kit Invitrogen K2100-04 
QIAprep Spin Miniprep Kit Qiagen 27106 
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4 Methods 
4.1 Standard molecular biology techniques 
4.1.1 Polymerase Chain Reaction  
To specifically amplify deoxyribonucleic acid (DNA) sequences, a polymerase chain 
reaction (PCR) was performed. Following components were mixed in PCR vials: 
 
10x Taq DNA- polymerase buffer 5 µL 
2 mM dNTP mix 5 µL 
25 mM MgCl2 2-4 µL 
Template DNA 1 ng 
Primer 1 100 pmol 
Primer 2 100 pmol 
Taq DNA-polymerase 2.5 Units 
Ultrapure H2O ad 50 µL 
 
Template DNA was amplified in a thermocycler using the following program. The pri-
mer annealing temperatures were adjusted to be 2-10°C below their melting tempera-
tures (TM): 
 
Step Time Temperature 
 
Initial denaturation 5 min 95°C 
 
Denaturation 0.5 min 95°C 
30 cycles Primer annealing 2 min Variable 
Elongation 1-2 min 72°C 
Final elongation 7 min 72°C 
 
Storage ∞ 4°C 
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4.1.2 Digestion of DNA using restriction endonucleases  
DNA was specifically cleaved by use of restriction endonucleases. To that end 1 µg of 
DNA was incubated with 10 units of restriction endonuclease(s) for 1 h at 37°C in cor-
respondent buffer. In case of double digests the reaction buffer was chosen according to 
the manufacturer’s recommendations. Digested DNA was separated according to its size 
by agarose gel electrophoresis to monitor success or to purify the DNA fragment of in-
terest.  
4.1.3 Agarose gel electrophoresis 
The following buffers were used for agarose gel electrophoresis: 
 
50x Tris-acetate-EDTA buffer  
(TAE-buffer); pH 8.0 
2.5 M Tris-HCl 
100 mM  EDTA 
1 M NaAc (NaC2H3O2) 
Loading buffer; pH 7.0 0.25 mM Bromphenole blue 
30% Glycerole 
10 mM Tris-HCl 
 
Agarose gels were cast by boiling a 1-2% agarose suspension in 1x TAE-buffer until 
dissolved. After addition of ethidium bromide (final conc. 0.7 µg/mL), the solution was 
poured into a casket, a comb was inserted and the solution was allowed to polymerize, 
forming a gel. Gels were loaded with DNA in loading buffer and electrophoresis was 
performed in 1x TAE-buffer applying 80-120 V. Ethidium bromide, intercalated into 
DNA was visualized by ultraviolet (UV)-light using the agarose documentation system.  
4.1.4 DNA Extraction and purification from agarose gels 
The DNA fragment of interest was excised from the agarose gel using a scalpel and low 
intensity UV-light to visualize ethidium bromide stained DNA. DNA in gel slices was 
then purified using the PureLink® Gel Extraction Kit.  
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4.1.5 Ligation and transformation of E. coli 
DNA fragments, e.g. generated by PCR, and target vectors were digested with the same 
restriction endonucleases. 20 ng of vector DNA were incubated for 1 h at RT with a 3-
4-fold excess of insert in presence of one unit of T4 DNA-ligase (Thermo Scientfic). 
Success of the procedure was confirmed by agarose gel electrophoresis followed by 
transformation of ligated vectors into E. coli cells. E. coli (strain XL-1 blue) were made 
chemical competent according as described previously (Sambrook et al. 1989). 10 ng of 
DNA were incubated at 0°C for 30 min per E. coli aliquot (still partially frozen). After a 
heat shock (42°C for 45 sec) and further incubation at 0°C for 5 min, 1 mL of LB-
medium was added. After an incubation period (1 h, 37°C, 200 rpm), 10-100 µL of the 
mixture was plated on LB-plates containing antibiotics for selection of positive clones. 
After culture at 37°C o.n., colonies were picked and liquid culture was performed. 
4.1.6 Phenol/chloroform purification and DNA precipitation 
To purify DNA and remove proteins, phenol/chloroform precipitation was performed. 
400 µL of DNA in water were mixed with 400 µL of phenol/chloroform/isoamylalcohol 
(25:24:1) for 30 sec. After centrifugation (15,000 g, 5 min) the upper aqueous phase 
was removed and mixed with an equal volume of chloroform. This step was repeated 
and the upper phase was mixed with an equal volume of isopropanol and centrifuged for 
5 min at 15,000 g to precipitate DNA. The pellet was washed with 300 µL of 70% etha-
nol, centrifuged and the supernatant discarded. After air-drying the pellet, DNA was 
resuspended in 10-20 µL of ultrapure H2O.  
4.2 Standard protein-biochemistry techniques 
4.2.1 Determination of protein concentrations 
The here employed Biorad DC assay is based on the Lowry reaction and was performed 
according to the manufacturers protocol in 96-well plates. In brief working reagent A’ 
was prepared by addition of 20 µL of reagent S per mL of reagent A. 5 µL of sample or 
bovine serum albumin (BSA) standard were pipetted into each well. Sequentially, 25 µL 
of working reagent A’ and 200 µL of reagent B were added and the plate was gently 
shaken by using a Vortex shaker. After incubation for 15 minutes the absorbance at 
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750 nm was measured using a microplate reader. Protein amounts in samples were de-
termined by calculation from the standard curve. 
4.2.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Following solutions and volumes were used for casting of two gels using the BioRad 
Mini-PROTEAN® Tetra Cell Casting Stand: 
 
 
Resolving gel 
 
Stacking gel 
 
 
Volume [mL] Final conc. Volume [mL] Final conc. 
Water 4.79 - 3.02 - 
40% acrylamide 2.5 10% 0.625 5% 
1.5 M Tris-HCL, pH 6.8 - - 1.25 375 mM 
1.5 M Tris-HCL, pH 8.8 2.5 375 mM - - 
10% SDS 0.1 0.1% 0.05 0.1% 
10% APS 0.1 0.1% 0.05 0.1% 
TEMED 0.01 0.1% 0.005 0.1% 
 
After boiling in Lämmli-buffer (95°C, 5 min), the sample was centrifuged. Up to 20 µL 
of supernatant or, in one lane, 2-3 µL of molecular weight protein standard (Fermentas, 
PageRuler; #SM0671) were loaded onto the gel, into the pockets. Gels were run at 
200 V in BioRad Mini-Protean Tetra Cell devices until the loading front reached the 
bottom of the gel. The recipes used for running gel and 4x Lämmli buffers were: 
 
4x Lämmli buffer 4% (v/v) β-mercaptoethanol 
8% (w/v) SDS  
40% (v/v) Glycerol 
4% (w/v) Bromphenol blue 
240 mM Tris-HCl  
10x SDS-running buffer, pH 8.6 1.9 M Glycine 
1% SDS SDS 
250 mM  Tris-HCl 
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4.2.3 Coomassie staining of polyacrylamide gels  
After SDS-PAGE, gels were washed twice for 10-20 min in water, and then stained for 
1h-o.n. in PageBlue Coomassie staining solution under gentle agitation. After staining, 
gels were washed several times with water until background staining was minimal. 
4.2.4 Semi-dry Western Blot 
A stack of Whatman paper, nitrocellulose membrane (pore size 0.1 µM), SDS-PAGE-
gel and again Whatman paper was assembled on a PerfectBlue Semi-Dry Electro Blot-
ter (peqlab). All components were pre-soaked in Western blot transfer buffer: 
 
Western blot transfer buffer 39 mM  Glycine 
0.037% (w/v) SDS 
20% (v/v) Methanol 
48 mM Tris-HCl 
 
The transfer was performed at 0.15 A, for 50 min per gel. Then the nitrocellulose mem-
brane was transferred into a 50 mL reaction tube. The following steps were performed 
to specifically visualize the band (protein) of interest. 
 
Step Solution / antibody Concentration Incubation param-
eters 
Blocking Dried milk powder 5% (w/v) in washing sol. 1h, RT or o.n., 4°C 
Primary antibody Anti-ASA antiserum 
(‘BE#3’), rabbit 
Anti-MPR-fragment 
antiserum, rabbit 
1:10,000 in blocking sol. 
 
1:1,000 in blocking sol. 
2h, RT or o.n., 4°C 
Washing TBS-T 0.05% Tween 20 in TBS 3-4x, 5 min  
Secondary anti-
body 
Peroxidase conjugat-
ed goat anti-rabbit 
1:20,000 in washing sol. 1h, RT 
Washing TBS-T 0.05% Tween 20 in TBS 3-4x, 5 min  
Development ECL-solution 
(Pierce) 
 
1 min, RT 
 
The nitrocellulose membrane was developed using the Western blot documentation sys-
tem.  
32  4 Methods 
4.2.5 Enzymatic deglycosylation of proteins using Endo Hf 
This method was performed using Endo Hf (New England Biolabs, #P0703S) according 
to the manufacturer’s protocol. 3 µg of protein were diluted in 10 µL containing 1 µL of 
10x Glycoprotein Denaturing Buffer. The solution was incubated at 100°C for 10 
minutes. Then 2 µL of 10x G5 Reaction Buffer, 2 µL of Endo Hf (2,000 Units) and 8 µL 
of water were added (20 µL). After incubation at 37°C for 1 hour, 15 µL of this solution 
were incubated with 5 µL of 4x Lämmli buffer and incubated for 5 minutes at 100°C 
and then loaded onto a 10% SDS-PAGE (2.25 µg of glycoprotein). After electrophore-
sis, the gel was Coomassie stained. As controls samples were treated the same, but wa-
ter was added instead of Endo Hf solution.  
4.2.6 Protein purification by affinity chromatography 
Affinity purification of His-tagged proteins from culture supernatants was performed by 
gravity flow using a 1 mL Protino nickel-nitrilotriacetic acid (Ni-NTA) column (Ma-
cherey & Nagel). All buffers as well as the column itself was stored and used at 4°C. 
The following buffers were used: 
 
Loading solution 100 mM NiSO4 (x 6 H2O) 
Equilibration buffer, pH 8.0 50 mM NaH2PO4 (x 2 H2O) 
300 mM NaCl 
20 mM Imidazole 
Elution buffer, pH 8.0 50 mM NaH2PO4 (x 2 H2O) 
300 mM NaCl 
500 mM Imidazole 
50 mM EDTA 
 
All solutions were sterile filtered (0.2 µm). The pH of cell culture supernatants was ad-
justed to pH 7-8 followed by their centrifugation (1,750 g, 10 minutes, 4°C). The super-
natant was sterile filtered (0.2 µm). 
The Ni-NTA column was regenerated by sequentially applying 10, 5, 10 and 10 mL of 
water, loading buffer, water and equilibration buffer, respectively. Then up to 1 L of the 
particle free protein solution was applied overnight, without letting the column drain. 
After washing with 15 mL equilibration buffer, bound His-tagged proteins were eluted 
4 Methods 33 
using 5 mL of elution buffer; 1 mL elution fractions were collected. The column was 
washed with 10 mL elution buffer, capped and short term stored at 4°C. Protein concen-
trations in each elution fraction were estimated using the Biorad DC assay. Elution frac-
tions containing the highest protein concentrations were pooled and dialyzed three times 
against 2 L of TBS at 4°C for 4-18 hours using dialysis tubing (Servapor, # 44139; 
MWCO 12-14 kDa). 
Success of the protein purification was analyzed by performing Western blot of same 
volume fractions of cell culture supernatant (before purification), flow through, wash 
before elution and pooled elution fractions. If the protein of interest was still present in 
the flow through fraction, purification was repeated. 
4.3 Cell culture techniques  
4.3.1 Culture conditions 
 
Complete growth medium 90% DMEM Invitrogen, #21969-035 
10% FCS Invitrogen, #10270 
2 mM L-glutamine Invitrogen, #25030-024 
100 U/mL Penicillin Invitrogen, #15140 
100 µg/mL Streptomycin Invitrogen, #15140 
 
Mouse embryonic fibroblasts (MEFs) were cultured in complete growth medium in an 
incubator at 37°C and 5% CO2 at 100% air humidity. Before reaching confluence, cells 
were washed with warm PBS and detached by addition of 0.05 % trypsin (Invitrogen, 
#25300054). After 2-4 minutes of incubation in the incubator, cells were harvested and 
transferred into a conical centrifuge tube. After centrifugation at 1,000 g for 5 min, the 
supernatant was removed and the cells were resuspended in 5-10 mL of growth medi-
um. For sustaining culture in 10 cm dishes, cells were split 1:5. For culture in 12-well 
plates, cells were split 1:10 and 1 mL of the cell suspension was added per well.  
4.3.2 Cryopreservation 
Cells were cultured to confluence on 10 cm dishes. After washing with warm PBS 
(37°C), 0.05% trypsin was added to detach cells. Cells were harvested and centrifuged 
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for 5 min at 1,000 g. The supernatant was removed and cells were resuspended in 5 mL 
of cryopreservation medium (normal growth medium supplemented with 10% FCS and 
10% dimethyl sulfoxide - DMSO). Cell suspensions were transferred into multiple cry-
opreservation vials and gradually frozen to -80°C in a styrofoam box. After one day, 
cryovials were transferred into gaseous phase nitrogen tanks. 
To revitalize cells, cryovials were quickly thawed at 37°C and transferred to the bottom 
of a conical centrifuge tube filled with 10 mL ice-cold growth medium. After inverting 
the tube the cell suspension was centrifuged at 1,000 g for 5 min and the supernatant 
was removed. Cells were resuspended in 10 mL of warm growth medium and seeded 
onto a 10 cm dish. 
4.3.3 Endocytosis experiments  
 
Acidic washing solution (pH 3.0) 50 mM Glycine 
150 mM NaCl 
Lysis buffer (pH 8.0) 1%  Trition X-100 
20 mM  Tris-HCl 
50 mM NaCl 
5 mM EDTA 
 
After 30 minutes of coincubation in complete growth medium supplemented with 10 
mM HEPES at pH 7.0 at 37°C, ASA and the MPR300 dom 9 were added to confluent 
MEF cells in 12-well plates (0.5 mL per well). 2.5 µg/mL of ASA were coincubated 
with equimolar amounts (0.88 µg/mL) or a tenfold excess (8.8 µg/mL) of the MPR300 
dom9. After 24 hours of incubation, the supernatant was removed; cells were washed 
with prewarmed PBS (37°C) and then with 0.5 mL of acidic washing solution for 3 min 
at 37°C to remove unspecifically bound ASA from cell surfaces and plastic material. 
200 µL of lysis buffer were added per well and cells were detached from the plastic 
surface using a cell scraper and by rigorous pipetting. The suspension was transferred 
into a new reaction vial, vortex-mixed, treated by ultrasound in an ultrasonic bath (5 
min) and vortex-mixed again to lyse the cells. Cell fragments were removed by centrif-
ugation (15,000 g, 5 min), the supernatant transferred into a new reaction vial and stored 
at -20°C for further analyses. 
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4.4 Cloning and expression of MPR300 domain 9 constructs 
The Pichia pastoris expression vector pPICZα-B by Invitrogen was used. Cloning and 
expression in P. pastoris were performed according to the manufacturer’s manual. All 
buffer- and solution-recipes are provided in the manual.  
4.4.1 Cloning and in vitro mutagenesis 
The nucleotide sequence of the domain 9 of the MPR300 was amplified by PCR using 
the primers A and B (material, table 2) and the human MPR300 gene (provided by Prof. 
Pohlmann, Münster University) as template. Both the PCR product as well as the 
pPICZα-B were digested using the restriction enzymes PstI and XbaI. After ligation of 
the insert into the vector, competent E. coli (strain XL-1) were transformed by heat 
shock and Zeocin resistant clones were selected and propagated. After purification of 
plasmid DNA using the QIAprep Spin Miniprep Kit, the clones carrying the correct 
insert were identified by analytical restriction enzyme digest. Correct clones were prop-
agated and plasmid DNA was isolated by using the PureLink HiPure Plasmid Midiprep 
Kit. The nucleotide sequence was confirmed by sequencing (GATC Biotech AG, Kon-
stanz, Germany) using the sequencing primers C and D.  
The vector containing the insert (named pPICZαB_MPR300 dom9) was used as a tem-
plate for mutagenesis PCR using either the primer pair E & F, G & H or E & H to insert 
(an) amino acid substitution(s) at position 28 (N28Q), 94 (N94Q) or 28 & 94 (N28Q & 
N94Q), respectively. Each amplification product was cloned into the pJET vector, prop-
agated in E. coli in presence of ampicillin and purified using the QIAprep Spin Mini-
prep Kit. Success of the insertion into pJET and the mutations were monitored by ana-
lytical restriction enzyme digest using PfoI, AfeI or both, respectively. Both the pJET 
and the pPICZαB_MPR300 dom9 were linearized with two identical restriction en-
zymes each:  
N28Q:    PasI and XbaI  
N94Q:    PstI and SacII 
N28Q & N94Q: PasI and SacII 
After purification of the insert using the PureLink Gel Extraction Kit, ligation into the 
target vector was performed. Competent E. coli were transformed and propagated in 
presence of Zeocin (Invitrogen). After purification of the plasmid DNA using the QI-
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Aprep Spin Miniprep Kit, positive clones were identified by analytical restriction en-
zyme digest using PfoI, AfeI or both, respectively. Positive clones were propagated fur-
ther and their plasmid DNA was extracted and purified using the PureLink HiPure 
Plasmid Midiprep Kit. The nucleotide sequence was confirmed by sequencing (GATC 
Biotech AG, Konstanz, Germany) using the sequencing primers C and D. 
4.4.2 Transformation of Pichia pastoris  
Wildtype (wt) P. pastoris cells (strain X33) were grown overnight, then made electro-
competent (manufacturer’s protocol) and used on the same day. 80 µL of electrocompe-
tent P. pastoris cells were mixed with 5-10 µg of SacI-linearized and by phe-
nol/chloroform purified pPICZαB-vector DNA in electroporation cuvette at 0°C. Elec-
troporation was performed by applying 1 kV at 1 Ω and 25 µF using the Gene Pulser II 
(Biorad). The time constants were 11-17 msec. Further steps were performed according 
to the manufacturer’s protocol.  
4.4.3 Expression of pPICZα-B constructs in P. pastoris 
After selection, 10 Zeocin resistant clones were picked and cultured in YPD-medium 
containing Zeocin overnight at 30°C. These liquid cultures were used for cryopreserva-
tion (glycerol stock, -80°C) and the inoculation of a 10 mL BMMY culture. After three 
days (50 µL of methanol added daily), supernatants were harvested and screened for 
expression of the myc-tagged proteins by Western blot. 
Large scale expression was performed using best producing clones from cryocon-
servates following the manufacturer’s protocol.  
4.5 Techniques involving nanoparticles 
4.5.1 Determination of ASA activity after incubation in solvents 
5 µg/mL ASA were incubated in different solutions and organic solvents used for 
polymerization of nanoparticles, namely ehthylacetate, chloroform, dichlorethan, and an 
aqueous solution of 1% (w/v) dextran and 10 mM HCl. As control ASA was incubated 
in the same solution without dextran and in 1% (w/v) BSA in TBS. 1 µL of ASA solu-
tion (0.5 mg/mL) and 99 µL of said solvents or solution were mixed and incubated for 
2.5 hours at room temperature. Then, 2 µL of each sample was used in the standard 
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ASA-activity determination assay in 96-well plates using its artificial substrate 4-
nitrocatechol sulfate. The measured absorption values were normalized on the BSA in 
TBS control. 
4.5.2 Unspecific, adsorptive binding of ASA to nanoparticles 
Nanoparticles provided by our collaboration partners were freeze dried. For the follow-
ing experiments the content of one entire vial (10-20 mg of nanoparticles) was weighed. 
The obtained weight was used to calculate the weight corresponding to 1 mg of nano-
particle. For adsorptive binding studies, 1 mg of one nanoparticle batch was used per 
pH to be tested. 70 µL of an ASA solution in water (1 mg/mL) whose pH was adjusted 
with small amounts of acid or base (0.01 M HCl / NaOH) or buffer were used to resus-
pend the nanoparticles. After two hours of incubation under constant shaking (800 rpm) 
at room temperature, surfactants were added to a final concentration of 1% (w/v), fol-
lowed by incubation for another 30 minutes under same conditions. Thereon the suspen-
sions were centrifuged for 10 min at 16,800 rpm and room temperature. The supernatant 
was removed and the pellet was washed three times with 90 µL of water (pH adjusted 
with small amounts of acid/base, accordingly). Finally the pellet was resuspended in 
60 µL of same pH-adjusted water. A standard ASA-activity assay in 96-well plates un-
der shaking was performed to determine the amounts of active ASA bound to the nano-
particles.  
4.5.3 Covalent binding of ASA to nanoparticles 
To this end, commercially available, amine modified PLA-nanoparticles were used 
(LGFG200N, Phosphorex Inc.). In brief, 1 mg of these nanoparticles was resuspended 
and washed twice with PBS. After resuspension in 10 µL of PBS using an ultrasound 
probe (Hielscher) at 80% amplitude in 5 second pulses, 0.42 µL of a 1 mM solution 
(10% DMSO) of the heterobifunctional crosslinker NHS-PEG12-maleimide crosslinker 
was added. After 30 minutes of incubation at room temperature under constant shaking 
(Eppendorf Thermomixer, 800 rpm) thiolated ASA was added. For thiolation of ASA, 
an ASA-variant (T365C) was used. This protein was stably expressed in Chinese ham-
ster ovary suspension (CHO-S) cells and purified by affinity chromatography as shown 
before (Höcker 1999). The sulfhydryl-residue on its surface was used to covalently react 
with the maleimid-group of the crosslinker. To that end 60 µg (1.0 nmol) of ASA-
T365C in PBS were reduced under mild conditions using 69 µg (225 nmol) TCEP for 2 
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hours at room temperature to ensure availability of crosslinkable sulfhydryl groups. 
Subsequently, the modified nanoparticles and the thiolated ASA T365C variant were 
coincubated over night at 4°C and 800 rpm. A standard ASA-activity assay in 96-well 
plates under shaking was performed to determine the amounts of active ASA bound to 
the nanoparticles.  
Secondly, HSA nanoparticles were used to covalently bind ASA with a similar cross-
linking strategy. The crosslinking procedure was performed by collaboration partners of 
the working group of Prof. Dr. J. Kreuter of the Goethe University of Frankfurt. In 
brief, 400 µg of ASA were thiolated using 48 µg of Traut’s reagent (2-iminothiolane) 
and 20 hours of incubation at room temperature. 1 mg of HSA nanoparticles were react-
ed with 0.74 µg of the crosslinker Malhex-NH-PEG-O-C3H6-CONHS (RAPP Polymere, 
Germany). 1 mg of these activated HSA-nanoparticles were then reacted with 400 µg of 
thiolated ASA for 18 h at room temperature and constant shaking, and then washed 
three times. 
The subsequent binding and release analyses were performed in this work. To that end, 
a standard ASA-activity assay in 96-well plates under shaking was performed to deter-
mine the amounts of active ASA bound to the nanoparticles.  
4.5.4 High affinity binding of ASA to PLA- and PLGA-nanoparticles 
Two strategies were pursued to bind ASA with high affinity to nanoparticles. (1)  
Biotinylated ASA was to be bound to neutravidin-modified nanoparticles. (2) Unmodi-
fied ASA was to be bound with high-affinity to nanoparticles that had been covalently 
modified with the M6P binding domain 9 of the MPR300.  
4.5.4.1 Biotinylation of ASA 
For biotinylation 300 µg (5.3 nmol) of purified ASA-T365C was buffer exchanged into 
PBS. To ensure that the cystein residue is available for crosslinking, a mild reduction 
reaction was performed using 400 µg (1300 nmol) of TCEP (in water, pH adjusted to 
7.4.). Then 300 nmol of maleimid-PEG2-biotin were added and incubated for 2 hours at 
room temperature. Excess reaction reagents were removed by dialysis using Slide-A-
Lyzer mini-dialysis devices (Thermo).  
To determine biotinylation yields, a pull-down assay with streptavidin-agarose was per-
formed. Streptavidin-agarose was washed three times with 1% (w/v) BSA in TBS, then 
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10 µL of the slurry was incubated with 1 µg of biotinylated ASA in a final volume of 
40 µL containing 1% (w/v) of BSA in TBS. Samples were incubated over night at 4°C 
under constant shaking (1300 rpm), then centrifuged at 10,000 g for 3 minutes at room 
temperature. 20 µL of the supernatant was carefully removed and the pellet was washed 
three times with 1 mL of 1% (w/v) BSA in TBS. Finally the pellet was resuspended in 
40 µL of same buffer. ASA activity was assessed in supernatant, washes and pellet in 
the 96-well ASA activity assay. The absolute activity of ASA found in the pellet, corre-
sponding to biotinylated ASA, was normalized on the total absolute activity of the ini-
tially employed ASA (sum of all fractions).  
4.5.4.2 Covalent binding of neutravidin to PLA- and PLGA-nanoparticles 
PLA- and PLGA-nanoparticles were neutravidin-modified using the protocol described 
by Nobs et al., (2004) in a slightly modified version. In this protocol carboxylic end 
groups of PLA- or PLGA-polymers are thiolated, followed by reaction with maleimide-
activated neutravidin. The following buffers were used: 
 
Reaction buffer 1 (RB1): pH 4.7 
 
100 mM MES 
0.9% (w/v) NaCl 
Reaction buffer 2 (RB2): pH 6.5 100 mM MES 
0.9% (w/v) NaCl 
  
Nanoparticles were precipitated by centrifugation at 16,000 rpm for 15 minutes at room 
temperature in between reaction steps and in washing procedures. Resuspension was 
achieved by ultrasound treatment using a probe (Hielscher) at 80% amplitude in 5 sec-
ond pulses until the suspension appeared homogenous and no pellet was visible. All 
incubation steps were performed in a Eppendorf Thermomixer at 1,100 rpm at room 
temperature. 
Before starting, 1 mg of nanoparticle was resuspended in and washed three times with 
300 µL reaction buffer 1 (RB1). After resuspension in 100 µL of RB1, 100 µL EDC-
solution (24 mg/mL) and 50 µL of cystamine dihydrochloride solution (71 mg/mL) 
were added. After 24 hours of incubation, excess reaction reagents were removed by 
washing twice with 300 µL of RB2. 10 µL of TCEP solution (6 mg/mL, pH 7.0) were 
then added to 200 µL of resuspended nanoparticles. The reaction mixture was incubated 
for three hours. Excess TCEP and 2-aminoethanthiol, resulting from the reduction reac-
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tion, were removed by washing three times with RB2. To remove agglomerates from 
the maleimide-activated neutravidin solution, a freshly prepared 5 mg/mL stock in wa-
ter was centrifuged for 5 minutes at 15,000 g. The pellet was discarded and the superna-
tant was used. Thiolated nanoparticles were incubated with 50 µL of agglomerate free 
maleimide-neutravidin solution for 6 hours at 4°C. Excess neutravidin was removed by 
washing three times with 300 µL of TBS. 
4.5.4.3 High affinity binding of biotinylated ASA to neutravidin-modified 
nanoparticles 
2.0-6.0 µg of biotinylated ASA were added per mg neutravidin-modified nanoparticle. 
After incubation over night at 4°C, nanoparticles were precipitated and the pellets were 
washed twice with 300 µL and finally resuspended in 40 µL of TBS. A standard ASA-
activity assay in 96-well plates under shaking was performed to determine the amounts 
of active ASA in the pellet. 
4.5.4.4 Covalent binding of the MPR300 domain 9 fragment to PLA- and 
PLGA-nanoparticles 
Two nanoparticle systems were used to covalently bind the receptor fragment. First of 
all, PLGA-nanoparticles (batch 1311) were reacted with EDC and cystamine to create 
amine reactive nanoparticles. This was performed according to the protocol described in 
chapter 4.5.4.2. Secondly, commercially available N-PLGA nanoparticles (LGFG200N, 
Phosphorex Inc.) were used. The same crosslinker (NHS-(PEG)12-maleimide), reactive 
towards thiol- and amine-groups, as mentioned before (chapter 4.5.3) was added to a 
final concentration of 2.5 mM.  
The non-glycosylated MPR fragment was thiolated using Traut’s reagent: 210 µg of the 
non-thiolated receptor fragment were incubated with 30 µg of Traut’s reagent (2-
iminothiolane) and incubated for 1.5 h at RT. Excess reaction reagent was removed by 
dialysis (three times, against 2 L of PBS at 4°C for >4 h) using Slide-A-Lyzer mini-
dialysis units. 5-20 µg of thiolated receptor fragment were incubated with 1 mg of 
amine-modified nanoparticles for 1.5 h at RT under constant agitation (1300 rpm). After 
washing twice with 215 µL of TBS, the pellet was resuspended in 40 µL of TBS. 
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4.5.4.5 Binding of ASA to MPR300 domain 9 fragment-nanoparticles 
1 mg of the receptor-fragment modified nanoparticle formulations were coincubated 
with 3-5 µg of unmodified ASA in a total volume of 50 µL. After 2 h of incubation at 
4°C under constant agitation (1300 rpm), samples were centrifuged and the supernatant 
was removed (25 µL). The remaining 25 µL containing the nanoparticles were washed 
twice with 215 µL of TBS. The pellet was resuspended in 50 µL of TBS. A standard 
ASA-activity assay in 96-well plates under shaking was performed to determine the 
amounts of active ASA bound to the nanoparticles.  
4.5.5 Release of ASA from nanoparticles in vitro  
0.2 mg of ASA-nanoparticles were centrifuged (17,000 g, 15 min at 4°C) and resus-
pended in 12 µL of serum of ASA-/- mice or water and incubated for two hours at 37°C 
under shaking at 1,100 rpm. After another centrifugation step 10 µL of supernatant were 
withdrawn and the pellet was resuspended in 18 µL of 1% (w/v) BSA in TBS. ASA 
activity of supernatants and washes were determined by ASA activity assay in 96 well 
plates. Absolute ASA activities in supernatant and pellets were calculated, arithmetical-
ly subtracting the ASA activity of 2 µL of supernatant not withdrawn for pellet samples. 
ASA activities measured in the pellets were normalized on initially employed ASA 
(sum of ASA activities in supernatant and pellet).  
4.6 In vivo experiments 
Animals were kept with food and water ad libitum. All experiments were performed in 
accordance with the German ‘Tierschutzgesetz’. To avoid a cross reaction with murine 
ASA when analyzing tissue concentrations of injected human ASA, ASA-/- mice were 
used (Hess et al. 1996). 
4.6.1 Intravenous injections of various nanoparticle preparations 
For tail-vein injections ASA-/- mice were subjected to red-light radiation for warming, 
leading to swelling of their tail veins, facilitating the intervention. 300 –350 µL of each 
formulation were injected per non-anesthetized mouse, using a syringe with a small 
cannula. After receiving the injection, mice were put back into their cage with their lit-
termates. 5 min after injection, a blood sample (~50 µL) was taken by injuring the tail 
with a scalpel. 
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Tail vein injections and parameters of injected formulations used in this work are listed 
in the following table: 
 
Experiment Mice 
 (n) 
Nanoparticles Surfactant ASA 
 [U/kg] 
Injection 
vol. [µL] Polymer Conc. 
[mg/kg] 
Name Conc. 
[mg/kg] 
Tolerance 2 PBCA 200 PS80 100 - 300 
3 PBCA 100 PS80 50 - 300 
4 PLA 300 P188 100 - 300 
2 HSA 100 PS80 100 - 350 
Distribution 3 HSA 100 PS80 100 34 350 
3 - - PS80 100 34 350 
3 PLGA 240 P188 100 21.6 250 
3 - - P188 100 21.6 250 
PS80 = polysorbate 80; P188 = poloxamer 188 
 
Mice used in tolerance studies were observed closely for one hour for abnormal behav-
ior. In case severe adverse effects were noted, mice were euthanized by cervical disloca-
tion within 20 minutes. When this was not the case, mice were observed in regular in-
tervals the following two weeks and sacrificed subsequently. 
4.6.2 Dissection of tissues 
For distribution studies tail-vein injected mice were anaesthetized after 2 hours,  
transcardially perfused and their tissues dissected. Anesthesia was performed by  
intraperitoneal injection of 0.6-1.0 mL of 1% (w/v) tribromoethanol (Avertin). After 
approximately 5 minutes mice were tested for their reaction to pain by pinching their 
fore- and hind-paws. Only in case of negative response, mice were fixed to a styrofoam 
board with all paws. The visceral cavity was opened and the heart was exposed by scis-
soring left and right from the sternum. The right atrium of the still beating heart was 
punctured; the emerging blood was collected from the chest cavity and transferred into a 
reaction tube. For transcardial perfusion a butterfly cannula was inserted from the tip of 
the heart towards the left ventricle. PBS containing 1% (w/v) procain was pumped 
through the circulatory system at a flow rate of approximately 10 mL/min for 10 
minutes. 
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Perfused mice were dissected. Lungs, liver, spleen, kidneys, brain, spinal cord, nervus 
ischiadicus and plexus brachialis were transferred to reaction vials and immediately 
shock frozen on dry ice. Brain hemispheres were split and separately frozen. All tissues 
were stored at -20°C until further processing.  
4.6.3 Homogenization of tissues  
All tissues, but only one brain hemisphere and one kidney, were transferred into glass 
reaction vials containing 1.5 mL of ice-cold TBS (pH 7.4). Homogenization was per-
formed using an Ultra-turrax homogenizer at 24,000 rpm for 3-5 seconds. This step was 
repeated until all of the tissue was well dispersed.  
 
Homgenization buffer in TBS, pH 7.4 
 
0.5% Triton N-101 
0.9% NaCl 
2 μg/mL Aprotinin 
1 mM  EDTA 
50 mM Iodoacetamide 
0.5 μg/mL Leupeptin 
0.7 μg/mL  Pepstatin A 
100 μg/mL Pefabloc SC 
 
Raw homogenates of lungs, liver, spleen, kidney and one hemisphere of the brain were 
diluted 1:4 in homogenization buffer (333 µL + 999 µL). Spinal cord, nervus ischiadi-
cus and nervus brachialis raw homogenates were diluted 1:2 in homogenization buffer 
(500 µL + 500 µL). 
These dilutions and the residual raw homogenates (as reserves) were stored at -20°C 
until further processed. 
4.7 Biochemical assays 
4.7.1 ASA-ELISA 
For detection of ASA (0.05-2 ng of ASA) in tissue homogenates or other samples, a 
sandwich enzyme-linked immunosorbent assay (ELISA) method was performed 
(Matzner et al. 2000). Following solutions and antibodies were used: 
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Coating buffer; pH 7.00 25 mM Tris-HCl 
Washing buffer in PBS 0.1% (v/v) Triton X-100 
Blocking buffer in PBS 5% (w/v) Dried milk 
0.02% (v/v) Triton X-100 
Dilution buffer in TBS 1% (w/v) BSA 
Developing solution in ABTS buffer 1 mg/mL ABTS 
 
Capturing antibody:  monoclonal mouse hybridoma 19-16-3 antibody against hASA 
Primary antibody:  rabbit antiserum against hASA (‘BE3’) 
Detection antibody:  Peroxidase-coupled goat anti rabbit  
 
In brief, a 96-well tissue culture plate (Sarstedt, # 83.1835) was coated with capturing 
antibody at a concentration of 0.625 µg/mL in 200 µL coating buffer per well. After 
overnight incubation at 4°C, plates were washed once with 300 µL coating buffer to 
remove unbound antibody. Blocking of the plates was performed for at least 20 min at 
room temperature with 200 µL of blocking solution. After washing twice with 300 µL 
of washing buffer using an automated ELISA washer, 100 µL blocking solution were 
manually prefilled. Sample or standard solutions were added and the total volume was 
adjusted to 200 µL with sample dilution buffer. The mixture was incubated for 90 min 
at 37°C. After washing twice with 300 µL of washing buffer, 50 µL of primary antibody 
solution (diluted 1:2,000 in blocking solution) were added, followed by incubation for 
60 min at 37°C and washing twice with 300 µL of washing buffer. After incubation for 
another 60 min at 37°C with 50 µL of detection antibody solution (diluted 1:2,000 in 
blocking solution) and washing thrice with 300 µL of washing buffer, developing solu-
tion (ABTS) was added. Development took approximately 10-20 minutes until the OD 
405 nm (reference wavelength 505 nm) of the highest standard concentration (2 ng of 
ASA) reached approximately 1.0. 
ASA amounts in samples were calculated from the standard curve of pure enzyme. 
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4.7.2 Standard ASA activity measurements  
ASA activity can easily be assessed by using its artificial substrate 4-nitrocatechol sul-
fate. In presence of ASA the sulfate moiety is cleaved off. At alkaline pH the product 
nitrocatechol can be quantified by measuring the absorbance at 510 or 505 nm using a 
spectral photometer or a microplate reader (Tecan). 
 
ASA substrate solution; pH 5.0 10 mM 4-nitrocatechol sulfate 
1 g/L NaCl 
10 mg/mL BSA 
0.5 M NaAc (C2H3O2) 
Stop solution 1 M NaOH 
 
The assay was performed according to the following protocol: 
 
 
In cuvettes In 96-well plate 
Sample/standard 10-20 µL 2 µL 
ASA-substrate 200 µL 48 µL 
(Incubation)  30 min, 37°C 
Stop solution 500 µL 120 µL 
Detection OD 515 in spectrophotometer OD 505 in microplate reader 
 
The molar extinction coefficient of nitrocatechol is ε515 = 12,400 M-1 cm-1. To deter-
mine ASA activity in cuvettes the following formula applies: 
 
 
 
When performing the ASA-activity assay in 96-well plates, the equation above needs to 
be multiplied by a factor of 1.945, as was determined by directly comparing a set of six 
ASA standards in both assays. The factor is the quotient of the slopes of these standard 
curves. 
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4.7.3 Adapted ASA activity assay for high-throughput screenings 
  
ASA-inhibition substrate; pH 5.0 0.5 mM 4-nitrocatechol sulfate 
1 g/L NaCl 
0.2 mg/mL BSA 
0.5 M NaAc (C2H3O2) 
ASA solution in TBS 0.42 µg/mL ASA 
0.1 mg/mL BSA 
Compounds (varying conc.) 100% DMSO 
 
The assay was performed according to the following protocol: 
 
 
96-well plate assay 384-well plate assay Final concentration 
Compound 12 µL 0.3 µL (varying) 
Inhibition substrate 60 µL 15 µL 0.25 mM 
ASA solution 30 µL 7.5 µL 0.105 µg/mL 
Water 18 µL 7.5 µL 
 
Incubation 90 minutes, 37°C 
 
1 M NaOH 80 µL 20 µL 
Total volume 120 µL 30.3 µL 
 
In the initial high-throughput screening in 384-well plates a total of approximately 
30,000 compounds were tested at a concentration of 10 µM in single reads. Semi-
automated screening took place at the Leibniz-Institut for Molecular Pharmacology in 
Berlin, Germany.  
To determine the IC50 values of confirmed hits, the inhibition assay was performed in 
96-well plates in presence of increasing compound concentrations. 
In order to determine the Km- and Vmax-values of ASA in presence or absence of inhibi-
tor, varying substrate concentrations (0.039-5.0 mM) and varying inhibitor concentra-
tions were tested with the 96-well plate assay described above.  
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To determine the Z’-factor for each plate the following equation was used (Zhang et al. 
1999): 
 
 
(σ = standard deviation; µ = mean value; c+ = positive control; c- = negative control) 
4.7.4 KD determination 
For washing and loading, 150 µL of Ni-NTA-agarose (Qiagen, #30210) was sequential-
ly washed with water (1.35 mL), loaded with 750 µL NiSO4 solution (compare chapter 
4.2.6), washed again in water and then in 1% BSA in TBS. Finally, Ni-NTA agarose 
was resuspended in 187.5 µL BSA/TBS. For precipitation in between washes, the sus-
pension was centrifuged at 17,000 g for 5 min. 
For KD determination, 25 µL of MPR300-fragment solution (82.7 µg/mL in BSA/TBS) 
were serially diluted 1:2 in 1% BSA in TBS in a conical 96-well plate (Sarstedt, 
#82.1583). Then, 25 µL of ASA-solution (6.05 µg/mL in 1% BSA in TBS) were added 
per well and the mixture was incubated for 1 h at 1000 rpm and 37°C. 10 µL of washed 
and loaded Ni-NTA agarose were added per well. Samples were incubated for 2 h at 
1200 rpm and 37°C. Then the 96-well plate was centrifuged at 3150 g in a swing-out 
rotor (Eppendorf, A-4-62) for 20 min at room temperature. 45 µL of the supernatant 
were removed. 2 µL of supernatant were used to determine the ASA activity in the 96-
well plate assay (chapter 4.7.2). KD calculation was performed using GraphPad Prism 6.  
4.7.5 Dissociation experiments of ASA and receptor fragment 
For evaluation of the dissociation in presence of different solutions/buffers of varying 
pH, 8.9 µg of MPR300 fragment were first co-incubated with 6.48 µg of ASA in 
250 µL of 1% BSA in TBS for 1 h at 37°C at 1000 rpm and then precipitated by incuba-
tion with 50 µL of washed Ni-NTA agarose (compare chapter 4.7.4) for 2 h at 1200 rpm 
and 37°C and subsequent centrifugation (5 min, 17,000 g). After resuspension in 
300 µL 1% BSA in TBS, the suspension was split into 6 reaction vials (55 µL each). 
After centrifugation and removal of 50 µL of the supernatant each, the pellet was resus-
pended in 95 µL of the solution to be tested and incubated for 30 min at 37°C and 
1200 rpm. Subsequently, samples were precipitated by centrifugation, 90 µL of the su-
pernatant were removed and stored, the pellet was washed with 90 µL of 1% BSA in 
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TBS and finally resuspended in a final volume of 50 µL of 1% BSA in TBS. ASA activ-
ity was measured in washes, supernatant and resuspended pellet using the 96-well plate 
ASA activity assay (chapter 4.7.2). 
4.8 Mass spectrometric analyses of compounds 
Mass spectromic analyses were performed by direct injections of samples into an elec-
tro-spray-ionization ion trap mass spectrometer (Bruker, HCT Ultra – PTM discovery sys-
tem) using a Hamilton syringe (Gastight #1775) at a flow rate of 5 µL/min. The sample 
composition was: 100 µM of analyte in 81% acetonitrile, 9% ultrapure water, 9% meth-
anol and 1% DMSO.  
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Enzyme replacement therapy, based on repeated intravenous injections of recombinant-
ly produced lysosomal enzyme, is a treatment option for several LSDs (Desnick and 
Schuchman 2012). However, previous experiments in mice have shown that only a 
small fraction of the injected ASA reaches its target, the brain.  
Three approaches to increase brain delivery of intravenously injected ASA are de-
scribed here. The first involves the use of nanoparticles, which have previously been 
shown to increase brain delivery of drugs otherwise known to be unable to pass the 
blood-brain barrier. Secondly, the blood circulation time of ASA was to be increased, 
which has been suggested to enhance brain delivery of another lysosomal enzyme, β-
glucuronidase (Grubb et al. 2008). To this end, a M6P residue binding domain of the 
MPR300 is used in a novel approach. Thirdly, a combinational approach is pursued, 
coupling this M6P residue binding domain to nanoparticles, which are in turn used to 
bind ASA. This approach should ensure increased blood circulation times, mediated by 
the MPR300 binding domain, and specific transcytosis across the endothelial cells of 
the BBB, mediated by nanoparticles. 
5.1 Use of nanoparticles to increase brain delivery of 
Arylsulfatase A 
When doses of 20 mg of free ASA per kg body weight were tail-vein injected into  
ASA-/- mice, approximately 0.005% of the injected dose was found in the brain (calcu-
lated from unpublished data by Dr. A. Böckenhoff). In contrast, 0.1 and 0.93% of the 
injected doses were found in the brains of mice treated with PLGA- and PBCA-
nanoparticles, respectively (Ambruosi et al. 2006; Halder et al. 2008). Comparing these 
two delivery rates, 20- to 186-fold more ASA may be delivered to the brain using these 
nanoparticles. Therefore, injections of 0.1-1.0 mg nanoparticle bound ASA and 20 mg 
of free ASA per kg body weight should result in same absolute amounts of ASA reach-
ing the brain. Commonly, up to 300 mg/kg body weight of nanoparticles are injected 
intravenously. Thus, theoretically 0.1-1.0 mg ASA must be bound per 300 mg nanopar-
ticle = 0.33-3.33 µg of ASA per mg nanoparticle. Taking the specific activity of ASA 
into account (40 mU/µg), 13.3-133 mU of ASA must be bound per mg nanoparticle. 
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The threshold value of 13.3 mU/mg nanoparticle was defined as minimal binding of 
ASA necessary to allow for in vivo experiments. 
The nanoparticles used here, were made of biodegradable polymers. Their size, varying 
among batches, ranged between 75 and 350 nm in diameter. Different materials were 
used for these particles exposing different chemical functional groups on their surfaces. 
These groups determine the surface charge, defined as ‘zeta potential’, and may also be 
used for chemical crosslinking. The nanoparticles used in this work and their physico-
chemical properties are listed in chapter 3.3. To avoid uptake by the MPS and to 
achieve targeting to the brain, nanoparticles were surfactant coated prior to in vivo stud-
ies. 
Basically, there are three strategies to use nanoparticles as drug carriers: (1) incorpora-
tion of the drug during nanoparticle production, (2) adsorption or (3) covalent or high 
affinity binding of the drug on their surface. All of these methods were evaluated in the 
course of this thesis with regard to their efficacy and capacity of binding active ASA, 
the release of previously bound ASA (stability) and their capability to increase brain 
delivery of ASA in vivo. 
Before conducting experiments to bind ASA to nanoparticles, biotolerance studies of 
these particles were performed. To that end surfactant coated empty nanoparticles were 
injected into mice. 
5.1.1 Biotolerance of PBCA-, PLA- und HSA-nanoparticles 
In first experiments two mice received doses of 200 mg polysorbate 80 coated PBCA 
nanoparticles per kg body weight. Treated mice showed severe side effects and abnor-
mal behavior and were euthanized after 5-10 min due to reasons of humanity. In a fol-
lowing experiment the injected doses were halved (100 mg/kg body weight). Three 
mice received injections; all showed transient side effects such as reduced cage activity, 
horrent fur, red eyes and efforts to clean their faces.  
In contrast, mice that received poloxamer 188 coated PLA- (n=4) or polysorbate 80 
coated HSA-nanoparticle (n=2) formulations at a dose of 300 and 100 mg/kg body 
weight, respectively, showed no signs of adverse effects. This showed that in principle 
doses of at least 100 mg/kg of all three tested nanoparticle materials are suited for in in 
vivo studies. 
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5.1.2 Incorporation of ASA into nanoparticles 
Commonly, small substances such as peptides, dyes and small active compounds can be 
incorporated into nanoparticles. In contrast to these molecules, proteins like ASA are 
large molecules and need to retain their tertiary structure in order to function properly. 
Therefore, before encapsulation of ASA in nanoparticles, its activity needed to be ascer-
tained when incubated in presence of solvents and solutions used for nanoparticle pro-
duction. For formation of PBCA-nanoparticles, a 1% (w/v) solution of dextran contain-
ing 10 mM HCl is used. In case of PLA and PLGA, nanoparticle production is per-
formed in organic solvents like dichlorethane, ethylacetate or chloroform (Olivier 
2005). Remaining ASA activities were determined after incubation in these solvents and 
solutions by measuring the rate of 4-nitrocatechol sulfate hydrolysis (Figure 5.1). 
Figure 5.1: Residual ASA activity after incubation of ASA in solvents and solutions used 
for nanoparticle production.  
5 µg/mL ASA were incubated in dichlorethan, ethylacetate, chloroform or an aqueous solution 
of 1% (w/v) dextran and 10 mM HCl for 2.5 hours under constant shaking. As controls same 
amounts of ASA were incubated in water with or without 10 mM HCl or 1% BSA (w/v) in 
TBS. ASA activity was determined by measuring hydrolysis of 4-nitrocatechol sulfate. Meas-
ured absorption values were normalized to the positive control (ASA in 1% BSA in TBS). 
Shown are means ± SD of technical triplicates. 
 
As shown in Figure 5.1, ASA was active and thus stable after incubation in water or 1% 
BSA in TBS. ASA activity was depleted after incubation in the solvents used for for-
mation of PLA- and PLGA-nanoparticles (dichloroethan, ethylacetate, chloroform) and 
also when incubated in 10 mM of HCl in presence or absence of 1% dextran used for 
production of PBCA-nanoparticles.  
0%
20%
40%
60%
80%
100%
120%
Dic
hlo
re
tha
n
Eth
yla
ce
tat
e
Ch
lor
ofo
rm
1 %
 
De
xtr
an
, 
10
 
m
M 
HC
l
Wa
ter
, 1
0 m
M 
HC
l
Wa
ter
1 %
 
BS
A i
n 
TB
S
R
e
si
du
a
l A
SA
 a
ct
iv
ity
52  5 Results 
This result indicates that incorporation of ASA is not feasible under these conditions as 
ASA activity is depleted in presence of the solvents and solutions present during nano-
particle production. 
5.1.3 Adsorption of ASA to the surface of nanoparticles 
As incorporation led to insufficient results considering loss of ASA activity, other 
methods of binding had to be investigated. Unspecific adsorption of ASA to the surface 
of the nanoparticles potentially avoids functional loss of ASA.  
In first experiments ASA adsorption to PLA- and PBCA-nanoparticles was tested after 
their coincubation for two hours in different buffers or water followed by surfactant 
coating for another 30 minutes. Subsequently, nanoparticle suspensions were centri-
fuged and the pellet containing the nanoparticles was washed thrice. Then, the amount 
of bound ASA was analyzed by ASA activity determinations as described before and by 
immunoblot analysis.  
In buffer (TBS or NaAc) no adsorption of ASA was observed to any of the nanoparti-
cles tested, independently from the pH (data not shown). In water, however, after ad-
justing the pH, ASA was found to adsorb to PLA-, but not to PBCA nanoparticles (Fig-
ure 5.2).  
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Fig- ure 
5.2: Ad-
sorption of ASA on different nanoparticle batches. 
A)  ASA activity measurements of ASA adsorbed to three PLA- and one PBCA-nanoparticle 
batch in dependence of the pH (4-7) in water. After incubation for 2 hours at room tempera-
ture under constant shaking poloxamer 188 and polysorbate 80 were added to PLA/PLGA- 
and PBCA-nanoparticles respectively to a final concentration of 1% and further incubated 
for 30 minutes under unchanged conditions. After washing thrice, ASA activities of the pel-
lets were determined. Absolute ASA activities (mU) were normalized to total amount of na-
noparticles employed (mg). 
B) Immunoblot against ASA after adsorption experiments at pH 5.0 in water (same conditions 
as described for A; w/o = without nanoparticles). 6.5% (v/v) of each sample, namely of the 
initial ASA-nanoparticle suspension (‘I’), of the supernatant (‘S’) as well as of the washed 
and resuspended pellet (‘P’) were loaded onto a SDS-PAGE. The primary antibody was a 
polyclonal serum against human ASA (‘#BE3’, diluted 1:10,000), detected using a peroxi-
dase-conjugated goat anti rabbit antibody, followed by ECL development. 
C)  Adsorption of ASA to the same PLA- and PBCA-nanoparticles as well as two other PLA-
and PLGA-batches at pH 6.0 in water under otherwise identical conditions as determined by 
ASA activity measurements. Shown are the means ± SD. 
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As Figure 5.2, A suggests, adsorption of ASA to PLA- and PLGA- nanoparticles is in-
fluenced by the pH. A maximum of 202 mU of active ASA per mg nanoparticle was 
determined for PLA559 at pH 6.0. For PLA1027 maximal binding occurred at pH 5.0 
and 6.0 (134 and 126 mU/mg nanoparticle, respectively). Lower adsorption yields were 
found for PLA992 at pH 5.0 (116 mU/mg nanoparticle). Maximally 2.7 mU of active 
ASA were adsorbed to one mg of PBCA nanoparticles at pH 4.0. These results were 
further supported by immunoblot analysis against ASA in samples of adsorption exper-
iments conducted at pH 5.0 (Figure 5.2, B). Whereas bands attributed to ASA (molecu-
lar weight: 57 kDa) were detected in the resuspended pellets of PLA559, PLA1027 and 
PLA992, no signal was observed in the correspondent sample of PBCA-nanoparticles, 
nor the negative control (ASA without nanoparticles). This proves absence of ASA on 
PBCA-nanoparticles, and negates presence of inactive ASA. 
The results suggest that adsorption of ASA to nanoparticles is highest when incubated 
in water at pH 5.0-6.0. In further adsorption experiments performed at pH 6.0 the high-
est adsorption yields were confirmed for PLA 559 with 205 mU/mg nanoparticle (n=7; 
Figure 5.2, C). No significant difference between adsorption to PLA- or PLGA-
nanoparticles was observed, as one mg of PLA 992 or PLGA 555 both bound approxi-
mately 75 mU of ASA. Again, only 2.3 mU of ASA were adsorbed to PBCA nanoparti-
cles (n=4). Because of these low yields and their high toxicity observed in chapter 5.1.1, 
PBCA nanoparticles were not used for subsequent studies. 
 
An important factor for delivery of therapeutics adsorbed to nanoparticles in vivo is 
their release in serum. Therefore, before in vivo studies were performed, ASA release 
from nanoparticles was to be investigated in serum in vitro. Hence, ASA was adsorbed 
to two different PLA-nanoparticle batches (#559, 1027) in water at pH 6.0 followed by 
surfactant coating with poloxamer 188. Then nanoparticles were pelletized and resus-
pended in serum of ASA-/- mice and incubated for 0-60 min at 37°C. Bound ASA in the 
pellet and released ASA in the supernatant were analyzed by ASA activity determina-
tions (Figure 5.3). 
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Figure 5.3: Release of ASA from nanoparticles in serum or water over time after passive 
adsorption.  
ASA was adsorbed to different nanoparticle batches (PLA 559, 1027) at pH 6.0 in water. Nano-
particles were pelletized by centrifugation and resuspended in prewarmed serum (37°C). After 
varying incubation times (0, 5, 15, 60 minutes) at 37°C under constant shaking, the nanoparti-
cles were pelletized again and ASA activity in supernatants and pellets was determined. The 
sum of the activities of supernatant and pellet of each sample were set to 100% and were similar 
for all samples (14.1 ± 1.93 mU). 
 
Whereas ASA was largely retained on the PLA-nanoparticle surface after incubation in 
water, complete and rapid dissociation occurred in serum. It appeared that as soon as the 
nanoparticles came in contact with serum, all the ASA dissociated. These circumstances 
do not allow use of this method of binding as in vivo use of this ASA-nanoparticle for-
mulation could not result in increased transport of ASA across the BBB. 
5.1.4 Stable binding of ASA to nanoparticles 
In order to ensure binding without desorption in serum, ASA was to be bound stably to 
the nanoparticle’s surface. This can be achieved either covalently by direct crosslinking 
or by high affinity systems, such as the biotin-streptavidin system. To that end the func-
tional groups present on the surfaces of ASA and on the nanoparticles need to be ex-
ploited. PBCA, however, is not very susceptible to crosslinking because of the lack of 
reactivity of its functional groups. Due to this trait and the biotoxic side effects observed 
before (chapter 5.1.1), PBCA nanoparticles were not used for the following crosslinking 
procedures. 
Instead, three other nanoparticle core materials, namely PLA, PLGA and HSA with 
different functional groups on their surfaces, were employed. On PLA and PLGA nano-
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particles carboxylic groups are present, which can be used in crosslinking procedures. 
Moreover, amine modified PLGA nanoparticles are commercially available.  
Both ASA and HSA are proteins that display multiple reactive groups available for 
crosslinking. Commonly, primary amines of lysine residues are used to this end.  
In some crosslinking attempts a variant of ASA, from hereon named ‘ASA-T365C’, is 
used. The amino acid at position 365, threonin, has been substituted for a cysteine resi-
due. This modification introduces a sulfhydryl group on the surface of ASA without 
relevantly reducing specific ASA activity (results not shown). As this is the only cyste-
ine residue of the mature protein not involved in a disulfide bridge, its sulfhydryl group 
may be used for crosslinking, allowing for selective modification of ASA only at this 
specific position. 
5.1.4.1 Covalent binding of ASA to nanoparticles  
To covalently bind ASA to PLGA nanoparticles a heterobifunctional crosslinker was 
used (Figure 5.4, A). Its amine reactive N-hydroxysuccinimide (NHS) group was used 
to react with amine modified PLGA nanoparticles (Phosphorex Inc.). The sulfhydryl 
reactive maleimide moiety of the crosslinker was thereon used to react with ASA-
T365C, which had been reduced under mild conditions using the reducing agent tris(2-
carboxyethyl)phosphine) (TCEP) to uncover its sulfhydryl moiety. After multiple wash-
ing steps, the amount of active ASA bound to the nanoparticles was measured using the 
ASA activity assay. 
This method resulted in a yield of 8.92 mU of ASA bound per mg amine-modified na-
noparticle. This yield is relatively low and does not allow for in vivo experiments (com-
pare threshold determination in chapter 5.1). Therefore direct covalent binding of ASA 
to PLGA nanoparticles was not pursued further.  
  
Nano-
particle NH2 +
NHS     - PEG12 - Maleimide
Malhex-NH-PEG-O-C3H6-CONHS
HS+
ASA-T365C
Thiolated wt ASA 
Amine mod. PLGA
HSA-nanoparticle
A
B
5 Results 57 
Figure 5.4: Covalent crosslinking strategies of ASA binding to nanoparticles. 
A)  Amine modified PLGA-nanoparticles were reacted with the NHS-group of a heterobifunc-
tional crosslinker. The maleimid-group was used to covalently bind to the sulfhydryl group 
of reduced ASA T365C.  
B)  The same crosslinking strategy was pursued with another crosslinker to covalently bind 
wildtype ASA, which had been thiolated using Traut’s reagent, to HSA-nanoparticles. Sizes 
of molecules are not true to scale.  
 
Instead, HSA nanoparticles with a higher density of reactive groups on their surface 
than PLA-nanoparticles were used. Furthermore, a larger number of sulfhydryl groups 
was introduced into ASA by thiolation of wildtype ASA with Traut’s reagent (2-
iminothiolane). Again, a heterobifunctional crosslinker, consisting of a primary amine 
binding (NHS-group) and a sulfhydryl binding (maleimide-group) moiety, was em-
ployed (Figure 5.4, B). In a first step, the crosslinker was bound to the amine groups 
present on the nanoparticle’s surface. Thiolated ASA was then added to the modified 
nanoparticles, creating covalently bound ASA-HSA nanoparticles. The coupling proce-
dure was performed by collaboration partners (Prof. J. Kreuter and A. Mühlstein, Insti-
tute for Pharmaceutical Technology, University of Frankfurt a.M., Germany). This 
method resulted in binding of 340 mU (corresponding to 8.5 µg) of ASA per mg nano-
particle, as determined by ASA-activity measurements after three washing steps.  
This nanoparticle preparation was thereon incubated in serum in vitro to investigate 
release of ASA, as described before. In contrast to ASA adsorbed to nanoparticles 
(compare chapter 5.1.3), covalently bound ASA did not dissociate from the HSA core in 
serum after 2 hours of incubation at 37°C, with more than 90% of the ASA still found in 
the pellet (Figure 5.5, A). Consequently, in vivo studies were performed with this nano-
particle preparation. 
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To analyze whether nanoparticle-bound ASA is delivered more efficiently to the brain, 
three mice each received tail vein injections of the ASA-HSA-nanoparticle preparation 
or same amounts of non-nanoparticle bound (free) ASA as control. After two hours, 
mice were sacrificed and dissected. ASA concentrations in tissue homogenates were 
determined using a highly sensitive ASA-ELISA protocol (Matzner et al. 2000).  
 
Figure 5.5: In vitro and in vivo studies of ASA covalently bound to HSA nanoparticles.  
The NHS group of a heterobifunctional crosslinker was used to react with amine groups present 
on the HSA-nanoparticle surface. The maleimide moiety of the same crosslinker was thereon 
used to covalently bind thiolated ASA. 340 mU of ASA were bound per mg HSA-nanoparticle. 
A)  ASA release from nanoparticles after incubation for two hours in serum or water. As 
control, non-nanoparticle-bound ASA was used. The experiment was conducted as 
described for Figure 5.3.  
B)  Biodistribution of ASA two hours after injection of free ASA or nanoparticle bound ASA in 
ASA-/- mice as determined by ASA-ELISA in tissue homogenates. HSA-ASA nanoparticles 
were surfactant coated with polysorbate 80 prior to tail vein injections of 100 mg of the 
nanoparticle formulation (corresponding to 34 U of ASA) per kg body weight in ASA 
knockout mice. As control, unmodified, non-nanoparticle bound ASA of same dose was 
injected. After two hours, mice were sacrificed and dissected. ASA concentrations in tissue 
homogenates were determined by ASA-ELISA. ASA tissue concentrations were normalized 
to soluble protein of tissue homogenates as measured by Biorad DC-assay. Bars represent 
means ± SD of three mice per group. Statistical significances of differences (p < 0.05) were 
determined by students t-test and are indicated by an asterisk (‘*’). Sp. cord = spinal cord; 
N. isch. = ischiadic nerve; Pl. brach. = brachial plexus. 
 
A difference in the overall biodistribution of nanoparticle bound ASA to free ASA is 
apparent (Figure 5.5, B). A significant reduction of ASA levels in spleen, kidney and 
liver and an increase in brachial plexus were observed in comparison to the control (p-
values of 0.0024, 0.0007, 0.0020, 0.0003 respectively). No significant difference of 
ASA levels in the brain was measured. Thus it has to be concluded that this HSA nano-
particle preparation failed to increase brain delivery.  
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In further experiments other nanoparticle formulations were to be tested. Only few pub-
lications showed brain delivery of surfactant coated HSA nanoparticles so far; this na-
noparticulate system has not been in extensive use. In contrast, PLA and PLGA nano-
particles are widely used for brain delivery of therapeutics. However, as mentioned be-
fore, covalent ASA binding to PLA nanoparticles was inefficient as was expected con-
sidering the limited number of carboxylic end groups present on the surface.  
5.1.4.2 High affinity binding of ASA to PLA- and PLGA-nanoparticles 
To increase binding of ASA to PLA- and PLGA- nanoparticles, an amplification step 
was inserted using the streptavidin – biotin system. Streptavidin has a tetrameric quater-
nary structure and binds up to four biotinylated molecules with a KD of 10-100 fM 
(Humbert et al. 2005). With regard to future in vivo experiments neutravidin, a deriva-
tive of avidin, was used. Neutravidin is devoid of glycosylation and has a near neutral 
pI. In terms of affinity to biotinylated ligands, neutravidin is equivalent to streptavidin.  
Neutravidin PLA- or PLGA-nanoparticles were generated according to a previously 
published protocol (Nobs et al. 2004). In brief, the carboxylic groups of PLA/PLGA 
were used to introduce sulfhydryl groups by reaction with EDC and cystamine followed 
by its reduction with TCEP. These sulfhydryl-nanoparticles were then reacted with 
commercially available maleimide-activated neutravidin (Figure 5.6, A). 
For biotinylation, the ASA variant ASA-T365C was used. After gentle reduction using 
TCEP, biotin-maleimide was added. Excess reaction reagents were removed by dialysis. 
To determine biotinylation quantitatively, a pull down assay using streptavidin-agarose 
was performed. ASA activity was then measured in the supernatant, washes and pellet. 
The fraction of ASA found in the pellet represents the amount of biotinylated ASA. 
This procedure showed that 78% of the ASA was biotinylated by the described method. 
As a control wildtype ASA was used with the same reagents. Only 1% of wildtype ASA 
was biotinylated by this method, indicating that the biotinylation of ASA-T365C specif-
ically occurred at the modified amino acid residue. After incubation of biotinylated 
ASA with neutravidin-nanoparticles, the nanoparticles were washed and the ASA ac-
tivity associated with the nanoparticle fraction was determined (Figure 5.6, B). 
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Figure 5.6: High-affinity binding of biotinylated ASA to different PLA- and PLGA-
nanoparticle batches after their modification with neutravidin.  
A) Coupling scheme of covalent binding of neutravidin to carboxylic end groups of PLA- and 
PLGA- nanoparticles. Between coupling steps excess reaction reagents were removed by 
washing of the nanoparticles. 
B) Biotinylated ASA was added and ASA activity was determined in the pellet after three 
washing steps. Absoulte ASA activity (mU) was normalized to total amount of nanoparti-
cles employed (mg). 
 
The amounts of biotinylated ASA bound to the neutravidin nanoparticles depended pri-
marily on the stabilization agent of the nanoparticles (Figure 5.6, B). These stabilizers 
are added during the production process of the nanoparticles in order to avoid agglom-
eration. Interestingly, stabilization of the nanoparticles by HSA was favorable for ASA 
binding (10-90 mU of ASA per mg nanoparticle), whereas stabilization by poly(vinyl) 
alcohol (PVA) prevented efficient binding (12 mU of ASA per mg nanoparticle at best).  
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To control the specificity of ASA binding, neutravidin-modified nanoparticles (HSA 
stabilized) were also incubated with non-biotinylated ASA (wt ASA) which would be 
expected to result in low binding as binding to neutravidin would be impossible. As a 
second control, non-thiolated, amine modified (no TCEP added) nanoparticles were 
treated accordingly. It would be expected that neither biotinylated nor wt ASA binds to 
these nanoparticles, as covalent attachment of neutravidin should not occur. However, 
surprisingly these controls also revealed binding of ASA (Figure 5.7, A). 
Figure 5.7: Binding of biotinylated or non-biotinylated to thiolated or non-thiolated neu-
travidin nanoparticles and their release of ASA in serum and water. 
A)  Thiolated (‘+TCEP’) and non-thiolated, amine modified (‘-TCEP’) nanoparticles were re-
acted with maleimide-neutravidin followed by binding with biotinylated ASA (‘biot. ASA’) 
or non-biotinylated ASA (‘wt ASA’). After multiple washing steps ASA activity was de-
termined in the pellet and was normalized to the amount of nanoparticles applied. 
B)  All nanoparticle preparations from (A), except the ones where no ASA binding occurred 
(not defined, ‘n.d.’) were resuspended in 50% mouse serum or water and incubated for two 
hours at 37°C. Then ASA activity was measured in the pellets and the supernatants. Shown 
is the fraction of ASA found in the pellet of total ASA.  
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In general, binding of both biotinylated and wt ASA to non-thiolated, amine modified 
nanoparticles (-TCEP) was significantly greater in comparison to binding of  
biotinylated and wt ASA to thiolated nanoparticles (+TCEP). In both cases significantly 
more biotinylated ASA than wt ASA was bound. Overall, best binding occurred when 
using non-thiolated, amine modified nanoparticles and biotinylated ASA (average of 
110 mU/mg for all tested nanoparticle batches).  
One explanation for increased binding of biotinylated ASA to non-thiolated nanoparti-
cles may be unspecific binding. Reaction with cystamine and thiolation influence the 
physicochemical properties of the nanoparticle’s surface, therefore possibly enhancing 
unspecific adsorption. To test this, desorption experiments were conducted in vitro, as 
described before. The nanoparticles were centrifuged and resuspended in 50% serum or 
water. After two hours the activity of ASA in pellets and supernatants was determined 
by ASA-activity measurements (Figure 5.7, B). 
As would be expected for high-affinity binding, desorption of biotinylated ASA from 
neutravidin-modified, thiolated nanoparticles was low (10-25%). In contrast 70% of wt 
ASA bound to the same nanoparticle preparation were released, indicating that binding 
was non-specific. Surprisingly, only 5-18% of biotinylated ASA bound to non-thiolated, 
amine modified neutravidin-nanoparticles was released into the supernatant, indicating 
stable, high-affinity binding. Binding of wt ASA to the same nanoparticle preparations 
was also relatively stable in serum, as only up to 40% of the initially bound ASA was 
found in the supernatant. 
In summary, two effects contradicting the crosslinking procedure hypothesis were not-
ed. First of all, binding of biotinylated ASA was significantly higher when HSA-
stabilized nanoparticles were used instead of PVA stabilized nanoparticles (Figure 5.6). 
This effect may be explained by covalent binding to HSA instead of binding to the car-
boxylic end groups of the PLA- or PLGA-polymers. HSA may either be adsorbed to the 
nanoparticles or (partly) incorporated in their matrix. As virtually no release of biotinyl-
ated ASA was observed in serum (Figure 5.7, A), binding of HSA to the nanoparticles 
must be irreversible under these conditions. Secondly, binding of biotinylated ASA was 
profoundly increased when the reduction step using TCEP to create thiolated nanoparti-
cles was omitted (Figure 5.7, A). This means that binding was increased when the num-
ber of amine groups available on the nanoparticles surface was increased. This effect 
may be explained by covalent binding via amine groups. Indeed, maleimide is also able 
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to bind to amine groups; the rate of this reaction is, however, considerably lower than 
towards sulfhydryl residues at the chosen pH (Hermanson 2008). Addition of cystamine 
and omission of the reduction step using TCEP results in an increase of primary amine 
functions on the surface of the nanoparticles, as carboxylic groups of the polymer and of 
the attached HSA, are modified. Taken together these two findings indicate that cova-
lent binding of maleimide-activated neutraviding primarily occurred via amine groups 
of HSA used as colloidal stabilizer. When further introducing amine groups using 
cystamine (or putrescin, results not shown) more maleimide-activated neutravidin and 
consequently more biotinylated ASA was bound. 
Although contrary to the initial crosslinking hypothesis, binding of biotinylated ASA to 
non-thiolated, neutravidin-modified nanoparticles was substantial, and most importantly 
irreversible in presence of serum. Therefore this method of binding was used for further 
in vivo studies. 
To that end PLGA 1311 was modified accordingly. In total, 90 mU ASA were bound 
per mg nanoparticle. As shown before, little desorption occurred in 100% serum after 
incubation for two hours (11%, Figure 5.8, A).  
In previous modification attempts, an agglomeration of nanoparticles was found both by 
light microscopy and by dynamic light scattering experiments in case of neutravidin-
modified nanoparticles (data not shown). Agglomeration was shown to be reversible by 
treatment with an ultrasound probe. Therefore the nanoparticle preparations were soni-
cated immediately before in vivo experiments. Three mice received injections of 240 mg 
nanoparticles (corresponding to 21.6 U of ASA) per kg body weight, which had previ-
ously been surfactant coated with poloxamer 188. Three control mice received free 
ASA in combination with same concentrations of poloxamer 188. 
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Figure 5.8: In vitro and in vivo studies of biotinylated ASA high-affinity-bound to neu-
travidin-modified PLGA-nanoparticles (batch 1311).  
ASA binding to nanoparticles was performed by binding maleimide-neutravidin to PLGA 
nanoparticles that had been reacted with cystamine. Then biotinylated ASA was added. 90 mU 
of ASA were bound per mg nanoparticle. 
A)  ASA release from these nanoparticles (‘NPs’) after incubation for two hours in serum or 
water. As control, non-nanoparticle-bound ASA was used. The experiment was conducted 
as described for Figure 5.3.  
B)  Biodistribution of ASA two hours after injection of free ASA or nanoparticle bound ASA as 
determined by ASA ELISA in tissue homogenates of ASA-/- mice. Mice received 240 mg of 
nanoparticles (corresponding to 21.6 U ASA) per kg body weight or comparable amounts of 
free ASA after addition of 1% poloxamer 188. Immediately before tail vein injections, 
samples were sonicated to avoid agglomeration of nanoparticles. After two hours, mice 
were sacrificed, transcardially perfused and dissected. ASA concentrations in tissue 
homogenates were determined by ASA-ELISA and were normalized to the total tissue 
concentrations of extractable protein in each tissue, giving the amount of ASA (ng) per mg 
tissue protein. Shown are the means ± SD of three mice per group. Statistical significances 
of differences (p < 0.05) were determined by students t-test and are indicated by an asterisk 
(‘*’). Sp. cord = spinal cord; N. isch. = ischiadic nerve; Pl. brach. = brachial plexus. 
 
As was observed before for ASA-HSA nanoparticles, the tissue distribution of nanopar-
ticle-bound ASA differed from tissue distribution of free ASA two hours after tail-vein 
injections (Figure 5.8, B). Significantly more ASA was found in spleens and significant-
ly less in livers of nanoparticle treated animals in comparison to mice treated with free 
ASA. Most importantly, no increase, but a decrease of brain ASA tissue levels was ob-
served after injections of nanoparticle bound ASA compared to free ASA injections.  
However, tissue levels of ASA may have been underestimated by the detection method, 
the ASA-ELISA. By direct comparison of free and nanoparticle bound ASA standards 
(0.05 – 1.5 ng) it was found that nanoparticle bound ASA was 24-fold less detectable 
than free ASA (results not shown). The obtained ASA concentrations were therefore 
multiplied by this factor in the analyses of nanoparticle-bound ASA injections. The rea-
son for decreased detectability is most likely that the epitopes of nanoparticle bound 
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ASA are shielded by its binding to nanoparticles, resulting in less antibody binding and 
lower signal. However, the ASA tissue levels measured in the brain after injections of 
free ASA were already at the detection limit, the ones measured after injections of na-
noparticle bound ASA even below the detection limit. This means that in comparison to 
free ASA nanoparticle-bound ASA would have had to increase brain tissue levels 24-
fold in order to obtain measurable ASA concentrations. In other words, the conclusion 
of this experiment must be that ASA brain delivery was either not increased or increase 
was less than 24-fold and therefore not detectable. 
In summary, none of the investigated nanoparticle preparations led to a detectable in-
crease of brain delivery of ASA. As can be seen in both in vivo studies, ASA was well 
distributed in the peripheral tissues, without reaching the CNS in substantial amounts. 
One explanation for this observation may be that nanoparticle mediated brain targeting 
fails due to rapid clearance of the nanoparticles by peripheral cells. Therefore an effort 
was made to reduce uptake of ASA and thus nanoparticle-bound ASA by peripheral 
cells, possibly allowing for nanoparticle mediated brain targeting. 
5.2 Increasing blood circulation times by shielding the M6P 
residues of ASA 
The M6P residues of ASA are recognized by MPRs present on the cell surfaces of pe-
ripheral cells. Despite binding to nanoparticles and surfactant coating, M6P residues of 
nanoparticle bound ASA are likely to be bound by MPRs as well. Therefore ways to 
inhibit uptake by peripheral cells were investigated. 
To that aim, a physical shielding of the M6P residues of ASA was attempted. The work-
ing hypothesis was that a polypeptide consisting of the M6P binding domain 9 of the 
MPR300 binds the M6P residues of ASA, thereby preventing recognition of the latter 
by endogenous MPRs on the cell surfaces of peripheral cells. During the process of 
transcytosis at the endothelial cells of the BBB (e.g. mediated by the nanoparticle – 
apolipoprotein system), the pH drops to pH 5.5 in late endosomes. Under these condi-
tions the receptor fragment should release ASA. Unmodified, free ASA may thus be 
delivered to the brain, where M6P mediated endocytosis by brain cells could occur. 
To test this hypothesis, the M6P binding domain 9 (‘MPR300 dom9’) of the human 
MPR300 was cloned, expressed in a Pichia pastoris expression system and purified by 
affinity purification. To prove its ability to bind M6P bearing ASA, KD determinations 
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were performed. Furthermore, the release of ASA from the receptor fragment in de-
pendence of the pH was analyzed. In first in vitro experiments the endocytosis of recep-
tor fragment bound ASA was analyzed in mouse embryonic fibroblasts (MEFs).  
5.2.1 Cloning, protein expression and characterization of 
‘MPR300 dom9’ 
In brief, the coding sequence of the domain 9 (dom 9) of the human MPR300 receptor 
was cloned into a Pichia pastoris expression vector, pPICZαB. In total, four different 
vector constructs were cloned encoding for four different protein constructs, followed 
by their expression and secretion in P. pastoris. Proteins were purified by affinity chro-
matography exploiting their His6-tags. The first, named ‘wildtype’ (wt), has the same 
amino acid sequence as the domain 9 of the human MPR300, including its two (poten-
tial) N-glycosylation sites. The remaining three protein constructs, generated by in vitro 
mutagenesis, carry an amino-acid substitution (asparagine to glutamine) at either one of 
these glycosylation sites (‘N28Q’ and ‘N94Q’) or at both (‘N28Q & N94Q’). Primarily, 
the aim was to generate a non-glycosylated protein construct to avoid immunogenic 
complications possibly triggered by the yeast specific N-glycans in case of in vivo stud-
ies. However, as these oligosaccharide side chains may affect the functionality of the 
protein, each N-glycosylation site had been mutated independently and possible effects 
on stability and ASA binding were evaluated. 
To investigate glycosylation, all of the described proteins were analyzed by Endo Hf 
digest. This endoglycosidase cleaves off N-bound oligosaccharides of the high mannose 
type. Deglycosylation results in a size shift, which was monitored by SDS-PAGE and 
subsequent Coomassie-staining (Figure 5.9). 
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Figure 5.9: Coomassie stained SDS-PAGE of four M6P binding domain fragment con-
structs of the MPR300 (‘MPR300 dom 9’), deglycosylated by incubation with Endo Hf or 
not deglycosylated.  
The calculated size shift is indicated. The constructs are schematically shown underneath the 
correspondent lanes. The four protein constructs were expressed in P. pastoris and purified by 
affinity chromatography. They either carried no amino acid substitution (wt), one amino acid 
substitution at the first (N28Q) or second (N94Q) or two amino acid substitutions at both (N38Q 
& N104Q) asparagin residues serving as N-glycosylation sites. 3 µg of each protein construct 
were denatured and then digested with Endo Hf according to the manufacturer’s protocol. As a 
control identical amounts of the protein construct were incubated under same conditions without 
Endo Hf. 2.25 µg of each sample were loaded on a 10% SDS-PAGE after boiling in Laemmli 
buffer. Differences in molecular weight were calculated by ImageJ analysis. 
 
Deglycosylation by Endo Hf of the constructs resulted in a size shift for all constructs, 
except for the one lacking both N-glycosylation sites (N38Q & N104Q). The wt-, 
N28Q- and N94Q-constructs showed a decrease in molecular weight of 8.0, 3.4 and 
3.9 kDa, respectively. This indicates that both N-glycosylation sites of the wildtype 
fragment are glycosylated. 
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5.2.2 Functional characterization of MPR300 dom9 polypeptides 
To confirm the ability of the purified MPR300 dom9 constructs to bind ASA, a KD de-
termination was performed. The KD value describes the receptor concentration at which 
half of the available binding sites are occupied by its ligand. 
To that end, ASA was coincubated with increasing concentrations of the different 
MPR300 dom9 constructs. Thereon, the latter were precipitated exploiting their His-
tags using Ni-NTA agarose. ASA activity was determined in the supernatants of each 
sample. From these data the amounts of ASA precipitated by the receptor fragment 
were calculated. To evaluate coprecipitation, the common logarithm of the receptor 
fragment concentration was plotted against the amount of ASA precipitated. KD values 
were determined by a non-linear regression curve fitted by the software GraphPad 
Prism (Figure 5.10).  
Figure 5.10: KD determination of ASA binding to the MPR300 Dom9 constructs men-
tioned before.  
Constant amounts of ASA were incubated with increasing concentrations of the receptor frag-
ments under constant shaking for one hour at room temperature. An excess of Ni-NTA-agarose 
was added to the mixture. The MPR300 dom9 receptor constructs carry a His-tag, allowing 
binding to Ni-NTA. After two hours of incubation under vigorous shaking at room temperature, 
the suspension was centrifuged. The amounts of coprecipitated ASA were determined by meas-
uring the remaining activity in the supernatant. 
 
All purified variants of the receptor fragment were able to bind ASA as shown by co-
precipitation assays (Figure 5.10). Lack of either or both glycosylation sites did not re-
sult in loss of ability to precipitate ASA. The KD-values of the different MPR300 Dom9 
constructs calculated by non-linear regression were in the range of 30-57 nM for all 
30.2N28Q&N94Q
50.0N94Q
32.6N28Q
56.6Wildtype (wt)
KD [nM]Construct
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constructs. The constructs where the N-glycosylation site at position 28 was substituted 
bound ASA with slightly higher affinity (KD = 30-32 nM) than the wildtype and N94Q-
constructs still carrying this N-glycosylation site (KD = 50-57 nM). In further experi-
ments the construct lacking both glycosylation sites was preferentially used as no or 
little immunogenic response would be expected during in vivo studies.  
In further experiments the pH-dependent release from the receptor fragment was ana-
lyzed. As mentioned before, during transcytosis at the endothelial cells of the BBB, the 
pH drops to 5.5-6.0, which should result in dissociation of the receptor fragment from 
ASA.  
To test this, ASA and the receptor fragment were coprecipitated using Ni-NTA-agarose 
as before, followed by incubation of the precipitate at pH 5.0-8.5 at 37°C. Then the 
amount of ASA still bound to the receptor fragment was analyzed by ASA activity 
measurements (Figure 5.11). 
 
Figure 5.11: pH dependent dissociation of ASA from the receptor fragment.  
As described for Figure 5.10, ASA and the receptor fragment were coprecipitated using Ni-
NTA-agarose. After washing, pellets were resuspended in different buffer systems at pH 5.0-8.5 
and incubated for 30 minutes at 37°C under vigorous shaking. Suspensions were centrifuged, 
the supernatant was saved, the pellet resuspended after washing with BSA/TBS at pH 7.0. ASA 
activity was determined in supernatant, the wash fractions and resuspended pellet under vigor-
ous shaking. The residual amount of ASA found in the pellet was normalized to the sum of 
ASA activities in all fractions (supernatant + wash + resuspended pellet). Shown are the means 
± SD of three independent experiments. 
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As shown in Figure 5.11, ASA did not dissociate from the receptor fragment at pH 6.0-
7.4. At more acidic pH (5.0) approximately 50% of previously bound ASA dissociated. 
When incubated at alkaline pH (pH 8.0-8.5) the receptor fragment released 20-30% of 
the initially applied ASA. It is therefore assumed that under the acidic environment of 
the endosome, ASA would be partially released from the receptor fragment, allowing 
for brain delivery of unmodified ASA after transcytosis through the endothelial cells of 
the BBB.  
5.2.3  Endocytosis experiments of MPR300 dom9 (N28Q & N94Q) 
complexed ASA 
The previous KD determination studies clearly showed binding of the receptor fragment 
to ASA. Ultimately, the receptor fragment is supposed to bind ASA and shield its M6P 
residues, thereby reducing its uptake by peripheral cells.  
To test for reduced uptake of ASA after binding to the receptor fragment, in vitro endo-
cytosis experiments with MEFs were conducted (Figure 5.12). 
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Figure 5.12: Endocytosis of ASA after pre-coincubation with varying concentrations of 
receptor fragment in MEFs after 24 hours.  
ASA was coincubated without (‘w/o’), equimolar amounts (‘1x’) or a tenfold molar excess 
(‘10x’) of the receptor fragment for one hour in HEPES stabilized growth medium (pH 7.0), 
then added to confluent MEFs. As a negative control, the receptor fragment was applied without 
addition of ASA. After 24 hours of incubation, the supernatant was carefully withdrawn and an 
acidic wash was performed to remove ASA unspecifically bound to cell- or plastic surfaces. 
Then, cells were lysed.  
A) ASA activity measurements in lysates, normalized to the initially applied ASA activity 
(100%). Values represent the means of three independent experiments, each measured in 
technical triplicates (three wells). A significant difference, as calculated by the Student’s t-
test, is indicated by an asterisk (‘*’, p = 0.016; n.s. = not significant). 
B) Representative immunoblot against the MPR-fragment of the solutions before application 
onto cells (initial = ‘I’), the cell culture supernatant (‘S’) and lysates (‘L’) after 24 h show-
ing the localization of the receptor fragment. 15 µL of each sample were loaded onto the 
SDS-PAGE. The immunoblot was performed using a self-made polyclonal rabbit antiserum 
against the MPR-fragment (diluted 1:1,000). For detection a peroxidase conjugated goat anti 
rabbit antibody was used.  
 
As Figure 5.12, A shows, uptake of ASA was significantly reduced after coincubation 
with a tenfold molar excess of receptor fragment (40% of ASA endocytosed), but not 
after coincubation with equimolar amounts of receptor fragment in comparison to cells 
treated with same amounts of non-shielded ASA (47% of ASA endocytosed). In com-
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parison to non-shielded ASA, 15% less ASA was taken up after coincubation with a 
tenfold excess of receptor fragment.  
The immunoblot against the MPR-fragment (Figure 5.12, B) showed no signal in the 
lysates, whereas clear bands were detected for the initial solutions and the cell culture 
supernatants. This indicates that in contrast to the applied ASA the receptor fragment 
was not endocytosed but remained extracellularly located.  
5.2.4 Dissociation of ASA and receptor fragment in different solutions 
The reduction of ASA uptake of shielded compared to non-shielded ASA was less than 
expected. It was hypothesized that a component of the cell culture medium may possi-
bly have caused partial dissociation of ASA and the receptor fragment thereby allowing 
endocytosis of unshielded ASA. To investigate this, the release of ASA from the recep-
tor fragment was determined in presence of cell culture medium according to the same 
method applied for the pH-dependent desorption experiments (chapter 5.2.2). With re-
gard to future in vivo studies, dissociation experiments were conducted in serum. In case 
of rapid dissociation in serum, uptake by peripheral cells and consequently the serum 
half life times would be expected to be unchanged. As positive control for dissociation, 
a M6P solution was used in this assay. M6P should compete with ASA for receptor 
binding, thereby inducing release of ASA (Figure 5.13).  
Figure 5.13: Dissociation of ASA from the MPR-fragment in presence different solutions.  
The experiment was conducted as described for Figure 5.11. Bars represent the means ± SD of 
four independent experiments. Dissociation of ASA was analyzed in presence of 1% (w/v) BSA 
in TBS (pH 7.0), cell culture medium (DMEM+FCS+HEPES, pH 7.0), ASA-/- mouse serum and 
10 mM M6P (M6P; in 1% BSA in TBS, pH 7.0)  
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In presence of cell culture medium 20.0% (± 1.2%) of ASA dissociated from the recep-
tor fragment. This observation may partially explain the relatively low difference of 
uptake of ‘shielded’ versus non-shielded ASA by MEFs observed before (chapter 
5.2.3). Moreover, 37.5% (± 10.6%) of the initially bound ASA was released in serum. 
This indicates presence of either M6P containing proteins or endogenous, soluble M6P 
receptors. When pure M6P was added to a final concentration of 10 mM, 97% (± 0.4%) 
of ASA was released from the receptor fragment, proving that the receptor fragment 
binds to the M6P residues of ASA. 
5.2.5 Covalent binding of the receptor fragment to nanoparticles 
To bind the MPR-fragment to nanoparticles, amine modified nanoparticles were to be 
reacted with the thiolated MPR-fragment using the NHS-(PEG)12-maleimide crosslinker 
as was described previously (chapter 5.1.4.1). PLGA-nanoparticles (#1311) were amine 
modified by reaction with EDC and cystamine. Alternatively, the commercially availa-
ble amine modified nanoparticles (Phosphorex Inc.) were used. The non-glycosylated 
MPR fragment was thiolated using Traut’s reagent (Figure 5.14). 
 
 
 
Figure 5.14: Crosslinking strategy for covalent attachment of the MPR fragment to amine 
modified PLGA-nanoparticles. 
PLGA-nanoparticles were either reacted with cystamine after EDC activation or commercially 
available amine-modified nanoparticles (Phosphorex Inc.) were used. The MPR fragment was 
thiolated by Traut’s reagent. A heterobifunctional amine- and sulfhydryl-reactive crosslinker 
was used for covalent binding. 
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After the covalent crosslinking procedure, unmodified ASA was added to determine 
how much ASA can be bound by this nanoparticle system. As described before, 
amounts of bound ASA were evaluated by ASA activity determinations. 9.2 and 16.2 
mU of ASA were bound to PLGA 1311 and N-PLGA (Phosphorex Inc.) nanoparticles, 
respectively. These yields are comparable to the ones of direct crosslinking of ASA to 
N-PLGA observed in chapter 5.1.4.1 (8.92 mU/mg nanoparticle). However, this rela-
tively low binding of ASA to MPR-fragment nanoparticles does not allow for in vivo 
studies. Therefore crosslinking strategies to improve binding of the MPR fragment and 
consequently ASA need to be optimized. For instance, neutravidin-modified nanoparti-
cles may again be used to bind biotinylated MPR-fragment, followed by binding of 
(unmodified) ASA.  
 
In summary, four constructs of the domain 9 of the MPR300 were successfully cloned, 
expressed and purified. All constructs were able to bind ASA with high affinities (30- 
57 nM). The non-glycosylated construct was thereon analyzed further. It was shown 
that ASA was released from this construct in a pH dependent manner. However, the 
affinity of the receptor fragment towards ASA must be increased in the future, as 38% 
of initially bound ASA dissociated in presence of serum, limiting its applicability in 
vivo. Covalent binding of the receptor fragment to nanoparticles was achieved, but must 
be increased in future experiments. Most importantly, however, it was shown that a ten-
fold molar excess of the receptor fragment over ASA led to significantly lowered uptake 
by MEFs, confirming the working hypothesis. 
5.3 Identification of inhibitors for Arylsulfatase A 
ASA inhibitors are needed for two reasons:  
Primarily, ASA inhibitors may be used in a novel therapeutic approach for MLD, chap-
erone therapy. The rationale of chaperone therapy is that the inhibitor binds to the mis-
folded protein in the endoplasmic reticulum. Thereby the enzyme is stabilized and is 
not, as would physiologically happen, degraded by the ERAD. Consequently, these en-
zymes are then transported to the lysosome, where ideally the inhibitor dissociates from 
the enzyme due to the acidic pH. The at least partially active enzyme can then degrade 
the lysosomally accumulated storage material thus reducing the severity of the disease. 
However, this therapeutic approach will only be applicable for patients carrying gene 
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mutants responsible for expression of misfolded enzymes (with little or no residual ac-
tivity), but not complete lack of enzyme. More than 7 mutations are known leading to 
ASA misfolding and degradation by the ERAD system (Poeppel et al. 2005). 
Secondly, ASA inhibitors might prove useful to generate a cell culture model of MLD. 
All sorts of cells could be treated with such an ASA inhibitor, abolishing ASA-activity 
in the lysosome, possibly leading to intralysosomal storage of sulfatide, the substrate of 
ASA. Such a cell culture model would be useful to study the cellular and molecular 
pathomechanisms of MLD and might help find new therapeutic targets against this dis-
ease.  
5.3.1 Establishment of an assay suitable for high throughput 
screening 
In order to be able to identify potential inhibitors in high throughput screenings, it is 
necessary to adjust the assay parameters. First, substrate levels have to be minimized to 
avoid competition of excess substrate molecules with inhibitors for enzyme binding 
sites. As a gold standard the substrate concentration in inhibition assays should be in the 
range of or below the Km of the investigated enzyme. Secondly, the enzymatic hydroly-
sis of the substrate has to be constant over the time of the assay. Furthermore, the assay 
should tolerate DMSO, the solvent for most screening compounds. Under these condi-
tions the assay must be robust, which can be evaluated by determination of the Z’-
factor. In general, the higher the Z’ score (ranging between 0 and 1), the lower is the 
variability and the better suited is the assay for high throughput screenings. As a rule of 
thumb, a Z’ score ≥0.5 indicates that the assay is robust (Zhang et al. 1999). The Z’ 
score was evaluated for each measured plate separately. 
The high-throughput screenings were performed at a substrate (end-)concentration of 
0.25 mM, near the Km of 0.21 mM as previously described (Bognar et al. 2006). The 
rate of 4-nitrocatechol sulfate hydrolysis remained constant over 90 minutes at 37°C 
employing 105 ng/µL ASA in the assay (results not shown). The assay tolerated up to 
5% DMSO without significant loss of signal in comparison to 0% DMSO (results not 
shown). The performance of the assay was robust both in 96- and in 384-well plates as 
the Z’-factor was 0.89 on average for all plates. No plate had a Z’-factor below 0.5 (not 
shown). 
76  5 Results 
5.3.2 High throughput screening of libraries  
The first of two screenings was performed at the Leibniz-Institut for Molecular Pharma-
cology in Berlin (FMP Berlin). In this screening, five libraries containing a total of ap-
proximately 30,000 compounds were tested. Each compound was added to a final con-
centration of 10 µM and 1% DMSO in single reads. The assay was performed in 384-
well plates in a semi-automated fashion. 
Of the 30,000 compounds tested, 320 showed reduction of relative ASA-activity by 
10% or more (<90% residual ASA-activity). These hits were measured again in a con-
centration dependent manner (0.4 – 50 µM, 9 data points) to evaluate their IC50 values. 
Of the 320 tested candidate compounds, only ten decreased ASA-activity by 10% or 
more at the highest concentration of 50 µM (Figure 5.15, B). Therefore no IC50 values 
could be calculated. These ten candidate inhibitors were then manually retested in con-
centrations between 16.6-100 µM in a 96-well plate assay (Figure 5.15, A). It became 
apparent that six of the ten compounds formed precipitates after dilution in TBS. In 
summary, one (‘compound A’) of 30,000 compounds tested was confirmed to have an 
inhibitory effect on ASA activity. Its chemical structure is depicted in Figure 5.15, C. 
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Figure 5.15: Results of high throughput screening with approximately 30,000 compounds 
performed to identify ASA inhibitors. 
A)  Manual re-evaluation of the inhibitory effect of ten candidate compounds on ASA activity. 
Six of the compounds tested formed precipitates and only one (compound A) showed an in-
hibitory effect.  
B)  Concentration dependence of the most potent compound (‘compound A’).  
C)  Chemical structure of compound A: 1-{[6-(1,5-dimethyl-1H-pyrazol-4-yl)-3-methyl-1-
propyl-1H-pyrazolo[3,4-b]pyridin-4-yl]carbonyl}-4-[(1-ethyl-1H-pyrazol-4-
yl)methyl]piperazine. 
 
In a second screening, a drug library containing 440 compounds was tested, which was 
kindly provided by Prof. Dr. C. Müller, Pharmazentrum Bonn. Each compound was 
added to a final concentration of 10 µM and 1% DMSO. The assay was performed 
manually in 96-well plates in single reads (Figure 5.16, A). In this initial screening 13 
of the tested compounds reduced ASA-activity by 10% or more in comparison to the 
negative control (ASA without any compounds, but 1% DMSO). These compounds 
were then re-evaluated in duplicates at the same concentration (10 µM) as before (data 
not shown). Three drugs, namely primaquine diphosphate, sulfathiourea and met-
amizole were confirmed to have an inhibitory effect on ASA activity. The inhibitory 
effects were concentration dependent (Figure 5.16, B). In summary, three of the 440 
compounds of this drug library decreased ASA activity. Their chemical structures are 
depicted in Figure 5.16, C. 
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Figure 5.16: Results of manual high throughput screening of 440 commercially available 
drugs. 
A)  ASA activation and inhibition upon incubation with 10 µM of each compound in the initial 
screening in single reads on five 96-well plates (P1-P5). 13 compounds (marked by arrows, 
bottom) inhibited ASA by ≥ 10%, one compound (marked by arrow, top) showed apparent 
activation of ASA, which could not be confirmed in later experiments (not shown). 
B)  Of the 13 inhibitory substances, three were confirmed. Residual ASA activity was measured 
in presence of increasing compound concentrations for primaquine, metamizole and sul-
fathioruea.  
C)  Chemical structure of sulfathiourea, primaquine diphosphate and metamizole. 
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5.3.3 Biochemical evaluation of inhibitors found in screenings 
The four potential ASA inhibitors, one from the first and three from the second high 
throughput screening were further analyzed. First, their IC50 values were determined. 
This value is defined as the inhibitor-concentration at which the enzyme activity is re-
duced by half in a given assay: the lower the IC50 value, the stronger the inhibition. Sec-
ondly, the type of inhibition was analyzed. To that aim Michaelis-Menten kinetics were 
performed, by measuring the rate of 4-nitrocatechol sulfate hydrolysis by ASA at vary-
ing substrate- and inhibitor-concentrations. From these enzyme kinetics, the maximal 
reaction rate (Vmax) and the Michaelis-constant Km in presence or absence of inhibitor 
can be evaluated.  
To test chemical stability of the compounds and to detect possible contaminants, the 
time dependence of the inhibition and mass spectromic analyses were performed. 
5.3.3.1 Determination of IC50 values 
The range of concentrations tested depended on the strength of inhibition previously 
measured. Compound A, primaquine diphosphate and sulfathiourea were tested in a 
range of 0.1-10,000 µM, metamizole 0.05-1,000 µM. Figure 5.17 shows the ASA inhi-
bition in dependence of the compound concentrations in logarithmic scale. 
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Figure 5.17: IC50 determination of compounds previously identified in high throughput 
screenings.  
Residual ASA activity was measured in the presence of 0.05-10,000 µM compound A (A), pri-
maquin diphosphate (B), sulfathiourea (C) or metamizole (D) in the inhibition assay. The IC50 
values, determined by the software ‘GraphPad Prism’, are indicated for each inhibitor.  
 
IC50 values were calculated using the software ‘Graphpad Prism’ by non-linear regres-
sion and were 62.6 µM for primaquine diphosphate, 49.1 µM for compound A, 10.0 µM 
for sulfathiourea and 2.3 µM in case of metamizole.  
5.3.3.2 Type of inhibition – Michaelis-Menten kinetics 
For each of the compounds (compound A, primaquine, sulfathiourea and metamizole), 
the reaction rate of ASA hydrolyzing 4-nitrocatechol sulfate was analyzed for a total of 
six inhibitor concentrations at eight substrate concentrations. The enzyme kinetic pa-
rameters Km and Vmax were calculated by non-linear regression using the software 
IC50 = 49.1 µM IC50 = 35.6 µM
IC50 = 28.1 µM IC50 = 2.3 µM
A
C
B
D
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Graphpad Prism after plotting the reaction rate against the substrate concentration  
(table 5.1). 
 
Table 5.1: Enzyme kinetic parameters determined by Michaelis-Menten kinetics and sub-
sequent non-linear regression analysis using the software Graphpad Prism. 
Eight substrate concentrations and 5 or 6 inhibitor concentrations were tested for each inhibitor. 
Shown are the apparent Vmax [OD515 / 90 min] and Km [mM] values for each inhibitor concen-
tration [µM]. 
Compound A  0  3.13  6.25  12.5  25  50  100 µM 
Vmax 0.5076 0.5368 0.5402 0.548 0.4581 0.5408 0.3636 
Km [mM] 0.4162 0.557 0.621 0.8435 0.841 1.5675 1.7385 
        
Primaquine 0  3.56  7.13  14.25  28.5  57 µM 
  
Vmax 0.8323 0.8504 0.8371 0.8569 0.8859 0.9313  
Km [mM] 0.3258 0.3643 0.4005 0.4839 0.6635 1.162  
        
Sulfathiourea 0 5 10 20 30 40 50 µM 
Vmax 0.6173 0.5978 0.6145 0.5971 0.5926 0.5990 0.6000 
Km [mM] 0.2737 0.2943 0.3348 0.3663 0.4857 0.5856 0.6684 
 
       
Metamizole 0  0.25  0.5  1  2  4  8 µM 
Vmax 0.6492 0.62555 0.6244 0.5945 0.61105 0.61125 0.57485 
Km [mM] 0.26775 0.42865 0.57725 0.7771 0.98505 1.4815 1.94 
 
None of the potential inhibitors changed the maximal reaction rate Vmax, whereas the 
apparent Km increased with increasing inhibitor concentrations. To illustrate this corre-
lation graphically, a double reciprocal plot of the reaction rate versus the substrate con-
centration was drafted (Figure 5.18). In this Lineweaver-Burk plot, a common intersec-
tion point on the y-axis indicates competitive inhibition, a common intersection at the x-
axis non-competitive and an intersection point in quadrant II a mixed-type inhibition. In 
case of all ASA inhibitors the lines intersect on the y-axis, clearly indicating a competi-
tive type of inhibition.  
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Figure 5.18: Inhibition 
kinetics of previously 
found candidate ASA 
inhibitors in different 
concentrations and vary-
ing substrate concentra-
tions to determine the 
type of ASA inhibition. 
Shown is the double recip-
rocal plot of the reaction 
velocity over the substrate 
concentration (Line-
weaver-Burk plot). The 
best-fit lines are based on 
the Km- and Vmax-values 
previously calculated by 
non-linear regression us-
ing the software 
‘GraphPad Prism’. The 
average interception point 
of all best-fit lines is indi-
cated by a red cross. com-
pound A (A), primaquine 
diphosphate (B), sulfathi-
ourea (C) and metamizole 
(D). 
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5.3.3.3 Specificity of ASA inhibitors 
In order to perform pathomechanistic studies of MLD in cell culture, it must be assured 
that ASA is the main target and that other enzymes are not inhibited. To test the speci-
ficity, candidate ASA inhibitors were used in activity assays of arylsulfatase B (ASB).  
As ASA and ASB both are able to hydrolyze 4-nitrocatechol sulfate, the ASA inhibition 
assay only had to be slightly modified to also be applicable for ASB. The enzyme con-
centration was increased from 0.105 µg/mL for ASA to 0.25 µg/mL for the ASB-
inhibition assay in order to measure the same rate of 4-nitrocatechol sulfate hydrolysis. 
The Km value of ASB towards 4-nitrocatechol sulfate is 3.6 mM (McGovern et al. 
1982). Therefore competitive inhibition can be investigated at the previously chosen 
substrate concentration of 0.25 mM. 
This assay was thereon used to determine the specificity of candidate ASA inhibitors 
(Figure 5.19). The ASB-activity was diminished in presence of each of the investigated 
compounds. It must therefore be concluded, that all compounds with inhibitory potential 
for ASA also inhibit ASB.  
Figure 5.19: Specificity of ASA inhibitors.  
Shown is the residual enzyme activity of arylsulfatase B (ASB) in presence of increasing con-
centrations of compound A (crosses), primaquine (open circles), sulfathiourea (closed triangles) 
and metamizole (closed diamonds).  
 
 
0%
20%
40%
60%
80%
100%
120%
0 10 20 30 40 50
Compound concentration [µM]
R
e
s
id
u
a
l A
SB
 
a
c
tiv
ity
 
ASA Metamizole
ASA Primaquine
ASA Sulfathiourea
Compound A
Primaquine
ulfathiourea
Compound A
Metamizole
5 Results 85 
5.3.3.4 Chemical stability of potential ASA inhibitors  
To investigate their chemical stability, ASA activity was determined in presence of the 
potential inhibitors over time. In case of their hydrolysis, residual ASA activity should 
change over time, as the concentrations of the substances themselves and their hydroly-
sis products change. 
Previously, in the standard ASA inhibition assay an endpoint measurement was per-
formed; absorption cannot be measured before stopping the assay. To test time depend-
ence of the ASA inhibition, shorter incubation periods were to be chosen. However, 
especially short incubation times result in low measurable absorbances. Therefore, the 
shorter the incubation time, the more ASA was added to the assay in order to maintain 
constant absorbance readouts. The highest ASA end-concentration of 6 µg/mL was used 
when incubated for 1 min and the lowest of 0.1 µg/mL when incubated for 90 min. ASA 
activity was determined in presence of compound A, primaquine, sulfathiourea or met-
amizole (Figure 5.20). 
 
Figure 5.20: Residual ASA activity after incubation for varying time periods (1-90 min) in 
the presence or absence of compound A (crosses), primaquine (filled squares), sulfathiou-
rea (filled triangles) or metamizole (filled circles).  
Decreasing amounts of ASA were employed with longer incubation times leading to constant 
OD readouts. All substances were either freshly weighed in and dissolved or diluted from 
DMSO stock solutions immediately before use. End-concentrations in the ASA inhibition assay 
were 150, 30, 150 and 3 µM for compound A, primaquine, sulfathiourea and metamizole, re-
spectively. Shown are the means ± SD of technical triplicates. 
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In this setup it is possible to identify hydrolysis of inhibitors and to evaluate whether the 
starting material or one of its hydrolysis products is responsible for inhibition. Whereas 
ASA inhibition was independent of time in case of compound A and primaquin, inhibi-
tion of ASA increased over time after addition of sulfathiourea or metamizole. This 
suggests that these substances do not affect ASA activity themselves. Instead these 
compounds are likely to react to active compounds under assay conditions.  
To confirm these results and to identify the substances responsible for inhibiting ASA, 
mass spectromic analyses of metamizole and sulfathiourea were performed after incuba-
tion for zero and 90 minutes under assay conditions (pH 5.0, 37°C). 
Metamizole or sulfathiourea solid was weighed in and then dissolved or taken from 
DMSO-stock solutions and diluted in prewarmed ammonium acetate buffer, ph 5.0, to 
obtain a 10 mM solution. After zero and 90 minutes samples were drawn, diluted to a 
final concentration of 100 µM in methanol/acetonitrile (10:90, v/v) and measured by 
direct injection into an ESI-ion trap mass spectrometer (Figure 5.21). 
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Figure 5.21: Mass spectra of metamizole (A, B) and sulfathiourea (C) after incubation 
under assay conditions (37°C, pH 5.0 for 0-90 minutes).  
A)  Negative mode spectra of metamizole. Only one peak at 309.9 m/z appeared, corresponding 
to the mass of the intact compound. MSn analyses confirmed this peak to be Metamizole.  
B)  Positive mode spectra of metamizole. After 90 minutes of incubation a peak at 218.1 m/z is 
visible. This mass corresponds to the mass of 4-methylaminoantipyrine (4-MAA), a known 
hydrolysis product of metamizole. The MSn fragmentation pattern confirmed 4-MAA iden-
tity (data not shown).  
C)  Negative mode spectra of sulfathiourea. For sulfathiourea a peak at 229.9 m/z correspond-
ing to the mass of the intact compound is visible in the negative mode. This peak was con-
firmed to be sulfathiourea by MSn fragmentation. Another peak at 195.9 m/z was detected. 
After 90 minutes of incubation at 37°C the intensity of this second peak increased slightly, 
whereas the peak at 229.9 m/z was no longer detectable. No peaks were detected in positive 
mode (not shown). 
Although the absolute amounts of the substances cannot be determined by this method, 
a qualitative evaluation is possible. The peak at 309.9 m/z in the negative spectra (con-
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firmed by MSn fragmentation to be metamizole) decreases, whereas the peak attributed 
to 4-methylaminoantipyrin at 218.1 m/z (4-MAA, MSn confirmed) in the negative spec-
tra increases in intensity after 90 minutes. By hydrolysis of metamizole, 4-MAA and 
sulfite (SO32-) are generated (Wessel 2004). Sulfite is a known, potent inhibitor of ASA 
(Matzner et al. 2009a). 
The inhibitory effect previously attributed to metamizole, can therefore be attributed to 
sulfite. Further experiments showed that sulfite has a similar IC50 value as metamizole 
(chapter 5.3.3.1) and is a competitive inhibitior of ASA (results not shown). 
The mass spectrometry analyses of sulfathiourea also showed a time dependent intensity 
decrease of its corresponding peak at 229.9 m/z. After 90 minutes this peak was no 
longer detectable. Instead the peak intensity of the peak at 195.9, present also at ‘0 
minutes’, increases after 90 minutes of incubation. This peak could not be identified by 
MSn fragmentation and may be a contaminant. Its mass however, corresponds to the 
mass of sulfathiourea (229.9 g/mol) after arithmetic subtraction of the mass of hydrogen 
sulfide (H2S, 34.1 g/mol). This result further confirms hydrolysis of sulfathiourea, hint-
ing at, but not proving splitting off of hydrogen sulfide. 
5.3.3.5 Inhibition of ASA by phosphate 
Primaquine diphosphate was shown to have a time independent inhibitory effect on 
ASA activity (IC50 of 35.6 µM). It is known that phosphates inhibit ASA in the mM-
range (Matzner et al. 2009a). To test whether the phosphate salts of the primaquine sol-
id are responsible for ASA inhibition, phosphate was added to the assay up to the same 
concentrations present in primaquine diphosphate. 4-nitrocatechol sulfate hydrolysis by 
ASA was analyzed in presence of up to 200 µM of phosphate in presence or absence of 
up to 100 µM of primaquine (Figure 5.22). 
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Figure 5.22: ASA inhibition in presence of increasing concentrations of sodium phosphate 
in presence (+) or absence (-) of primaquine. 
  
ASA inhibition by phosphates was independent from the presence of primaquine. It can 
therefore be excluded that the inhibitory effect previously observed for primaquine solu-
tions is caused by primaquine itself, but is rather caused by the phosphate ions present 
in the solution. 
In total, the potential of approximately 30,500 compounds to influence ASA activity 
was investigated. Four compounds seemed to decrease ASA activity with IC50 values in 
the range of 2-50 µM. All showed competitive inhibition. However, in two cases hy-
drolysis of the compounds occurred and the product of hydrolysis inhibited ASA. A 
third compound did not inhibit ASA itself, but phosphate ions were the reason for ASA 
inhibition. Therefore only one compound (‘compound A’) was confirmed to be an in-
hibitor of ASA. To find more specific and stronger inhibitors, a virtual docking screen-
ing was performed using compound A as a lead structure. 
5.3.4 Identification of ASA inhibitors by Virtual Screening 
Binding of compound A, 4-nitrocatechol sulfate and sulfatide into the active site of 
ASA was simulated by molecular docking studies (cooperation with Prof. Dr. J. Bajo-
rath and Prof. Dr. M. Gütschow, University of Bonn). Using the calculated fit of these 
substances as references, a fingerprint similarity search (MACCS structural keys) of the 
ZINC 12 Clean Leads subset was performed (Irwin and Shoichet 2005). The 1000 com-
pounds with the highest Tanimoto similarity index (Willett 2006) were selected for mo-
lecular docking studies using AutoDock 4.2 (Morris and Huey 2009). The 200 candi-
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date compounds with the lowest binding energies were then manually evaluated for 
their fit. Of 16 proposed compounds, eight were commercially available. Two other 
substances which fitted well into the active site in silico were synthesized by our col-
laboration partners. The chemical structures of these 10 compounds and their influence 
on ASA activity are depicted in Figure 5.23. ASA activity was not influenced by any of 
the tested substances, only compound A (positive control) showed the previously ob-
served inhibitory effect. As none of the 4-nitrocatechol sulfate resembling compounds 
inhibited ASA, this indicates that only sulfates, but not sulfonic acids or sulfamidic ac-
ids are able to bind to the active site of ASA.  
It must therefore be concluded that this rational design approach did not result in the 
identification of more potent inhibitors. Instead, all proposed substances proved to be 
non-inhibitory. It has to be noted, however, that compound A binding to the active site 
in silico was not distinct. Instead, it appeared to cover the active site, forming a ‘lid’, 
thereby probably hindering entrance of 4-nitrocatechol sulfate and its cleavage. This 
relatively unspecific binding exacerbated definition of other chemical structures binding 
in a similar manner with higher affinity.  
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Figure 5.23: Compounds identified by virtual screening approach (A) and evaluation of 
their effect on ASA activity (B). 
A)  The eight commercially available and two synthesized compounds found in virtual screen-
ings. Compounds of the 12 Clean leads subset of the ZINC library were fitted into the active 
site of ASA and their binding energies were calculated. The 200 substances with the lowest 
binding energies were evaluated manually for their binding into the active site. Of 16 com-
pounds, the 8 compounds depicted here were commercially available. Two other substances 
showing good fits were synthesized. 
B)  ASA activity in presence of these ten compounds in varying concentrations (6.25-100 µM). 
Compound A served as positive control and was the only substance inhibiting ASA. 
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Compound A remains the only confirmed inhibitor of ASA. This compound had an IC50 
value of 49.1 µM and was proven to be a competitive inhibitor. Inhibition was not spe-
cific for ASA, as also ASB was inhibited at similar inhibitor concentrations.  
To find more active and/or more specific inhibitors of ASA, further libraries may be 
screened using the here established ASA inhibition assay. Moreover, the here identified 
inhibitor may be used as a lead structure for further virtual screenings. The chemical 
structure of compound A may be modified at different parts of the molecule followed 
by empirically testing for inhibitory potential. This would allow identification of more 
active substances step by step. 
Moreover, compound A is to be used in cell culture experiments in the future to evalu-
ate its efficacy of inhibiting ASA in vitro. Further cell culture experiments using cells 
expressing mutant, inactive ASA that is degraded by the ERAD, are then to be treated 
with the inhibitor. It will have to be investigated whether compound A can function as a 
chaperone to ASA, thereby increasing the transport of functional ASA to the lysosomal 
compartment. Before conducting in vivo experiments, the ability of compound A to 
traverse the BBB will be analyzed in a well established porcine BBB model (Prof. H.-J. 
Galla, Münster). 
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6.1 Enzyme replacement therapy and use of nanoparticles 
Although ERT is a common approach to treat lysosomal storage disorders, its use for 
diseases with CNS pathology is limited by the impermeability of the BBB. Therefore, 
only high dose treatment with intravenously injected ASA has led to improvements in a 
mouse model of MLD in terms of sulfatide storage and performance in behavioral tests 
(Matzner et al. 2005; Matzner et al. 2009b). However, therapeutic benefits are out-
weighed by the costs of high dose treatment posing yearly costs of several million € per 
year and patient – global treatment of MLD would not be possible. It is consequently 
necessary to reduce the amounts of ASA needed for treatment. This can only be 
achieved by surmounting the BBB, one of the ‘holy grails’ of modern medicine.  
Many strategies to increase brain delivery have been proposed in the past decades. Two 
of them were investigated in this work in detail to be used for ERT of MLD. The first 
strategy is the use of polymeric nanoparticles to transport drugs into the brain. Second-
ly, shielding of M6P residues of recombinant ASA was performed to decrease uptake 
by peripheral cells and increase brain delivery by prolonging the blood circulation 
times.  
Numerous nanoparticle preparations have been described to reach the brain. Recently, 
1481 publications (1970-2012) attributed to the field of brain delivery and targeting of 
drugs or drug delivery systems were screened (Kozlovskaya and Stepensky 2013). Only 
a fraction of all publications (< 123) described the portion of drugs found in the brain 
quantitatively after parenteral administration using different nanoparticle systems (Fig-
ure 6.1). Curiously, the percentage of the drug dose found in the brain using nanoparti-
cles ranges from less than 0.01% to more than 10% in these publications. This hetero-
geneity is attributed to several factors. For instance, the authors state that in the majority 
of the publications drugs and nanoparticles left in the circulation system are not re-
moved by (transcardial) perfusion before dissecting the brain and analyzing its drug 
content and may therefore overestimate the percentage of the drug dose in the brain. 
Also, due to limitations of the applied analytical methods, a significant number of stud-
ies may have over- or underestimated the percentage of the drug dose in the brain. 
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Figure 6.1: Publications describing brain delivery 
of drugs by different nanoparticle preparations.  
The criteria were (1) publication date 1970-2012; (2) 
in vivo experiments; (3) administration via intrave-
nous, subcutaneous, or intraperitoneal injection; (4) 
quantitative data on brain targeting and/or extent of 
brain delivery of a drug or model compound (adapted 
from Kozlovskaya & Stepensky 2013). 
 
 
 
 
 
Recently, nanoparticle mediated enzyme replacement therapies for two LSDs have been 
investigated (Hsu et al. 2011a, 2011b). The authors described use of a polymeric nano-
particle system for enhanced brain delivery of α-glucosidase and α-galactosidase, the 
enzymes deficient in Pompe and Fabry diseases, respectively. Interestingly, a 4-6 fold 
increase in brain delivery of both enzymes was calculated. Moreover in another study 
the same nanoparticle system was used to deliver acid sphingomyelinase, deficient in 
Niemann Pick A and B diseases, to the brain (Papademetriou and Garnacho 2013). In 
comparison to injections of free acid sphingomyelinase, the nanoparticles bound en-
zyme was calculated to increase brain delivery by 7-9 times. However these nanoparti-
cles are made of polysterene, therefore not biodegradable and not suitable for clinical 
use. The experiments have not yet been conducted with biologically degradable nano-
particles.  
Based on literature, a minimal threshold of binding of 13.3 mU ASA per mg nanoparti-
cle was calculated to allow for in vivo experiments (chapter 5.1). The underlying studies 
showed 0.1-0.93% of the injected doses in the brain (Ambruosi et al. 2006; Halder et al. 
2008). In both studies radioactively labeled nanoparticles were injected and radioactivi-
ty was measured in organs by scintillation counting. Inauspiciously, in both studies an-
imals were not perfused prior to the analyses. Thus, results must be interpreted with 
caution. 
However, one may not only consider quantitative data. Qualitative data such as micro-
scopic images of the brain or behavioral data (e.g. pain resistance after application of an 
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analgesic drug) are also valuable, especially as behavioral assays prove functionality of 
the administered drug (van Rooy et al. 2011). Several qualitative studies were able to 
prove brain delivery of PBCA- (Reimold et al. 2008; Andrieux and Couvreur 2009; 
Reukov et al. 2010), PLA- and PLGA (Gelperina et al. 2010; Li et al. 2011; Chaturvedi 
et al. 2014), as well as HSA-nanoparticles (Hoffmann et al. 2006; Ulbrich et al. 2009; 
Zensi et al. 2009). 
6.1.1 Choice of nanoparticles 
Different sizes, core materials and surface modifications have been studied in last dec-
ades to increase brain delivery of therapeutics. For ERT repeated injections of recombi-
nant enzyme over long periods of time are necessary. Therefore, nanoparticles used for 
ERT need to be biodegradable; otherwise their accumulation over time may lead to ad-
verse effects. All nanoparticles used in this work fulfill this criterion. Poly(acryl cy-
anoacrylate)-, HSA- and PLA-containing nanoparticles are physiologically degraded by 
esterases, cathepsin B and hydrolysis, respectively (Kreuter et al. 2007; Andrieux and 
Couvreur 2009; Samarajeewa et al. 2012).  
In most studies of polymeric nanoparticles for brain delivery, their average diameter is 
in the range of 50-400 nm (Wohlfart et al. 2011). Accordingly, only nanoparticles in the 
range of 75-357 nm were used here. 
The most important factor for tissue targeting of nanoparticles appears to be their sur-
face characteristics – these play important roles in respect to biodistribution (Aggarwal 
et al. 2009). Brain targeting has been reported in multiple studies by using polysorbate 
80- or poloxamer 188-surfactant coating. Interestingly, the efficiency of surfactant me-
diated brain delivery depends on the employed core material. Best brain delivery of 
PBCA-nanoparticles was observed after polysorbate 80-coating, other classes of surfac-
tants led to poor brain delivery (Kreuter et al. 1997). HSA nanoparticles have also been 
surfactant coated to increase brain delivery using polysorbate 80 (Michaelis et al. 2006; 
Avachat et al. 2014). In case for PLA- and PLGA-nanoparticles poloxamer 188-
surfactant coating resulted in superior brain delivery versus polysorbate 80-coating 
(Gelperina et al. 2010), although another study also proved significant brain delivery by 
means of polysorbate 80-coated PLGA-nanoparticles (Chaturvedi et al. 2014). Accord-
ingly, in this work HSA- and PBCA-nanoparticles were surfactant-coated with poly-
sorbate 80, whereas for PLA- and PLGA-nanoparticles poloxamer 188 was used. 
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6.1.2 Strategies to combine ASA and nanoparticles 
To bind ASA to these nanoparticles, all three possible approaches were investigated – 
inclusion during the production of the nanoparticles, passive adsorption and covalent / 
high affinity-binding to the nanoparticles surface.  
6.1.2.1 Incorporation into PBCA-, PLA- and PLGA-nanoparticles 
Inclusion of drugs and their brain delivery is frequently described in literature. Howev-
er, the drugs incorporated are usually small, e.g. the anthracycline doxorubicin (Gulyaev 
et al. 1999; Dreis et al. 2007) or paclitaxel (Sahoo and Labhasetwar 2005; Ren et al. 
2011). Proteins, like ASA, need to retain their tertiary structure to fulfill their function. 
Protein stability depends mainly on the solvents used in the production process of nano-
particles as the interface between water and a solvent is a well-known destabilizing fac-
tor. Ethyl acetate has been described to cause less protein denaturation than other sol-
vents for encapsulation in microspheres (Bilati et al. 2005). 
Here, ASA was shown to be unstable in presence of solvents (e.g. ethyl acetate) and 
solutions used for nanoparticle formation (Figure 5.1, results). Consequently, ASA can-
not be incorporated into PBCA-, PLA- and PLGA-nanoparticles. Incorporation into 
HSA nanoparticles is not possible as glutaraldehyde is used to covalently connect pri-
mary amine groups of HSA (Langer et al. 2003). As ASA also displays primary amine 
groups, these would be covalently bound. Besides possibly abolishing ASA activity, 
release of bound ASA could not occur.  
6.1.2.2 Adsorption to PBCA-, PLA- and PLGA-nanoparticles 
Adsorption of various drugs to nanoparticles for brain delivery has been shown in sev-
eral studies. 277 molecules of the lysosomal enzyme α-glucosidase were adsorbed per 
non-biodegradable polystyrene, Intercellular Adhesion Molecule 1 (ICAM-1) modified 
nanoparticle and evidence for their brain delivery was found (Hsu et al. 2011a). Koffie 
and colleagues adsorbed BBB-impermeable fluorophores, MRI contrast agents, but 
most importantly also therapeutic antibodies to PBCA nanoparticles and found evidence 
for their brain delivery after polysorbate 80 surfactant coating (Koffie et al. 2011). 
Moreover, nerve growth factor (NGF) was transported into the brain using the same 
delivery system (Kurakhmaeva et al. 2009). However, these studies did not analyze the 
release of these proteins in presence of serum.  
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Naturally, success of protein adsorption and release in serum depends on the surface 
characteristics of the nanoparticle system as well as the protein itself. In case of PBCA-
nanoparticles, only little ASA activity was found to be in the pellet. To prove that no 
ASA was bound instead of bound ASA becoming inactive, immunoblot analyses 
against ASA were performed (Figure 5.2, B). No signal was detectable in the pellets, 
proving that in fact no ASA was bound. This is in contrast to findings of Kurakhmaeva 
et al., 2009 who showed binding of 2.4 µg of NGF per mg nanoparticle. However, NGF 
is smaller than ASA (27 kDa versus 57 kDa, respectively) and has an alkaline isoelec-
tric point (pI) in contrast to the acidic pI of ASA (pI 9.94 versus 5.65, respectively; the-
oretical calculations based on the primary amino acid sequences performed using the 
ExPASy pI/MW calculator); both factors influence adsorption yields.  
In contrast, up to 200 mU, corresponding to 5 µg of ASA were adsorbed per mg of 
PLA- and PLGA-nanoparticles. However, when these nanoparticles were subjected to 
incubation in serum, release of adsorbed ASA occurred rapidly, as even after the short-
est incubation time (‘0 min’, immediately centrifuged after resuspension in serum) all of 
the adsorbed ASA was found in the supernatant. This was true for all PLA- and PLGA-
nanoparticle preparations tested, rendering them useless for in vivo studies.  
It is long known that plasma proteins interact with nanoparticles. Which proteins adsorb 
depends on the surface characteristics influenced by addition of surfactants and the size 
of the nanoparticles (Lück et al. 1998; Cedervall et al. 2007; Walkey and Chan 2012; 
Sempf et al. 2013). It is highly likely that the ASA desorption observed in presence of 
serum is induced by competition for binding sites with plasma proteins. These proteins 
exhibit a higher binding affinity to the nanoparticle surface, thereby promoting rapid 
release of ASA into the supernatant. 
6.1.2.3 Covalent binding to PLA-nanoparticles 
Therefore, more stable binding methods, using direct crosslinking or the high-affinity 
neutravidin-biotin system, were investigated with regard to their efficiency of binding 
and the release of bound ASA in serum. Both involve the chemical modification of 
functional groups on the nanoparticle’s surface. As PBCA nanoparticles can only be 
modified under harsh conditions (e.g. Pinner reaction, Oh et al. 2011) and showed high 
biotoxicity in the study at hand (chapter 5.1.1) they were disregarded for these experi-
ments. PLA- and PLGA-nanoparticles, however, bear crosslinkable carboxylic groups 
on their surfaces (Nobs et al. 2003). Moreover, amine modified nanoparticles are com-
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mercially available. Their amine groups were used in a direct covalent crosslinking at-
tempt employing a NHS-maleimide heterobifunctional crosslinker and the thiolated 
ASA-variant T365C. This approach led to poor covalent binding (8.9 mU of ASA per 
mg nanoparticle) due to the limited amount of crosslinkable functional groups. 
6.1.2.4 Covalent binding to HSA-nanoparticles 
Therefore, HSA nanoparticles were used for further direct crosslinking attempts, as 
these nanoparticles display a high density of amine groups on their surface available for 
crosslinking (Michaelis et al. 2006; Zensi et al. 2009). Using a similar crosslinking ap-
proach, employing a NHS-maleimide heterobifunctional crosslinker and thiolated ASA, 
340 mU (8.5 µg) of active ASA were bound per mg HSA-nanoparticles. Considering 
the molecular weight of ASA (57 kDa), 0.15 nmol of ASA were bound per mg nanopar-
ticle. Similar binding yields (0.37 nmol per mg) were found using neutravidin by Mich-
aelis et al. (2006). In contrast to ASA bound by adsorption, this ASA-HSA nanoparticle 
formulation did not release ASA in presence of serum, confirming covalent binding and 
most importantly, allowing for in vivo studies. 
6.1.2.5 High affinity binding to PLA- and PLGA-nanoparticles 
As direct covalent binding of ASA to amine-modified PLGA-nanoparticles was poor, 
an amplification step had to be inserted. To this end the neutravidin-biotin system was 
used as one molecule of neutravidin (tetramer) can bind up to four biotinylated mole-
cules. Covalent binding of neutravidin to PLA-nanoparticles followed by high affinity 
binding of biotinylated molecules has previously been performed (Nobs et al. 2004). In 
this work, PLA- and PLGA-nanoparticles were modified using the same protocol. Bio-
tinylated ASA was bound to these nanoparticles. The success of this method was ana-
lyzed by determination of nanoparticle bound ASA activity. On average 37 ± 19.7 mU 
of ASA were bound per mg to HSA stabilized PLA-/PLGA-nanoparticles. Taking the 
specific activity of ASA (40 mU/µg) and its molecular weight (57 kDa), as well as the 
average diameter of nanoparticles (200 nm) and their reported polymer densities (1.25 
and 1.2 g/cm3 for PLA and PLGA-, respectively, Vauthier et al. 1999) into account, 23 
molecules of biotinylated ASA were bound per (HSA-stabilized) nanoparticle. Howev-
er, binding did not occur via the carboxylic groups of the PLA-/PLGA-nanoparticles, 
but via amine groups of the HSA used for the stabilization of the nanoparticles in their 
production process as figure 5.6 suggests. 
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In contrast, Nobs et al. (2004) report covalent attachment of up to 975 molecules of neu-
travidin per PLA-nanoparticle. However, the authors state that each neutravidin tetram-
er merely bound 1.8 (instead of 4) biotinylated molecules. Taking these numbers into 
account up to 440 biotinylated molecules may have been bound per nanoparticle.  
The yields found in the study on hand correspond to only 5% of the previously reported. 
These deviant findings may be due to three factors. First of all, ASA is considerably 
larger than biotin-4-fluorescein or D-biotin used to assess biotin binding properties in 
the previously cited study. This difference in size may cause steric hindrance resulting 
in less biotinylated ASA bound per nanoparticle-bound neutravidin. Secondly, binding 
of ASA may be underestimated in this work, as inactive, bound ASA is not considered. 
Thirdly, binding of biotinylated molecules to the neutravidin-modified nanoparticles 
may have been drastically overestimated by Nobs et al. (2004): Both in their study, as 
well as in this work, physical instability of neutravidin was observed – agglomeration of 
neutravidin was evident. In contrast to the experiments performed in this work, these 
agglomerates were not removed before incubation with nanoparticles in the cited study. 
Subsequently, neutravidin agglomerates and nanoparticles were probably coprecipitated 
in the following centrifugation steps. Excess neutravidin was therefore likely still pre-
sent when conducting experiments to determine yields of bound neutravidin and biotin. 
This may explain the significantly higher amounts of binding found by Nobs et al. 
(2004) in comparison to the findings shown in this work. 
Although considerably lower amounts of ASA were bound per neutravidin-modified 
PLA- and PLGA-nanoparticle than would have been expected based on the literature, 
binding of biotinylated ASA was stable in presence of serum. Consequently the nano-
particle formulations were suitable for in vivo studies. 
In summary only stable binding to the nanoparticles surface allowed for in vivo studies. 
Strategies to encapsulate ASA during the nanoparticle production process and non-
specific adsorption to their surface was shown to either result in depletion of ASA activ-
ity or in rapid and complete desorption in presence of serum.  
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6.1.3 In vivo experiments with nanoparticles 
6.1.3.1 Biotolerance of non-loaded PBCA-, HSA-, PLA- and PLGA-
nanoparticles 
In initial in vivo experiments empty polysorbate 80-surfactant coated PBCA- and HSA-, 
as well as poloxamer 188-surfactant coated PLGA-nanoparticles were tested for their 
biotoxicity in ASA-/- mice. In concordance to published results no adverse effects were 
observed at doses of 100 and 300 mg per kg body weight for HSA- and PLGA-
nanoparticles, respectively (Michaelis et al. 2006, Material Safety Data Sheet for 
RESOMER®, Sigma). 
In contrast, a dose of 200 mg per kg body weight of polysorbate 80 coated PBCA-
nanoparticles was lethal. Reducing the dose by half still led to serious adverse effects, 
but not to death of the treated mice. The LD50 of orally administered polysorbate 80 is 
reported to be 25 g/kg in mice (Material Safety Data Sheet, Sigma Aldrich), therefore 
the concentration of 0.1 g/kg intravenously administered in this experiment is unlikely 
to be the cause for the observed adverse effects. Also, no side effects were noted after 
intravenous injections of polysorbate 80 coated HSA-nanoparticles. Instead the PBCA-
nanoparticles are responsible for the biotoxicity observed. At relatively low doses of 33 
mg/kg of PBCA nanoparticles injected intravenously, no adverse effects were reported 
(Ambruosi et al. 2005). However, another study found the LD50 of PBCA-nanoparticles 
to be 230 mg per kg body weight (Couvreur et al. 1982), which is a similar concentra-
tion to the one used here. Biotoxicity and its possible influence on the BBB integrity at 
lower concentration have been discussed in the literature (Olivier et al. 1999). In one 
study it was shown that polysorbate 80 coated PBCA nanoparticles (13.3 µg/mL) in-
duced a reversible disruption in an in vitro model of the BBB (Rempe et al. 2011).  
Besides lack of ASA activity after incubation in 1% dextran, 10 mM HCl, the solvent 
for PBCA-nanoparticle formation, and low yields of ASA adsorption, their low biotol-
erance render PBCA-nanoparticles unfeasible for use in ERT with ASA. HSA- and 
PLA-/PLGA- nanoparticles, however, show high biotolerance and may be well suited 
for this purpose. 
6.1.3.2 Biodistribution of ASA covalently bound to HSA-nanoparticles 
The biodistribution studies in ASA-/- mice performed using ASA covalently bound to 
HSA-nanoparticles, surfactant coated with polysorbate 80, showed a difference in tissue 
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distribution of nanoparticle bound ASA in comparison to free ASA. In comparison to 
free ASA injections, uptake by cells of the MPS was even less for nanoparticle bound 
ASA as levels in liver, spleen and kidney were reduced. However, contrary to the work-
ing hypothesis, brain delivery of nanoparticle bound ASA was not higher than that of 
free ASA. 
This result contradicts the previous findings (Michaelis et al. 2006). In their study the 
opiate loperamide was adsorbed to HSA nanoparticles. After surfactant coating with 
polysorbate 80 and tail-vein injection into mice, a strong analgesic effect, as measured 
by the tail-flick test, was observed after 15-45 minutes, indicating brain delivery of 
loperamide. It has to be noted, however, that loperamide is able to cross the endothelial 
layer of the BBB. The reason for lack of transport into the CNS of free loperamide is 
that it is a substrate of efflux transporters, such as P-glycoprotein, and is actively trans-
ported back into the blood stream (Upton 2007). Interestingly, it has been shown in in 
vitro experiments using the adenocarcinoma cell line Caco-2 that polysorbate 80 may be 
a P-glycoprotein inhibitor (Hugger et al. 2002). Therefore brain delivery of loperamide 
may not be mediated by the HSA-nanoparticles, but by polysorbate 80 in the study of 
Michaelis et al. (2006). Unfortunately no control injections of loperamide and polysorb-
ate 80 without nanoparticles were performed.  
Notably, this nanoparticle system using polysorbate 80-coated HSA-nanoparticles has 
not been used in further studies. Instead direct, covalent attachment of apolipoproteins 
has been used to deliver substances into the brain, as has also initially been shown by 
Michaelis et al. (2006). Brain delivery of this nanoparticle formulation was further 
strengthened by electronmicroscopic analyses (Zensi et al. 2009). The use of this system 
has not been evaluated here, as amounts of covalently attached ASA would be expected 
to be decreased as also amine groups are used for crosslinking. 
6.1.3.3 Biodistribution of ASA bound to PLA-nanoparticles by high affinity  
As observed for HSA-nanoparticles before, PLA-nanoparticle bound ASA resulted in a 
different biodistribution in comparison to free ASA. Tissue levels of ASA two hours 
after injections of this nanoparticle formulation were increased in spleen and lungs in 
comparison to injections of free ASA. Although tissue levels of nanoparticle bound 
ASA were significantly decreased in the liver, these findings hint at clearance by cells 
of the MPS. Most importantly, however, no increased brain delivery of ASA was ob-
served when using this nanoparticle preparation. 
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Both ASA nanoparticle preparations used for biodistribution studies were less detecta-
ble in the ASA-ELISA than free ASA. As described in the results section the ASA con-
centrations in the brain after the neutravidin-nanoparticle preparation were below the 
detection limit. To evaluate ASA brain delivery of nanoparticle bound ASA, the inject-
ed dose would need to be increased in order to reach the detection limit. Increasing the 
dose of nanoparticles may, however, lead to adverse effects and is limited by the injec-
tion volume. Instead, the aim must be to increase the yields of ASA binding to nanopar-
ticles or to find other, more sensitive ways to detect nanoparticle bound ASA or the na-
noparticles themselves (e.g. by radioactive labeling). 
However, the results allow the calculation that the increase in nanoparticle mediated 
brain delivery of ASA was below 27-fold. Considering the findings of other studies 
mentioned before nanoparticle mediated brain delivery of ASA was expected to be up to 
200-fold higher than that of free ASA (chapter 5.1). However, as stated above, literature 
may partly overestimate the brain delivery of drugs, e.g. by disregarding perfusion or by 
using imprecise or inadequate detection methods. Here, in contrast, transcardially perfu-
sion was performed. Moreover the detection assay (ASA-ELISA) used here is sensitive, 
reproducible and robust and has been used frequently in our working group to detect 
ASA in tissue homogenates (Matzner et al. 2000; Matzner et al. 2005; Matthes et al. 
2011; Böckenhoff et al. 2014). 
In case of the neutravidin-nanoparticle formulation the possible clearance by cells of the 
MPS and decreased brain uptake may indicate that surfactant coating using poloxamer 
188 was impeded. Possibly, modification of the surface of the nanoparticles using neu-
travidin and biotinylated ASA changes or prevents the binding of poloxamer 188. Con-
sequently, opsonins may bind to the nanoparticles surface thereby triggering uptake by 
macrophages of the MPS. More importantly, adsorption of serum-apolipoproteins to 
these nanoparticles would be expexted to be reduced. Reduced or abolished adsorption 
of apolipoproteins would be detrimental for brain delivery as this process supposedly 
enables LDL-receptor-mediated transcytosis across the BBB.  
Another reason both for decreased brain delivery and increased uptake by cells of the 
MPS could be the size of nanoparticles. After modification with neutravidin, Nobs et al. 
(2004) report a moderate increase in diameter from 276 to 322 nm. However, as stated 
before, the amount of neutravidin bound may have been less than the authors state. 
Michaelis et al. (2006), who covalently bound neutravidin to HSA-nanoparticles, do not 
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mention an increase in size. In the study on hand, an agglomeration of neutravidin mod-
ified nanoparticles was observed. Therefore directly before injections, nanoparticles 
were treated with ultrasound, which reversed agglomeration (not shown). Nonetheless, 
an increase in size or partial agglomeration may have occurred. However, Voigt et al. 
(2014) state that the surface characteristics of nanoparticle formulations have a stronger 
influence on brain delivery than their size.  
Besides the described reasons of impeded surfactant coating and increased size, one 
further explanation for failure in brain delivery may be that by binding ASA to their 
surface, nanoparticles obtain a new targeting moiety, influencing their biodistribution 
stronger than the surfactant. ASA displays M6P residues. These residues are recognized 
by MPRs, ubiquitously expressed on the cell surfaces throughout the body. Therefore 
uptake of ASA-nanoparticles by MPR-mediated endocytosis by peripheral cells may 
impede their brain delivery by removing them from the blood stream.  
6.2 Physical shielding of the M6P residues of ASA  
Based on this hypothesis, a novel approach was pursued. The M6P-residues of ASA 
were to be physically shielded in order to increase blood circulation times, decrease 
uptake by peripheral cells and allow for surfactant/nanoparticle mediated brain target-
ing.  
It has already been shown that by chemically modifying the M6P residues of β-
glucuronidase its serum half-life time was increased 100-fold (from 0.2 to 18.5 hours). 
As Grubb et al. (2008) state, this effect resulted in 5.7-fold more β-glucuronidase in the 
brain in comparison to non-modified β-glucuronidase. Exploiting this effect in combina-
tion with nanoparticle mediated brain targeting may potentiate this increase several-
fold.  
However, chemical modification of lysosomal enzymes is irreversible and also influ-
ences their lysosomal stability after pinocytosis. Moreover, in case of ASA, chemical 
modification using sodium periodate leads to loss of its activity (Matthes 2010). There-
fore a different strategy was pursued here. Instead of chemical modification, physical 
shielding of M6P residues was performed. To this end the M6P binding domain 9 of the 
human MPR300 was used. The domain 9 of the bovine MPR300 has previously been 
reported to bind with high affinity towards two other lysosomal proteins, acid alpha-
glucosidase and beta-glucuronidase (Bohnsack et al. 2009). Not only should shielding 
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of ASA result in similar effects concerning blood circulation times and brain delivery as 
observed after chemical modification of β-glucuronidase, but once ASA is taken up by 
cells, the binding domain used for shielding should dissociate due to a pH drop in the 
endosome consequently releasing unmodified ASA. Thus, after transcytosis at the BBB, 
released, unmodified ASA would be delivered to the brain. Uptake of the unmodified 
ASA by cells of the brain could then occur via MPR-mediated endocytosis. In contrast 
to chemically modified enzyme, no decreased lysosomal stability would be expected.  
To avoid immunogenic complications in future in vivo studies, a non-glycosylated form 
of the receptor fragment was produced. To that end three constructs besides the wt con-
struct were generated. Two of these lacked either one, and the third lacked both N-
glycosylation sites as was confirmed by EndoHf digest. The KD values of all four con-
structs were in the range of 30.2-56.6 nM. These findings are similar to the KD observed 
by Bohnsack et al. (2009) for the recombinantly produced domain 9 of the bovine 
MPR300 towards acid α-glucosidase and β-glucuronidase (71 ± 20 nM). The slightly 
higher affinity of binding towards ASA observed here may have its cause in the use of a 
different KD determination method, species-dependent differences in the primary se-
quences of the domain 9 or use of a different lysosomal enzyme (ASA instead of acid α-
glucosidase or β-glucuronidase).  
The non-glycosylated receptor fragment construct was then analyzed with respect to 
dissociation from ASA in dependence of the pH. Although a pH-dependence was clear, 
dissociation both under acidic (pH 5.0) and alkaline conditions (pH 8-9) was moderate 
with approximately 50% and 20-30% respectively. Only little dissociation occurred at 
pH 6-7.4. This result is directly comparable with the observations of Gonzalez-Noriega 
et al., 1980, where the effect of the pH on the dissociation of β-glucuronidase from 
MPR300 on the cell surface was investigated (Figure 6.2, B) (Gonzalez-Noriega et al. 
1980). In their study binding was stable at pH 7.0 (10% dissociation), but approximately 
80% and 60% dissociation were observed at pH 5.0 and 9.0, respectively. As less disso-
ciation was found in this work using the isolated domain 9 of the MPR300, the pH de-
pendent release must be partially mediated by another domain.  
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Figure 6.2: Comparison of the pH dependent dissociation of the non-glycosylated MPR 
dom9 fragment and ASA observed in this work (A) and of the whole MPR300 on the cell 
surface of fibroblasts and β-glucuronidase as described by Gonzalez-Noriega et al. (1980) 
(B). 
 
To prove that binding of the receptor fragment to ASA inhibits its cellular uptake, in 
vitro experiments were performed with MEFs at pH 7.0. Interestingly, uptake of ASA 
was only significantly reduced after its coincubation with a tenfold excess of the recep-
tor fragment, but not after coincubation with equimolar amounts. The number of M6P 
residues on the surface of ASA may explain this. The ASA employed here was recom-
binantly produced in CHO cells. It has been reported that this ASA carries N-glycans at 
all three N-glycosylation sites (Schröder et al. 2010). Moreover the authors report 3.4 
mol of M6P per mol ASA. Taking this into account, it appears logical that equimolar 
amounts of the receptor fragment cannot inhibit cellular uptake of ASA, as statistically 
2.4 M6P residues per molecule ASA are still unshielded and can thus be recognized by 
MPR300 on the cell surfaces. Indeed, when a tenfold excess of the receptor fragment is 
used, reduction of ASA endocytosis was observed.  
Surprisingly, this effect was moderate (-15%). This may indicated that ASA is taken up 
via another endocytosis process such as unspecific pinocytosis. However, in experi-
ments conducted by Böckenhoff et al. (2014), uptake of ASA in MEFs was annihilated 
when free M6P was added to compete with the M6Ps displayed by ASA thereby inhibit-
ing MPR300 mediated endocytosis. This indicates that in this work ASA is still taken 
up via this pathway, despite its pre-coincubation with a tenfold excess of receptor frag-
ment in an effort to shield its M6P residues.  
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First of all, endocytosis of the receptor fragment itself could explain this finding. It has 
been suggested that the MPR300 forms homodimers (Byrd et al. 2000), therefore the 
receptor fragment may form heterodimers with endogenous MPR300 on the cell surface 
followed by its endocytosis. However, this possibility was ruled out by performing an 
immunoblot against the receptor fragment in supernatants and lysates of treated cells 
(Figure 5.12, B). No signal was detected in the lysates, but only in the supernatants, 
indicating that the receptor fragment is not endocytosed. 
Secondly, the endogenous MPR300 on the cell surfaces may compete for binding to 
ASA with the receptor fragment used for physical shielding, thereby triggering endocy-
tosis. As for each receptor-ligand interaction binding of the receptor fragment to ASA is 
reversible and thus time dependent. Once a single M6P residue of ASA is released, en-
dogenous MPR300 binding would be more likely than receptor fragment binding due to 
its higher affinity. Subsequent endocytosis would remove ASA from the equilibrium. 
This notion is supported by findings of Bohnsack et al. (2009), who show that the total 
(bovine, soluble) MPR300 has a higher affinity towards M6P bearing acid alpha-
glucosidase than the binding domain 9 alone. Two reasons could explain this higher 
affinity: (1) Another receptor domain binds to M6P with higher affinity. This is true as 
the domains 1-3 have been reported to bind M6P residues (Bohnsack et al. 2009). (2) 
The higher affinity of the endogenous receptor versus the receptor fragment is due to 
bivalent binding of two M6P residues per ligand. This also has been confirmed. It is 
controversially discussed whether this effect is caused by cooperative binding of two 
domains of one receptor molecule or by receptor dimerization (Byrd et al. 2000; 
Hartman et al. 2009). Thus, one strategy to reduce endocytosis of physically shielded 
ASA may be to decrease the affinity of the endogenous MPR300 towards ASA. This 
may be achieved by reducing the number of M6P residues of ASA to one per molecule, 
thereby prohibiting bivalent binding of the endogenous MPR300. To that end, an ASA 
mutant enzyme with amino acid substitutions at two of the three N-glycosylation sites 
could be expressed and purified. Secondly, the same may be achieved by controlled 
digest of wt ASA using acid phosphatase 5 (Sun et al. 2008). Alternatively, the affinity 
of the receptor fragment towards the M6P residues of ASA may be increased by protein 
engineering thereby reducing dissociation and consequently recognition by endogenous 
MPRs. Moreover, the whole, soluble MPR300 could be used as its affinity towards 
M6P containing proteins is higher than its domain 9 alone. However, the size of this 
protein may be disadvantageous.  
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Finally, dissociation of the receptor fragment from ASA in presence of cell culture me-
dium may explain its MPR300-mediated uptake. The dissociation constant of a ligand 
from its receptor is dependent on various properties of the buffer system and other com-
ponents. Moreover, dissociation of the receptor fragment from ASA would be expected 
in presence of other, competing ligands. 
Indeed, 20.0 ± 1.2% of dissociation of the receptor fragment occurred upon incubation 
in cell culture medium. Therefore one or more components of cell culture medium af-
fect binding of the receptor fragment to ASA. Possibly, supplemented FCS (10%, v/v) 
caused this effect, as even more dissociation was found upon incubation in 100% mouse 
serum: on average, 37.5 ± 10.6% of the initially bound ASA were found to dissociate 
from the receptor fragment. First of all, the soluble form of the MPR300 present both in 
FCS, and also in (human) serum (Causin et al. 1988; Li et al. 1991), may cause the ob-
served dissociation of the receptor fragment. However, this cannot explain the results of 
the endocytosis experiments, as uptake would be expected to be even decreased after 
binding of the soluble MPR300 in comparison to the receptor fragment due to its higher 
affinity. Secondly, dissociation may be explained by competition of other lysosomal 
enzymes present in serum (Koster et al. 1993).  
Importantly, the dissociation of the receptor fragment from ASA in presence of mouse 
serum limits the applicability of this system for physical shielding of the M6P residues 
of ASA in vivo. No relevant decrease of uptake by peripheral cells and thus no in-
creased blood circulation times would be expected, if competition of other lysosomal 
enzymes was the cause of the dissociation.  
In further studies it was shown that the receptor fragment can be covalently bound to 
nanoparticles. The yields of subsequently bound ASA were comparable to the low lev-
els of direct covalent binding of ASA to amine-modified PLGA nanoparticles. Further 
crosslinking strategies will be pursued to increase binding. Alternatively, HSA-
nanoparticles could be used to the same end as these carry many primary amine groups 
available for crosslinking (compare chapter 5.1.4.1).  
 
The working hypothesis that uptake of physically shielded ASA by MPR-expressing 
cells decreases, was verified. However, for use in in vivo studies, the affinities of ASA 
towards the receptor fragment need to be increased and/or decreased towards endoge-
nous MPR. First attempts to bind the receptor fragment to nanoparticles have led to 
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promising results, however binding still needs to be increased to allow for in vivo stud-
ies. When both issues, the dissociation of the receptor fragment in presence of serum 
and the low binding of the receptor fragment to nanoparticles, are resolved, this drug 
delivery system could not only be used for brain delivery of ASA, but for any lysosomal 
protein containing M6P residues. 
 
However, none of the ASA-nanoparticle formulations tested was found to be able to 
increase brain delivery in comparison to free ASA. Although several explanations were 
found, ultimately the reason for these findings is unclear. As the tested nanoparticulate 
drug delivery system did not meet the expectations, others are to be used in the future. 
Manifold different nanoparticle surface modifications have been investigated to increase 
brain delivery. Possibly, adsorbed or covalently bound targeting moieties such as trans-
ferrin anitibodies or apolipoproteins (Kreuter et al. 2007; Gan and Feng 2010) may be 
better suited for brain delivery of nanoparticle bound ASA than surfactant coating. Drug 
delivery systems such as nanospheres, liposomes and dendrimers have also been exten-
sively investigated (Kozlovskaya and Stepensky 2013) and may also serve to increase 
brain delivery of ASA. 
6.3 Identification of ASA inhibitors 
In the second part of this thesis, inhibitors of ASA were to be identified. ASA inhibitors 
may either serve to establish a cell culture model of MLD or be used as pharmacologi-
cal chaperones for misfolded ASA, reducing its degradation by the ERAD-system. Both 
prospects will be elucidated for the identified ASA inhibitor, compound A, shortly. 
In first experiments substrate- and enzyme-concentrations, as well as reaction times of 
the standard ASA activity assay were optimized to fulfill the criteria of (1) substrate 
concentrations close to the Km as to be able to identify competitive inhibitors, (2) ro-
bustness of the assay, and (3) cost control for high throughput screenings.  
The substrate concentration was 0.25 mM, close to the Km (0.21 mM) of ASA towards 
4-nitrocatechol sulfate previously reported (Bognar et al. 2006). It is therefore possible 
to find competitive inhibitors. Indeed, a competitive inhibitor of ASA was identified 
(compound A). The assay was robust as all plates had Z’ scores exceeding 0.5 (on aver-
age 0.89). Therefore, this assay is very well suited for high throughput screenings 
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(Zhang et al. 1999). The costs were considerably low with approximately 0.004 € per 
tested compound. 
Using this assay, a total of four inhibitory substances of 30,500 tested compounds were 
identified. Two of them later proved to be chemically instable (metamizole, sulfathiou-
rea) with the hydrolysis products inhibiting ASA. In case of metamizole it was shown 
and has already been described in the literature (Wessel 2004) that sulfite is released 
after its rapid hydrolysis under assay conditions. Sulfite is a known, potent inhibitor of 
ASA (Matzner et al. 2009a) and forms sulfur dioxide gas in presence of weak acids (as-
say conditions: pH 5.0). The hydrolysis product of sulfathiourea responsible for ASA 
inhibition has not yet been identified in this work, but may be hydrogen sulfide gas or 
its soluble form in water hydrosulfuric acid. As both hydrolysis products of metamizole 
and sulfathiourea may outgas, they are unsuitable for cell culture experiments. A third 
compound, primaquine, has been shown to be non-inhibitory. Instead the phosphates 
present in primaquine solid caused the observed inhibitory effect. Phosphates have al-
ready been described to inhibit ASA, also by Matzner et al., 2009a. Ultimately, only 
compound A was confirmed to be an inhibitor of ASA which was chemically stable. 
Compound A is not specific for ASA, as ASB was inhibited at similar inhibitor concen-
trations. 
6.3.1 Potential of compound A to establish a cell culture model of MLD 
This ASA inhibitor may be used to establish an in vitro model of MLD. The major ad-
vantage of inhibitors for cell culture experiments is that they are easily applicable and 
can be used for a wide variety of cells – most importantly primary cells or cell lines of 
human origin. In contrast to knockdown or knockout experiments, activity of the inhib-
ited enzyme can be quickly restored by withdrawing the inhibitor. Cell culture models 
of LSDs have been previously induced by addition of small compounds. For instance, 
progesterone and U18666A have been used to impede cholesterol transport routes lead-
ing to its accumulation and induction of a Niemann-Pick, type C-like phenotype (Lange 
and Steck 1994; Huang et al. 2006). Moreover, a specific inhibitor of glucocerebro-
sidase-1, conduritol-β-epoxide, has been used to create in vitro models of Gaucher dis-
ease (Berger et al. 2010; Cleeter et al. 2013; Dermentzaki et al. 2013). Experiments in 
such cell culture models of LSDs increase our understanding of the molecular and cellu-
lar pathomechanisms involved in these diseases. The establishment of a cell culture 
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model of MLD using compound A and sulfatide-loading may help to cast a light on the 
link between sulfatide accumulation and demyelination.  
However, the use of compound A to this end may be limited. As compound A also in-
hibits ASB, cells treated with this inhibitor may not only show a MLD-like, but also a 
mucopolysaccharidosis, type VI-like phenotype. Therefore, the interpretation of ob-
served effects would be difficult or even impossible.  
6.3.2 Potential of compound A as a pharmacological chaperone for ASA 
Moreover, inhibitors of ASA may be used for chaperone therapy. Several studies 
proved that inhibitors identified by high throughput screenings have the ability to rescue 
enzyme activity by acting as pharmacological chaperones. Zheng et al. (2007) identified 
three chemically distinct classes of glucocerebrosidase inhibitors. Although none of 
these compounds were competitive inhibitors, two were shown to function as chemical 
chaperones. 
Tropak et al. (2007) screened a library of 50,000 small molecules for inhibitors of β-
hexosaminidase A. Similar to the assay performed here, screening was performed at 
acidic pH and an endpoint assay was used. An end concentration of 20 µM of each 
compound was used in comparison to 10 µM used here. Of 64 hits reducing β-
hexosaminidase A activity by 50% or more, only 24 (0.048% of initially 50,000 com-
pounds) were confirmed to be ‘bona fide inhibitors’ in subsequent assays. This shows 
that high throughput screenings are susceptible to identify ‘false positives’. Vice versa, 
some factual inhibitors may not be recognized (‘false negatives’) (Inglese et al. 2006; 
Malo et al. 2006). Therefore, in this work all compounds that led to as little as 10% of 
inhibition were reevaluated, on the one hand increasing the likelihood for identification 
of false positives, but also minimizing the risks of false negatives. 
Interestingly, the three most potent β-hexosaminidase A inhibitors identified by Tropak 
et al. (2007) were also inhibitors of β-hexosaminidase B at similar concentrations. 
These inhibitors were used in cell culture experiments using fibroblasts of patients with 
a certain mutation causing infantile Sandhoff diseases. All three tested inhibitors were 
shown to act as pharmacological chaperones increasing the enzyme activities 2-3-fold 
depending on the inhibitor concentration applied.  
This example shows that, although not specific for ASA (as also ASB is inhibited), the 
identified, competitive ASA inhibitor may serve as a pharmacological chaperone. In 
6 Discussion 111 
comparison to the three β-hexosaminidase B inhibitors described above (IC50: 0.2-
5.8 µM) the potency of compound A is rather low (IC50: 49.1 µM). First attempts to find 
similar compounds with higher potency by a virtual screening approach have not been 
successful (Figure 5.23). However, further attempts to find similar compounds using 
rational design will be made. Importantly, the potency of compound A may already be 
sufficient for chaperone therapy considering that N-butyl-deoxynojirimycin (Miglustat), 
which is in clinical use for treatment of Gaucher (type I) and Niemann-Pick (type C) 
diseases, has an IC50-value of 20-37 µM for its target glucosylceramide synthase (data 
sheet for Zavesca®).  
Before conducting cell culture experiments on fibroblasts of MLD patients, the pH de-
pendence of the inhibition is to be analyzed. Only if compound A is able to bind to ASA 
at neutral pH of the endoplasmic reticulum, it may be used as a pharmacological chap-
erone. Ideally, inhibition decreases at the more acidic pH of the lysosome as to allow 
enzymatic degradation of storage material. These criteria were shown to be fulfilled for 
the pharmacological chaperone pyrimethamine, another inhibitor of β-hexosaminidase 
A. Almost 100% inhibition was observed at pH 6.5, whereas inhibition was only ap-
proximately 70% at pH 4.0 (Maegawa et al. 2007).  
 
In summary, one ASA inhibitor (‘compound A’) was identified. This compound is a 
good lead structure, possibly allowing for identification of more potent inhibitors by 
rational design. Compound A may have limited use to establish an in vitro model of 
MLD since it also inhibits ASB, thereby potentially causing a mucopolysaccharidosis, 
type VI, like phenotype. In contrast, its prospects for use as pharmacological chaperone 
for MLD are promising. Further biochemical, in vitro and in vivo experiments will show 
whether this compound is ultimately suitable for first clinical trials for treatment of 
MLD. 
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Plasmid map of pPICZα A/B/C vectors; pPICZα B was used. 
 
(Source: Invitrogen: User 
Manual: ‘pPICZα A, B, 
and C - Pichia expression 
vectors for selection on 
Zeocin™ and purification 
of secreted, recombinant 
proteins’ 
 
 
 
 
 
Plasmid map of pJET1.2 (interim cloning vector) 
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